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Structure- and Ligand-Based Design of Novel Antimicrobial Agents
Abstract
The use of computer based techniques in the design of novel therapeutic agents is a rapidly emerging
field. Although the drug-design techniques utilized by Computational Medicinal Chemists vary greatly,
they can roughly be classified into structure-based and ligand-based approaches. Structure-based
methods utilize a solved structure of the design target, protein or DNA, usually obtained by X-ray or NMR
methods to design or improve compounds with activity against the target. Ligand-based methods use
active compounds with known affinity for a target that may yet be unresolved. These methods include
Pharmacophore-based searching for novel active compounds or Quantitative Structure-Activity
Relationship (QSAR) studies. The research presented here utilized both structure and ligand-based
methods against two bacterial targets: Bacillus anthracis and Mycobacterium tuberculosis. The first part
of this thesis details our efforts to design novel inhibitors of the enzyme dihydropteroate synthase from B.
anthracis using crystal structures with known inhibitors bound. The second part describes a QSAR study
that was performed using a series of novel nitrofuranyl compounds with known, whole-cell, inhibitory
activity against M. tuberculosis.
Dihydropteroate synthase (DHPS) catalyzes the addition of p-amino benzoic acid (pABA) to dihydropterin
pyrophosphate (DHPP) to form pteroic acid as a key step in bacterial folate biosynthesis. It is the
traditional target of the sulfonamide class of antibiotics. Unfortunately, bacterial resistance and adverse
effects have limited the clinical utility of the sulfonamide antibiotics. Although six bacterial crystal
structures are available, the flexible loop regions that enclose pABA during binding and contain key
sulfonamide resistance sites have yet to be visualized in their functional conformation. To gain a new
understanding of the structural basis of sulfonamide resistance, the molecular mechanism of DHPS
action, and to generate a screening structure for high-throughput virtual screening, molecular dynamics
simulations were applied to model the conformations of the unresolved loops in the active site. Several
series of molecular dynamics simulations were designed and performed utilizing enzyme substrates and
inhibitors, a transition state analog, and a pterin-sulfamethoxazole adduct. The positions of key mutation
sites conserved across several bacterial species were closely monitored during these analyses. These
residues were shown to interact closely with the sulfonamide binding site. The simulations helped us gain
new understanding of the positions of the flexible loops during inhibitor binding that has allowed the
development of a DHPS structural model that could be used for high-through put virtual screening
(HTVS). Additionally, insights gained on the location and possible function of key mutation sites on the
flexible loops will facilitate the design of new, potent inhibitors of DHPS that can bypass resistance
mutations that render sulfonamides inactive.
Prior to performing high-throughput virtual screening, the docking and scoring functions to be used were
validated using established techniques against the B. anthracis DHPS target. In this validation study, five
commonly used docking programs, FlexX, Surflex, Glide, GOLD, and DOCK, as well as nine scoring
functions, were evaluated for their utility in virtual screening against the novel pterin binding site. Their
performance in ligand docking and virtual screening against this target was examined by their ability to
reproduce a known inhibitor conformation and to correctly detect known active compounds seeded into
three separate decoy sets. Enrichment was demonstrated by calculated enrichment factors at 1% and
Receiver Operating Characteristic (ROC) curves. The effectiveness of post-docking relaxation prior to
rescoring and consensus scoring were also evaluated. Of the docking and scoring functions evaluated,
Surflex with SurflexScore and Glide with GlideScore performed best overall for virtual screening against
the DHPS target.
The next phase of the DHPS structure-based drug design project involved high-throughput virtual
screening against the DHPS structural model previously developed and docking methodology validated

against this target. Two general virtual screening methods were employed. First, large, virtual libraries
were pre-filtered by 3D pharmacophore and modified Rule-of-Three fragment constraints. Nearly 5 million
compounds from the ZINC databases were screened generating 3,104 unique, fragment-like hits that
were subsequently docked and ranked by score. Second, fragment docking without pharmacophore
filtering was performed on almost 285,000 fragment-like compounds obtained from databases of
commercial vendors. Hits from both virtual screens with high predicted affinity for the pterin binding
pocket, as determined by docking score, were selected for in vitro testing. Activity and structure-activity
relationship of the active fragment compounds have been developed. Several compounds with
micromolar activity were identified and taken to crystallographic trials.
Finally, in our ligand-based research into M. tuberculosis active agents, a series of nitrofuranylamide and
related aromatic compounds displaying potent activity was investigated utilizing 3-Dimensional
Quantitative Structure-Activity Relationship (3D-QSAR) techniques. Comparative Molecular Field Analysis
(CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA) methods were used to produce
3D-QSAR models that correlated the Minimum Inhibitory Concentration (MIC) values against M.
tuberculosis with the molecular structures of the active compounds. A training set of 95 active
compounds was used to develop the models, which were then evaluated by a series of internal and
external cross-validation techniques. A test set of 15 compounds was used for the external validation.
Different alignment and ionization rules were investigated as well as the effect of global molecular
descriptors including lipophilicity (cLogP, LogD), Polar Surface Area (PSA), and steric bulk (CMR), on
model predictivity. Models with greater than 70% predictive ability, as determined by external validation
and high internal validity (cross validated r2 > .5) were developed. Incorporation of lipophilicity descriptors
into the models had negligible effects on model predictivity. The models developed will be used to predict
the activity of proposed new structures and advance the development of next generation nitrofuranyl and
related nitroaromatic anti-tuberculosis agents.
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ABSTRACT

The use of computer based techniques in the design of novel therapeutic agents
is a rapidly emerging field. Although the drug-design techniques utilized by
Computational Medicinal Chemists vary greatly, they can roughly be classified into
structure-based and ligand-based approaches. Structure-based methods utilize a
solved structure of the design target, protein or DNA, usually obtained by X-ray or NMR
methods to design or improve compounds with activity against the target. Ligand-based
methods use active compounds with known affinity for a target that may yet be
unresolved. These methods include Pharmacophore-based searching for novel active
compounds or Quantitative Structure-Activity Relationship (QSAR) studies. The
research presented here utilized both structure and ligand-based methods against two
bacterial targets: Bacillus anthracis and Mycobacterium tuberculosis. The first part of
this thesis details our efforts to design novel inhibitors of the enzyme dihydropteroate
synthase from B. anthracis using crystal structures with known inhibitors bound. The
second part describes a QSAR study that was performed using a series of novel
nitrofuranyl compounds with known, whole-cell, inhibitory activity against M.
tuberculosis.
Dihydropteroate synthase (DHPS) catalyzes the addition of p-amino benzoic acid
(pABA) to dihydropterin pyrophosphate (DHPP) to form pteroic acid as a key step in
bacterial folate biosynthesis. It is the traditional target of the sulfonamide class of
antibiotics. Unfortunately, bacterial resistance and adverse effects have limited the
clinical utility of the sulfonamide antibiotics. Although six bacterial crystal structures are
available, the flexible loop regions that enclose pABA during binding and contain key
sulfonamide resistance sites have yet to be visualized in their functional conformation.
To gain a new understanding of the structural basis of sulfonamide resistance, the
molecular mechanism of DHPS action, and to generate a screening structure for highthroughput virtual screening, molecular dynamics simulations were applied to model the
conformations of the unresolved loops in the active site. Several series of molecular
dynamics simulations were designed and performed utilizing enzyme substrates and
inhibitors, a transition state analog, and a pterin-sulfamethoxazole adduct. The positions
of key mutation sites conserved across several bacterial species were closely monitored
during these analyses. These residues were shown to interact closely with the
sulfonamide binding site. The simulations helped us gain new understanding of the
positions of the flexible loops during inhibitor binding that has allowed the development
of a DHPS structural model that could be used for high-through put virtual screening
(HTVS). Additionally, insights gained on the location and possible function of key
mutation sites on the flexible loops will facilitate the design of new, potent inhibitors of
DHPS that can bypass resistance mutations that render sulfonamides inactive.
Prior to performing high-throughput virtual screening, the docking and scoring
functions to be used were validated using established techniques against the B.
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anthracis DHPS target. In this validation study, five commonly used docking programs,
FlexX, Surflex, Glide, GOLD, and DOCK, as well as nine scoring functions, were
evaluated for their utility in virtual screening against the novel pterin binding site. Their
performance in ligand docking and virtual screening against this target was examined by
their ability to reproduce a known inhibitor conformation and to correctly detect known
active compounds seeded into three separate decoy sets. Enrichment was
demonstrated by calculated enrichment factors at 1% and Receiver Operating
Characteristic (ROC) curves. The effectiveness of post-docking relaxation prior to
rescoring and consensus scoring were also evaluated. Of the docking and scoring
functions evaluated, Surflex with SurflexScore and Glide with GlideScore performed best
overall for virtual screening against the DHPS target.
The next phase of the DHPS structure-based drug design project involved highthroughput virtual screening against the DHPS structural model previously developed
and docking methodology validated against this target. Two general virtual screening
methods were employed. First, large, virtual libraries were pre-filtered by 3D
pharmacophore and modified Rule-of-Three fragment constraints. Nearly 5 million
compounds from the ZINC databases were screened generating 3,104 unique,
fragment-like hits that were subsequently docked and ranked by score. Second,
fragment docking without pharmacophore filtering was performed on almost 285,000
fragment-like compounds obtained from databases of commercial vendors. Hits from
both virtual screens with high predicted affinity for the pterin binding pocket, as
determined by docking score, were selected for in vitro testing. Activity and structureactivity relationship of the active fragment compounds have been developed. Several
compounds with micromolar activity were identified and taken to crystallographic trials.
Finally, in our ligand-based research into M. tuberculosis active agents, a series
of nitrofuranylamide and related aromatic compounds displaying potent activity was
investigated utilizing 3-Dimensional Quantitative Structure-Activity Relationship (3DQSAR) techniques. Comparative Molecular Field Analysis (CoMFA) and Comparative
Molecular Similarity Indices Analysis (CoMSIA) methods were used to produce 3DQSAR models that correlated the Minimum Inhibitory Concentration (MIC) values
against M. tuberculosis with the molecular structures of the active compounds. A
training set of 95 active compounds was used to develop the models, which were then
evaluated by a series of internal and external cross-validation techniques. A test set of
15 compounds was used for the external validation. Different alignment and ionization
rules were investigated as well as the effect of global molecular descriptors including
lipophilicity (cLogP, LogD), Polar Surface Area (PSA), and steric bulk (CMR), on model
predictivity. Models with greater than 70% predictive ability, as determined by external
validation and high internal validity (cross validated r2 > .5) were developed.
Incorporation of lipophilicity descriptors into the models had negligible effects on model
predictivity. The models developed will be used to predict the activity of proposed new
structures and advance the development of next generation nitrofuranyl and related
nitroaromatic anti-tuberculosis agents.
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CHAPTER 1. INTRODUCTION
1.1 Computer-Aided Drug Design and Molecular Modeling
The role of computers in the design of novel therapeutic agents has a long
history. As early as the 1960’s computers were being used to visualize drug-target
interactions. In fact, the origin of the use of computers for molecular graphics and
modeling in drug discovery has been traced to Project MAC (Multiple Access Computer)
at MIT in 1963.1 By the early to mid 1970’s, x-ray crystal structures of biological drug
targets were being visualized and the insights gained employed in lead optimization.
Over the last several decades, the exponential increase in computing power, technology,
and the number of solved target structures using high-throughput X-ray, NMR, and
homology modeling methods has resulted in a dramatic rise in the use of computers in
many aspects of drug design. Computational techniques including quantum mechanical
calculations, molecular mechanics operations, molecular simulations, graphical
visualization, cheminformatics, molecular docking and quantitative structure-activity
relationship studies are all being used with increasing frequency and success in the
discovery and development of clinical drug candidates. These methods are being
applied in almost every area of drug design, from hit identification and lead modification
to metabolism, distribution and toxicology predictions. Table 1.1 lists several
representative examples of clinical drugs for which computational techniques played a
Table 1.1. Examples of Clinical Drugs Developed Using Computer-Aided Methods
Compound

Target

Therapeutic Use

Company

Approved

Captopril

Angiotensin
Converting Enzyme
HIV Protease1
Acetylcholinesterase
HIV Protease1
Carbonic Anydrase
HIV Protease1
Neuraminidase
Neuraminidase
HIV Protease1
bcr-abl Kinase
EGFR Kinase
Thrombin
HIV Integrase

Hypertension

Par Pharma

1982

HIV Infection
Alzheimer’s
HIV Infection
Glaucoma
HIV Infection
Influenza
Influenza
HIV Infection
Leukemia
Cancers
Anticoagulant
HIV Infection

Roche
Eisai
Pfizer
Merck
GlaxoSmithKline
GlaxoSmithKline
Roche
Abbott
Novartis
OSI Pharma
AstraZeneca
Merck

1995
1996
1997
1998
1999
1999

Saquinavir
Donepezil
Nelfinavir
Dorzolamide
Amprenavir
Zanamivir
Oseltamivir
Lopinavir
Imatinib
Erlotinib
Ximelogatran
Raltegravir

2000
2003
2004
20042
2007

1. Nearly all of the 10 marketed HIV protease inhibitors were developed using Structure-Based
Computational Techniques.
2. Ximelogatran was only approved in Europe and subsequently withdrawn for high incidence of liver
toxicity.
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large role in their development. The compounds listed in the table were discovered
and/or developed using a variety of the techniques listed above. Captopril, for example,
was developed using rational drug design techniques where a homology model of the
drug target, angiotensin converting enzyme (ACE), was built using the available x-ray
structure of carboxypeptidase A, whose active site was hypothesized to be similar to
ACE.2,3 The HIV protease inhibitors and the neuraminidase inhibitors, used for HIV and
influenza infections, respectively, were discovered (and are still being discovered) using
molecular modeling and visualization techniques that utilize the solved x-ray crystal
structures of their respective target enzymes.4,5 The newly developed HIV integrase
inhibitor, raltegravir, was discovered using a type of virtual screening known as
pharmacophore searching, which will be discussed below.6 Ligand-based 3D-QSAR
methods were applied in the discovery efforts that led to the development of donepezil
as a potent inhibitor of acetylcholinesterase for the treatment of Alzheimer’s disease.7
Finally, the kinase inhibitors imatinib and erlotinib were identified using molecular
docking as the lead identification tool.8,9 In addition to currently marketed agents, there
are a large number of drug candidates in clinical trials that have been or are being
investigated using computational methods; including muscarinic antagonists,
somatostatin and growth hormone analogs, urotensin II antagonists, and other GPCR
binding agents.10 It is obvious that computational methods can make a large
contribution to drug discovery efforts, and that as computational power continues to
increase and technology advances, the role of computers in drug discovery will also
continue to expand. Although there are a number of ways that computers can aid drugdesign projects (as described above), the work discussed herein utilized two main
computational approaches which will be described below: virtual screening and
molecular simulations.

1.2 Virtual Screening for Lead Identification
Virtual screening (VS), as it applies to drug discovery, can be defined as the use
of computational methods to discover novel compounds with activity against biological
targets. It is primarily employed as a lead identification technique and has gained
considerable acceptance in recent years. This compares with the traditional lead
identification method of high-throughput screening (HTS), where test compounds are
physically screened against the biological target at a standard concentration, usually 10
μM, using a specialized enzyme or receptor assay. Virtual screening has been shown to
be a complementary tool to HTS.11 It has several advantages over HTS as a lead
identification method: First, the number of compounds that can be screened within a
reasonable amount of time is much greater than HTS, on the order of 1015 versus 106
compounds with HTS. Second, because only those compounds with predicted activity
against the biological target are actually tested in vitro, the cost of performing a virtual
screen is considerably less than that associated with HTS. Third, compounds can be
built into virtual libraries for screening that have not yet been synthesized, saving the
considerable time and expense of building a screening library for high-throughput
screening. Finally, because VS yields a the smaller number of compounds that are
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actually tested in vitro, the hit rates from virtual screening can be 2 to 3 orders of
magnitude greater than those normally seen with HTS.11 Virtual screening is not without
its disadvantages, however.12 It is considered an information rich method and in many
cases requires structural knowledge of the target or some existing knowledge of active
compounds, neither of which may be available. Although steadily improving in predictive
ability, speed, and accuracy, the computational algorithms employed in virtual screening
are still limited by inaccurate activity predictions. Additionally, virtual screening requires
expert users to work with the programs and algorithms as well as to build and maintain
the virtual compound libraries that are to be screened. Finally, in some cases the ‘hit’
compounds from virtual screening may not be synthetically feasible. Although HTS has
advantages over VS in the areas listed above, it also is not without its disadvantages,
including high cost, lower number of compounds that can be screened and lack of
structural binding information for ‘hit’ compounds. Additionally, high-throughput screens
can be troubled by frequent-hitting, false positive compounds that must be identified and
eliminated.13,14 Interestingly, studies comparing HTS and VS side by side have shown
that although VS can be expected to produce higher hit rates, the hits produced are
often different that those confirmed hits from the corresponding high-throughput
screens.11,15 This may imply that rather than acting as competing methods of lead
identification, high-throughput screening and virtual screening should be considered
complementary methods and used together to identify and test promising leads.
Although there are numerous methods for performing a virtual screen, they can
be roughly classified into two main types: ligand-based approaches which do not utilize
the structure of the biological target in screening, and docking-based approaches, which
utilize the structure of the biological target, usually obtained by NMR or x-ray methods,
and a variety of molecular docking algorithms and scoring functions. Hybrid approaches
which combine aspects from ligand-based and docking-based methods are also
frequently employed in virtual screening studies.
1.2.1 Ligand-Based Approaches
Ligand-based approaches typically utilize knowledge of a set of compounds with
known activity against the biological target. These approaches are frequently employed
in the absence of structural information on the target in question and in addition to lead
identification, can also be used as a lead modification strategy. The key concept in
ligand based approaches is that compounds that are structurally similar or have similar
structural components to the known active compounds are more likely to have activity
themselves. A variety of ligand-based screening methods have been developed that
are being used with increasing frequency, such as substructure searching, similarity
searching, pharmacophore searching, clustering methods, and finally QSAR and 3DQSAR methods. Each of these methods is similar in that they utilize the structural
features of known active compounds, but they differ in their computational requirements,
search algorithm, and the features of the hits compounds they return. Interestingly,
several of the methods discussed below have been successfully used in ‘lead-hopping’
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or ‘scaffold-hopping’ studies, which reflect the ability of ligand-based approaches to
identify lead compounds outside the structural class of the known active compounds
upon which the screen was based.16-22 The methods listed above can also be classified
by whether they employ 2-dimensional (2D) or 3-dimensional (3D) methods for
searching the virtual compound databases. 2D methods utilize the chemical structure of
the active compounds, whereas 3D methods incorporate the 3-dimensional shape of the
active compounds in addition to the chemical structure and/or structural features. 3D
methods make assumptions as to the binding conformation of the known active
compounds.
Substructure searching is a relatively simple screening method that performs a
search of a compound database to match a specified structural feature, i.e. functional
group, ring system, etc. Typically, in compound databases, the structural features are
represented by searchable bitstrings, or binary representations. Two types of bitstrings
are commonly used, structural keys and hashed fingerprints. In a structural key, every
position in the bitstring represents a particular structure. The structural key utilizes a
fragment dictionary and assigns a 0 if the structure is absent from the compound and a 1
if the structure is present. Structural keys are easily and quickly searched but require
the added structure library and recalculation of bitstrings when compounds are added to
the compound database with new structures. A hashed fingerprint bitstring does not use
a fragment dictionary; instead an algorithm is employed to assign bits to specify given
structural patterns in a compound. All possible linear paths of atom connectivity are
calculated up to a predefined number of atoms (typically 8) and bits are assigned to
represent each path. Each pattern may require several bits to be represented. For
example glyceraldehyde, shown in Figure 1.1, contains the following paths of length 4:
O-C-C-O, O-C-C-C, O-C-C=O, and C-C-C=O. Each pattern (or path) would be assigned
a unique, searchable set of bits which are each set to a value of 1. A given compound
can be represented by bitstrings of up to several thousand bits after all atom paths have
been calculated.
While substructure searching is a useful and quick method of searching a
compound library for 2D features, it does not take into account 3-dimensional
conformations of the compounds or physicochemical properties of the atoms or
functional groups being searched. Pharmacophore searching can be considered a
special type of 3D substructure searching that in addition to the 3D conformations, can
also take into account functional group features such as polarity, hydrogen bond
potential, aromaticity, and hydrophobicity. An added advantage to pharmacophore

Figure 1.1. Glyceraldehyde with Hydrogens Suppressed

4

searching is that, unlike 2D substructure searching, this method can identify lead
compounds that are structurally dissimilar to those already known, a process known as
‘scaffold-hopping’ or ‘lead-hopping’. In pharmacophore searching, a set of features
common to the known active compounds is identified and used for the search criteria. A
3D pharmacophore search can include structural fingerprints, 3D spatial constraints and
‘macros’ which define the physicochemical properties for substructures (H-bond donor or
acceptor, hydrophobic, etc.). Figure 1.2 shows an example of a defined 3D
pharmacophore search using a DHPS product analog. Three key features have been
defined: an aromatic center, a hydrogen bond acceptor, and a hydrogen bond donor
atom. In order to match these criteria, a searched compound must not only contain the
three features specified, but also in the correct 3D alignment. In addition to searching
3D space, some advanced search algorithms are even able to modify torsional angles of
compounds being searched to test whether the compound can adopt the specified
pharmacophore alignment, a process commonly called flexible searching. It is also
common to use constraints to limit the number of compounds being searched and
reduce computational expense. Constraints can include simple drug-like criteria such as
Lipinski or Veber rules for molecular weight, numbers of rotatable bonds, and other key
features.23,24 They can also incorporate known structural information of the biological
target’s active site, if any is known, in the form of exclusion spheres or a molecular
surface, both of which create barriers the compounds being searched are not permitted
to encroach.
Similarity searching is another popular method of identifying compounds with
similar structural features to the known active compounds. It differs from substructure
searching and pharmacophore searching in that there is no precise query that the
molecule being searched can match. This search technique involves calculating and
comparing similarity coefficients between the known active compound and the
compounds being screened. The similarity coefficients can be based upon any number
of molecular descriptors. The compounds which score the highest in the similarity
search are considered the hit compounds and theoretically would be tested for biological
activity. Some common molecular descriptors that have been used in similarity
searches include molecular weight; hashed fingerprints and structural keys; counts of
atoms, rings, or other features; octanol/water partition coefficient; molar refractivity;
molecular connectivity (χ) indices; shape (κ) indices; electrotopological indices; atom
pairs and topological torsions; dipole moment; molecular volume, surface area, or polar
surface area; quantum chemical descriptors (HOMO, LUMO, energies, etc.); partial
atomic charge and polarizability; pharmacophore keys; and geometric atom pairs,
torsions, and angles.25 After the appropriate molecular descriptors have been calculated
for the compounds of interest, similarity coefficients are calculated to make the
comparison. These coefficients can be calculated using one of several different
methods, with probably the most common being the Dice coefficient, the Cosine
coefficient, and the Tanimoto coeffiecient.25 The Tanimoto coefficient is commonly used
for binary data (structural keys, fingerprints, etc.) and the formula is given below in
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Figure 1.2. A Ligand-Based 3D Pharmacophore Search
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Equations 1.1 and 1.2 for continuous variables and binary variables, respectively.
Similarity can be calculated based on 2D as well as 3D descriptors. Similarity
measurements using 2D descriptors will generally associate molecules with similar
substructures, while those using 3D descriptors are able to account for 3D
pharmacophore and molecular recognition and binding. The advantage of using 3D
descriptors, therefore, is the increased potential for locating active compounds with
unique scaffolds.

∑

∑
∑

Equation 1.1

∑

Equation 1.2
Occasionally it may be desirable to select a set of diverse compounds from a
library for screening. This is often done in order to decrease the number of compounds
being tested while still sampling the maximum diversity of the screening library. In this
case, a method known as cluster analysis or clustering can be very helpful. Clustering
utilizes essentially the same methods as similarity searching, with the exception that
compounds are selected based upon dissimilarity. In a cluster analysis, groups of similar
compounds (clusters or bins) are created from which representative compounds can be
selected. There are a number of clustering methods in popular use today, the most
common being Jarvis-Patrick clustering and Hierarchical clustering.26,27 Hierarchical
clustering seems to have outperformed Jarvis-Patrick clustering in terms of predicting
property values and activity by cluster placement in two recent studies and of the two, is
the more popular clustering method.28,29 Other methods for selecting dissimilar
compounds include dissimilarity-based methods and partition-based methods. Because
neither of these methods were utilized in the work described here, we will not expand on
them further.
The last and probably most frequently utilized ligand-based method that will be
discussed is the quantitative structure-activity relationship, QSAR. QSAR techniques
are methods used to correlate physicochemical descriptors from a set of related
compounds to their known molecular activity or molecular property values. QSAR
models can be very useful in predicting the activity of compounds which have not been
tested in vitro and are frequently used in virtual screening to identify lead compounds as
well as to prioritize synthetic efforts. The first QSAR studies are usually attributed to
Hansch and coworkers, who correlated biological activity of a series of compounds with
their hydrophobic and electrostatic properties.30 There are a variety of descriptors that
have been used to develop QSAR models, many of which were listed above in the
similarity searching discussion. They can range from connectivity and shape descriptors
to molecular descriptors for lipophilicity (cLogP and LogD)31,32, steric bulk (Molar
Refractivity, volume)33, and electrostatics (polar surface area, Coulombic charges, dipole
moments).34
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In addition to 2D and global molecular descriptors, QSAR models can be built
using 3-dimensional molecular descriptors. Most 3D-QSAR models require the
alignment of the active compounds into a known or theoretical binding conformation.
There are several different methods that are used for the calculation of 3D descriptors,
the most common being comparative molecular field analysis (CoMFA)35 and
comparative molecular similarity indices analysis (CoMSIA).36 CoMFA involves the
calculation of steric and electrostatic values using charged probe atoms at grid lattice
points while CoMSIA utilizes 3-D similarity indices. Other methods used to calculate 3D
descriptors include comparative molecular moments analysis (CoMMA),37 a molecular
vibration-based method (EVA),38 weighted holistic invariant molecular indices (WHIM),39
and hypothetical active site lattice (HASL).40 3D-QSAR methods have an advantage
over traditional QSAR in that they can provide information regarding the nature of the
biological target’s active site, in terms of favorable binding regions and characteristics,
which can be very useful to the drug design efforts.
Once the QSAR descriptors have been calculated, the QSAR equation is derived
using a regression tool that is applicable to the data being utilized. The independent
variables (descriptors) are used to derive the equation that predicts the dependent
variable (activity or property). For 2D QSAR models a simple linear regression or
multiple linear regression (MLR), if there are several independent variables, is usually
sufficient. MLR cannot be used for 3D-QSAR models where there the number of
independent variables greatly exceeds the number of dependent variables (i.e. the
number of compounds in the training set). In these cases, one of two methods are
commonly used, principal components regression (PCR) or partial least squares (PLS).41
In PCR the independent variables are subjected to a principal components analysis,
after which a regression is performed using the first (usually 2 or 3) principal
components. Validation methods (described below) can help the model developer
determine the appropriate number of components to use in the final model. PLS uses
linear combinations of the independent variables to describe the dependent variable. A
sample PLS equation follows:
…

Equation 1.3

where y is the dependent variable, bm is a calculated coefficient, and
Equation 1.4
The latent variables (or components) in a PLS analysis are the t values, calculated by
linear combination of the independent variables (x). PLS is different from PCR in that it
can explain variations not only in the dependent variables, y, but also variation in the
independent variables. The number of latent variables used in the final QSAR model is
again determined by a variety of validation methods. Other methods for deriving QSAR
equations include discriminant analysis, neural networks, and inductive logic
programming.42,43
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Once a QSAR model has been built, it must be validated prior to use by a variety
of internal and external validation methods. The goodness of fit of the QSAR equation is
usually given by the multiple correlation coefficient, r2, when deriving the equations.
Values close to unity are desirable and indicate a high degree of internal validity. The F
statistic and Standard Errors of Estimate (SEE) are also commonly used to validate the
goodness of fit. Cross-validation methods include the commonly used Leave-One-Out
(LOO) and Leave-Group-Out (LGO) methods. In cross-validation, one or more of the
training compounds (known actives used to derive the QSAR model) are left out during
model derivation and then the model derived is used to predict the activity of the
compound or compounds left out. This process is normally repeated many times and a
mean q2 (cross-validated r2) value is determined. The q2 value is a measure of
goodness of prediction of the QSAR model derived. Cross-validation is considered in
internal validation because it used training set compounds to generate the q2 value. One
of the most rigorous methods for validating QSAR models is known as external
validation, or test set validation, where compounds with known activity that were not
used in creation of the QSAR model are used for activity predictions and r2 values are
derived from these predictions. Finally, bootstrapping is a method that can be used to
obtain confidence intervals for the r2 and SEE values.
1.2.2 Docking-Based Approaches
Knowledge of the biological target’s structure, in particular the targeted binding
site, is most desirable from a drug discovery perspective because direct knowledge of
ligand binding interactions can be utilized in drug design efforts; a procedure that has
come to be called ‘Rational Drug Design’ or ‘Structure-Based Drug Design’ (SBDD).
Target structures are usually obtained by solving an x-ray crystal or NMR structure,
although homology modeling methods are also sometimes employed. There are a
variety of SBDD methods that can be used, the most common being de novo design and
molecular docking.
De novo design uses the 3-dimensional structure of the target’s active site to
guide the placement and linking of molecular fragments obtained from fragment
databases. There are two general methods of de novo design. In the first compounds
are selected based on observed or theoretically favored binding groups determined by
active site analysis, built and then placed into the active site for binding energy
calculation. In the second, the fragments are placed and linked directly in the active site
using build and grow strategies. Theoretically, de novo design will yield novel, active
compounds which are not already present in corporate or commercial databases.
Molecular docking is a specialized form of virtual screening in which compounds
are placed in the active site using a variety of search algorithms and then binding affinity
is estimated using one of a number of different types of scoring functions. Requirements
for molecular docking include a 3D representation of the active site, a library of
compounds in a recognized electronic format, and a validated docking algorithm and
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scoring function. Following docking and scoring, high scoring compounds are usually
selected for testing in an in vitro binding assay. In recent years, molecular docking has
become a very common method of virtual screening due to the exponential increase in
searchable 3D structures of biological targets and improvements in computational power
and technology. Figure 1.3 shows the dramatic rise in protein structures that are
available at the Protein Data Bank over the last 20 years.44 In 2007, there were over
800 articles published relating to molecular docking studies.45 The most common
docking programs in use today are shown in Figure 1.4.46-65 The percentage of citations
is shown for the most common programs (over 5 citations), determined by SCOPUS66
search considering the original references and limited to articles in 2007.
Molecular docking involves two main processes: pose prediction and scoring. In
pose prediction a search algorithm determines an optimal conformation and orientation
for a given compound in the receptor, or active site. This is followed by scoring to
determine whether the pose will be accepted or rejected. Generally, docking algorithms
use scoring in two ways, the first is for pose selection and often uses a more simplified
and rapid scoring method. The second use of scoring is when the final selected poses
for all the compounds tested are scored for ranking purposes. This is often performed
by a more advanced scoring function and may be computationally more intense than the
pose selection scoring. Historically, there are two general types of molecular docking:
rigid body docking, where the compounds are placed into the active site “as is” so to
speak, normally in a minimum energy conformation; and flexible docking, which test
multiple conformations of the compounds being docked. Although flexible docking is
computationally more expensive, the results generated are much more accurate and this
method has become the preferred method of performing molecular docking.
There are three main types of flexible ligand docking algorithms that are currently
is use: systematic docking algorithms, random or stochastic algorithms, and simulation
methods.67 Table 1.2 gives a breakdown of these search methods and some
representative examples of programs employing these methods. Systematic search
algorithms attempt to explore all the degrees of freedom of the compounds being
docked, and normally utilize one of three methods: conformational searching,
fragmentation, or database methods. In conformational searching, all degrees of
freedom of the compound being analyzed are explored by systematically modifying
torsion angles of rotatable bonds in the compound by predefined increments. This
method is very computationally expensive and is therefore rarely used. Fragmentation is
probably the most popular form of flexible docking. This method breaks the compound
being docked into fragments and then joins them in the active site, recreating the ligand
in an energetically preferred conformation. This procedure has been called the “placeand-join” method. Alternatively, a ‘core’ fragment can be initially docked and then
flexible sections added incrementally. This is called an “incremental construction”
method. Database methods are the third type of systematic docking algorithm. In this
approach, conformation libraries (or ensembles) are generated for each compound
being docked and then rigidly docked.
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Figure 1.3. Yearly Protein Data Bank Content Growth44
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Figure 1.4. Docking Programs by 2007 Citation
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Table 1.2. Flexible Docking Methods and Examples
Methods

Representative Examples

Systematic Docking Algorithms
Conformational Search
Fragmentation
Database Methods

LUDI,62 FlexX,52 DOCK,49 ADAM,68 Surflex65
FLOG53

Random/Stochastic Algorithms
Monte Carlo Methods
Genetic (Evolutionary)
Algorithms
Tabu Searching

PRO_LEADS63

Simulation (Deterministic) Algorithms
Molecular Dynamics
Minimization Techniques

Amber,72 CHARMM,73 NAMD,74 GROMACS75
Fletcher-Reeves, Newton-Raphson, Marquardt

ProDock,69 ICM,59 MCDOCK,70 QXP64
GOLD,57 AutoDock,46 DIVALI,71 DARWIN48
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Random or stochastic search algorithms generate random ligand conformations
(or random conformational changes), which are then docked and scored and accepted
or rejected based upon predefined criteria. Random methods have an advantage over
deterministic methods in that energy barriers can be bypassed, which can allow for a
more complete search of conformational space. The three most popular random
methods are Monte Carlo methods, Genetic Algorithms, and Tabu Searching. The
criterion for accepting or rejecting poses generated in the Monte Carlo method is based
on a Boltzmann probability function. Genetic algorithms utilize evolutionary techniques
to generate successive “generations” of compound poses. Ligand conformations and
orientations are defined by a set of variables (genes) and genetic operations perform a
series of mutations, crossovers, and migrations to generate new generations which are
accepted or rejected based upon a predefined fitness function. Successive generations
are optimized until a final generation is determined. Tabu search methods force the
search algorithm in new directions by imposing restrictions that prevent searching areas
of conformational space that have already been explored. The acceptance or rejection
of new poses generated is determined by RMSD calculations with a library of poses
already generated.
The last main type of flexible docking is the simulation methods, which include
molecular dynamics and minimization techniques. Molecular Dynamics (MD) methods
work by integrating Newton’s laws of motion to produce a trajectory that simulates how
the system in question, in this case a ligand bound into an active site of a target
biomolecule, behave over time. Dynamics methods can be very computationally
expensive, but they have an advantage over many of the methods discussed above in
that protein flexibility and induced fit can be taken into account. Molecular Dynamics will
be discussed in detail below as it applies to simulating protein movements and dynamic
structure. When MD is applied to molecular docking, typically the target macromolecule,
with the possible exception of active site residues and flexible loops near the active site,
is held rigid to minimize the computational expense.
The last type of search algorithm that will be discussed is energy minimization.
These technique involve modifying the structure of the ligand bound in the active site to
minimize the binding energy, as calculated by a variety of methods including direct
searches (simplex), gradient (steepest descent), conjugate-gradient, second-derivative,
and least squares methods.76 Minimization can typically find local energy minima very
well, but are not able to overcome barriers to locate global minima. These techniques
also have difficulty in cases, not so uncommon, that the ligand binds to the active site in
a high energy state. Minimization techniques are rarely uses as stand-alone docking
methods, but they are often incorporated with other search methods in multi-step
docking algorithms, for example the program Glide, which utilizes Monte Carlo and
Minimization methods.56
Once poses are selected, scoring functions are utilized to rank the compounds
by their predicted affinity for the target site. Table 1.3 lists several of the common types
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Table 1.3. Scoring Methods and Examples
Methods

Representative Examples

Force-Field Based Functions

D-Score,77 G-Score,77 GoldScore,78 AutoDock 3.046

Empirical Scoring Functions

LUDI,79 F-Score,52 ChemScore,80 Fresno81

Knowledge-Based Functions

PMF-Score,82 DrugScore,83 SMoG-Score84

Consensus Functions

Cscore,85 X-Cscore86

Solvation-Based Functions

HYDREN,87 GB/SA,88 SEED,89 ZAP,90 PB/SA91

of scoring functions utilized in molecular docking, along with some representative
examples of each type. Scoring functions can be generally classified into three main
types: force-field based, empirical, and knowledge-based. Additionally, consensus
scoring which involves combinations of scores from different functions and solvation
scoring which, as the name implies, takes solvation/desolvation into account when
generating a score.
Force fields (which are also called molecular mechanics) can be considered
functions which calculate the energy of a system as a function of atomic positions.
Force fields ignore electronic effects and typically contain bonded terms for bond
stretching, angle bending, and torsion rotation and non-bonded terms for van der Waals
and electrostatic interactions. Force fields and their energy terms will be described in
more detail in the molecular simulations section below. Force field based scoring
functions typically generate a score based upon two calculated energy values: the
internal energy of the ligand and the interaction energy between the ligand and the
receptor. Traditionally, force fields ignore entropic and solvation effects, which can be
considered a limitation.
Empirical scoring functions are designed and trained using experimental binding
energies that have been calculated from known ligand-receptor complexes. They can
consist of a variety of energy terms which use coefficients determined by regression
analysis of the training set binding energies. An advantage of empirical scoring
functions is their ease of low computational requirement. Disadvantages include the
requirement on a experimental training set and the non-transferability of the energy
terms due to the parameterization process. Knowledge-based scoring functions are
designed to reproduce experimental binding conformations, in contrast to empirical
functions which are trained to reproduce binding energies. They generally use simple
atomic interaction-pair potentials which are based on their frequency of occurrence in
the training set ligand-receptor complexes used.
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As mentioned above, consensus scoring combines information from several
scoring functions to generate a consensus score.85,92 The use of consensus scoring can
theoretically compensate for errors in a single scoring function and improve the
likelihood of identifying a correct pose. The disadvantage to consensus scoring is that
systematic scoring errors can be compounded when scoring functions are correlated
and this can lead to amplification of error rather than error compensation.
Many advanced scoring functions include terms that can take into account
entropic and solvation/desolvation effects, both of which have been traditionally ignored
in early generation scoring functions. Penalty functions that take into account the
number of rotatable bonds in a compound being docked are a simple means of taking
into account entropic effects. For example, the ChemScore function contains an explicit
energy term for rotational energy that is intended to, in part, account for entropic effects.
The effects of solvation can be accounted for in several different ways, with varying
degrees of computational intensity.93 One method that is used in force field scoring
functions is the modification of the dielectric constant in the electrostatic energy term to
account for the effects of solvation. Additional H-bonding terms can also be used to
account for donor-water and acceptor-water effects. Buried polar and ligand desolvation
energy terms have been used with success in some in empirical scoring functions, for
example Fresno.81 A more computationally expensive method is the use of a
generalized-Born/surface area (GB/SA) approach, which has been successfully
employed with the DOCK program.88 Finally, a very rigorous and very computationally
expensive method, Poisson-Boltzmann surface area (PB/SA) solvation scoring, has
been reported.93
As previously mentioned, most of the search algorithms (docking programs)
discussed above treat the receptor into which the compounds are being docked as a
rigid body. This is one of the caveats of molecular docking studies; they do not take
induced fit of the macromolecule into account. Although they are usually more
computationally intense, there are a number of approaches that have been utilized in
recent year to account, in some manner, for protein flexibility in docking including:
molecular dynamics, Monte Carlo methods, rotamer libraries, protein ensembles, and
soft receptor modeling. With the molecular dynamics and Monte Carlo methods, flexible
regions of the protein can be defined for the docking runs. Unfortunately the time
needed to dock a ligand will increase exponentially as the amount of flexible region is
expanded, up to several days in some cases of fully flexible targets.94 Alternatively,
using rotamer libraries for side chains can represent some protein flexibility and induced
fit, usually in the active site, and is less time-consuming.95 This method, however, does
not account for large protein movements. Another method is the use of an ensemble of
protein conformations, calculated by a variety of methods, into each of which is docked
the compounds in the screening library. This multiplies the docking time required by the
number of protein conformations in the ensemble but is significantly less time consuming
than the more rigorous dynamics and Monte Carlo methods. FlexE, derived from the
FlexX docking program, is a popular ensemble method.51 Finally, the soft receptor
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modeling technique combines different protein conformations into one “weighted
average” that is used for ligand docking.96,97 This typically leads to enlargement of the
active site as mutually exclusive binding areas are simultaneously considered, which can
be considered a disadvantage. Additionally, soft receptor modeling, like rotamer
libraries, cannot account for large scale protein movements.
Although we have separated virtual screening into ligand-based and dockingbased methods, it should be noted that large scale virtual screening projects can
incorporate aspects of both. For example, in order to decrease the time required to
screen a large library of compounds, ligand-based methods such as pharmacophore
searching can be utilized as filters prior to high-throughput docking. Alternatively, ligandbased methods can be used to post-process docking output in order to decrease the
number of compounds requiring in vitro testing. An example would be applying
clustering methods to docking output to select a diverse set of compounds for testing.
An example of such a hybrid virtual screening workflow is shown in Figure 1.5. Virtual
screening steps are listed with descriptions that include the computational intensity at
each step as well as the number of screening compounds that can be handled at each
stage in a reasonable amount of time; in this case the entire procedure can be
completed in approximately one to two weeks for a screening library that initially
numbers in the millions.
1.2.3 Compound Selection for Virtual Screening
The discussion on virtual screening is not complete without mention of selection
processing of compounds prior to screening. The creation of a virtual screening library
is a multistep process that must take into account many factors including the nature of
the screening target, the desired physicochemical properties of the screening library, the
time available for virtual screening, and even the type of experimental assay that will be
used to test hit compounds.98 The steps involved and considerations necessary at each
step are described below.
The first step is identifying the compounds to be placed in the virtual screening
library. Typically corporate or commercial libraries are screened, but the compounds
can also be created in silico using a variety of virtual library enumeration protocols.
Usually, one starts with 2D structural files, sdf or SMILES formats are most common.
Once the compound files are obtained they must be analyzed and cleaned. Compounds
represented in salt forms must be corrected and the salts removed, this is commonly
known as desalting and a variety of algorithms are available to accomplish this. Filters
can be applied at this step as well to remove unwanted compounds containing such
features as reactive functional groups, unstable or hydrolizable groups, and cytotoxic
groups. Figure 1.6 shows several examples of such undesirable compounds.
Additionally, broken or incomplete structures as well as structures containing metals are
often removed at this step. Finally, depending on the nature of the desired screening
library, methods can be applied to filter the screening library for diversity or to build a
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Figure 1.5. A Docking-Based Virtual Screening Workflow
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Figure 1.6. Characteristic Undesirable Functional Groups in Virtual Screening
Compounds
Modified with permission from Rishton, G. M. Reactive compounds and in vitro false
positives in HTS. Drug Discov Today 1997, 2, 382-384.13
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focused library retaining only compounds similar to known actives or containing key
pharmacophoric features. Screening libraries can also be filtered using lead-like or
drug-like filters including molecular weight, rotatable bond counts, ring counts, halogen
counts, and h-bond donor and acceptor counts.
The next step is the generation of 3-dimensional structures from the 2D structural
files. There are a variety of tools available to the molecular modeler for the generation of
3D structures from 2D structure files.54,99,100 The two most common programs are
Concord and Corina.101,102 At this step the modeler must make choices regarding
generating multiple conformations per compound, generating conformations for multiple
tautomeric states, expanding compounds to account for chiral centers and taking into
account protonation/deprotonation at specific pH ranges. These decisions will be based
on the type of virtual screen that is to be performed as well as the computational
resources available to the modeler. Depending on the detail of the 3D library that is
desired, this step can result in an exponential explosion in the number of screening
compounds in the virtual screening library.
Following 3D structure generation, the last step is normally loading partial atomic
charges on the compounds. The size of the library will normally determine the type of
charge calculation method that the modeler will choose to accomplish the procedure.
The most accurate method would be to use quantum mechanical methods for charge
calculation, unfortunately this very computationally expensive and is usually too timeconsuming, even for small libraries. For smaller screening libraries, semi-empirical
methods such as the PM3 method available in the MOPAC suite would be the most
accurate; however this method can also be time consuming taking several seconds to
minutes for a compound, depending on the size and complexity of the compound.103 A
variety of rules-based methods calculate charges based upon atom types, bonding and
free valences and are very quick and easily implemented for very large virtual screening
libraries. The disadvantage being that they do not utilize electronic calculations for
calculating the atomic charges and for compounds with complex electronic systems (pi
delocalization, internal h-bonding, strong electron donating or withdrawing functional
groups), the atomic charges generated can be less than reliable. Some commonly used
rules-based charge calculation methods are Del Re charges,104 Gasteiger/Marsili
charges,105 Hϋckel charges,106 Pullman charges,107 and MMFF charges.108 Once the
libraries have been generated and the charges loaded, they are typically saved in a
commonly used molecular file format for virtual screening, usually 3D sdf or multi-mol2
files.
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1.3 Molecular Simulation Methods
1.3.1 Introduction to Simulation Methods
Molecular simulations are a way to visualize a system by generating successive
configurations of the system. There are several advantages of using simulation methods
in drug discovery and design. Biological systems, for example proteins, can be
simulated under special conditions such as solvated and at different temperatures and
pressures and with different substrates bound into the active site. This is beneficial in
that, while techniques such as x-ray crystallography can generate a snapshot of a
protein (or other macromolecule), the positions of mobile elements, such as flexible
loops, may remain unclear. It is possible to visualize these mobile elements with
simulations. Additionally, x-ray crystallography and NMR methods are often employed
under non-physiological conditions (temperature, pressure, pH, solvent, etc.), which can
affect their results in unpredictable ways. Simulations methods, although time
consuming and computationally expensive, can provide information to the molecular
modeler about how a biological system behaves over a certain time period, under
physiological conditions.
There are two main types of simulation methods that will be discussed here:
Molecular Dynamics (MD) and Monte Carlo (MC) simulations. With MD, the
configurations are produced by integrating Newton’s laws of motion, resulting in a
trajectory that specifies how the system behaves with time. In this “deterministic”
method, any future configuration of the system can be predicted from its current state by
calculating energy and velocity for the atoms in a system using very small time steps,
usually on the order of femtoseconds. The forces on the atoms are used with their
current positions and velocities to predict new positions and velocities for the next time
step. Over a given time period, a “trajectory” is generated that describes how the
system being studied changes over time. Time averages for thermodynamic properties
such as internal energy, heat capacity, pressure, and temperature can be calculated.
Monte Carlo simulations differ from dynamics in that the configurations are
generated using a random approach where each configuration depends only upon the
previous one. Special algorithms based upon Boltzmann statistics and random number
generators are utilized to determine whether each new configuration generated is
“accepted” or “rejected”. The Monte Carlo procedure is as follows: a new configuration is
generated by randomly moving atoms or residues and then calculating the energy of the
new configuration using a potential energy function. If the energy of the new
configuration is lower than the previous, the new configuration is accepted. If the energy
is higher than the previous then the ‘Boltzmann Factor’ of the energy difference is
calculated using the following equation:
⁄

Equation 1.5
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is the energy of the system calculated by the potential energy function, kB is
where
the Boltzmann Constant, and T is the temperature. The calculated Boltzmann factor is
then compared to a random number generated between 0 and 1 and if it is higher, the
configuration is accepted, if it is lower, the configuration is rejected. In the case of
rejections, the original configuration is then used again to generate a new configuration.
The use of Boltzmann statistics with a given potential energy function ensures that
configurations with lower energies are generated more frequently than higher energy
configurations. The result is an ensemble of configurations for which desired property
averages or positional averages can be calculated.
There are several key differences between dynamics methods and Monte Carlo
methods which should be pointed out. First, as mentioned above, dynamics are a
deterministic method which can provide information about a system which is timedependent. Because Monte Carlo methods are random, there is no temporal
relationship between the configurations generated. Second, MD methods include a
kinetic energy component when calculating the total system energy, where in MC
methods; the total system energy is calculated from a potential energy function. Finally,
MC methods have the ability to sample higher energy configurations which may play a
role in structure and function, but are harder to reach using MD methods. Because
Monte Carlo methods were not employed in the studies discussed herein, we will limit
our discussion below to MD approaches and practical considerations.
1.3.2 Molecular Force Fields and Parameterization
Molecular force fields, or molecular mechanics, are the backbone of molecular
dynamics simulations. Force fields, which were mentioned above in the docking-based
virtual screening section, are energy functions which are used to calculate energies of
molecular systems based only upon the atomic positions and do not take into account
electronic effects like quantum mechanics and semi-empirical methods. Because of this,
force fields cannot be used to describe molecular properties that depend upon electron
distribution, such as chemical reactions. Force fields describe the energy of a system
using a series of energy terms that can be generally classified as internal (bonded)
terms and external (non-bonded) terms. The energy of the system is the sum of all the
internal and external terms calculated for all atoms, bonds, and interactions in a given
system. Typical bonded energy terms in a simple force field include bond length (or
bond stretching), angle bending, and torsional rotation, while the non-bonded terms
include energy terms to describe electrostatic and van der Waals interactions, usually a
Coulomb potential term and a Lennard-Jones potential term, respectively. The
functional form for such a simple force field is given by the following equation:
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where the bonding term and the angle term are harmonic potentials that increase in
energy as the bond length, , and angle length, , vary from their reference values, ,
and , . The torsional term describes how the energy changes as the torsion angle
changes; is the measured torsion angle, is the multiplicity (number of minimum
energy points as the torsion angle rotates through 360°) and is the phase factor which
determines where the torsion angle passes through its minimum value. The force
and in these terms are specially derived (parameterized) so that the
constants,
force field is able to reproduce known experimental energy or property values when it is
being trained or designed. The last term is the non-bonded energy term which includes
the 12-6 Lennard-Jones potential for calculating van der Waals interactions and a
Coulomb potential for calculating electrostatic interactions.
Equation 1.6 is an example of a simplified force field with the minimum necessary
terms to calculate the energy of a system. As mentioned in the scoring section above
force fields can include additional terms to describe special types of energetic
contributions such as aromatic or pi stacking, H-bonding, solvation/desolvation, and
rotatable bond restrictions. Additionally, some advanced force fields can contain ‘cross
terms’ which account for coupling between different energy components, such as bond
stretching with angle bending, and stretching and bending with torsional changes. Force
fields can be categorized as either Class 1, 2, or 3 depending on the energy terms they
incorporate and the complexity of those terms. Simple force fields which contain only
harmonic terms and do not contain cross terms (such as the example shown in equation
1.6) are called Class 1 force fields. Class 2 force fields may include anharmonic terms
(Morse potentials or cubic and quartic energy term expansions) as well as cross terms
while Class 3 force fields take into account chemical effects such as hyperconjugation,
polarization, and electronegativity. Table 1.4 lists examples of several commonly used
force fields in small molecule and biomolecular modeling. Obviously, as the complexity
of the force field increases, so does the time required to complete energy calculations for
a system. For the purposes of molecular simulations, Class 1 force fields are typically
utilized due their speed when compared to Class 2 and Class 3 force fields. Class 2 and
Class 3 force fields are generally used only for performing calculations on small
molecules.
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Table 1.4. Types and Examples of Commonly Used Molecular Mechanics Force
Fields
Type of Force Field

Representative Examples

Class 1 (Classical)

Amber,109,110 CHARMM,111 OPLS,112,113
GROMOS,114

Class 2 (2nd Generation)

CFF,115 MMFF,108 MM2/MM3116-118

Class 3 (3rd Generation)

MM4119,120

An important part of force field modeling is the assignment of the atom type. In
quantum mechanical calculations, the atomic number, spin multiplicity, and overall
charge of the nuclei present must be provided as input in order to obtain meaningful
results. Although force fields don’t require electronic information on the system under
analysis, some information is still necessary on the types and number of atoms present.
Atom types can provide the force fields with information regarding element,
hybridization, ionization, and valence. Atom types can be very general or very specific,
depending on the nature and purpose of the force field. Table 1.5 gives some examples
of atom types with their descriptions from a general force field, the Tripos FF, and the
Amber7 FF. The table lists all carbon, nitrogen, and oxygen atom types for the Tripos
FF and only carbon atom types for Amber FF. It is readily apparent that the Tripos FF is
much less specific than the Amber FF with respect to the number of atom types
necessary to describe a system. This is because the Tripos FF is considered a general
purpose FF that can be used to describe a wide variety of molecular types, usually small
molecules, while the Amber FF has been designed and parameterized to specifically
deal with large biopolymers composed of amino acids or nucleic acids (i.e. proteins and
DNA).
Atom types play a key role in parameterization of force fields as each force field
parameter, as in the force constants described above, is expressed in terms of atom
types. For example, in the example given above, there would be reference bond
lengths, angles and torsions with corresponding force constants for each combination or
set of atom types, two atom types for bonds, three for angles, and 4 for torsions.
Parameterization is the process of developing the reference values and force constants
for a given force field. This can be a time consuming process, but it is very important as
the overall performance of the force field is dependent on the quality of its parameters.
Parameterization can be considered a two step process, the first is to identify and define
the reference values for each atom type defined in the force field and the second is the
assignment of the force constants to be used. Reference values are usually obtained in
one of two ways, from experimental data or from quantum mechanical calculations.
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Table 1.5. Example Atom Types from Tripos and Amber Force Fields
Tripos FF

Description

Amber7 FF

Description

C.3
C.2
C.1
C.ar

sp3 carbon
sp2 carbon
sp carbon
aromatic carbon

C
C*
CA
CB

N.3

sp3 nitrogen

CC

N.2
N.1

sp2 nitrogen
sp nitrogen

CD
CK

N.ar
N.pl3

aromatic nitrogen
trigonal planar
nitrogen

CM
CN

N.am

amide nitrogen

CQ

N.4

sp3 positively
charged nitrogen
sp3 oxygen
sp2 oxygen

CR

oxygen in
carboxylate
oxygen in SPC
water model
Oxygen in TIP3P
water model

CW
CY

any carbonyl sp2 C
sp2 aromatic C in 5-membered ring
any aromatic sp2 C
sp2 aromatic C at junction between
5- and 6-memberd rings
sp2 aromatic C in 5-membered ring
with 1 substituent and next to an N
sp2 C atom in C=CD-CD=C
sp2 aromatic C in 5-membered ring
between N and N-R
any sp2 C, double-bonded
sp2 aromatic junction C between 5and 6-membered rings, bonded to
CH and NH
sp2 C in 6-membered ring lone pair
Ns
sp2 aromatic C in 5-membered ring
between 2 Ns
any sp3 C
sp2 aromatic C in 5-membered ring
between 2 a C and lone pair N
sp2 aromatic C in 5-membered ring
bonded to a C and an N-H
nitrile C

CZ

sp C

O.3
O.2
O.co2
O.spc
O.t3p

CT
CV
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Once the reference values are obtained, the force constants are usually developed by
“fitting” the force field to experimental data, which can be thermodynamic properties of a
system, known binding energies, or other properties obtained from quantum mechanical
calculations. This involves stepwise modification of the force field parameters give
progressively better fits to the data being used. Thus, parameterization is an iterative
process. Fortunately, most of the available commercial or academic force fields have
been well parameterized for use against the systems they were developed. However, in
some cases the molecular modeler will have to develop and add parameters for
compounds, atom types, bond types, etc. that are not explicitly described in the force
field being used.
1.3.3 Molecular Dynamics Approaches and Practical Considerations
Setting up and running a molecular dynamics simulation is a complicated
process which requires many considerations, such as the initial configuration of the
system being studied, choice of force field and dynamics integration method, time length
of the simulation and time steps, type of ensemble and energy calculations, boundary
conditions, and solvation. Each consideration can influence the outcome of the
simulation as well as the computational expense and time requirements.
The initial configuration of the system is usually obtained from experimental data,
theoretical models, or a combination of both. For example, for a protein simulation, the
structure of the protein may have been obtained from x-ray crystallography, NMR, or
homology modeling. Atom types for the force field being used must be defined and
parameters developed if necessary. Partial atomic charges are loaded using one of the
methods described above. Finally, the systems are frequently minimized prior to running
dynamics to eliminate high energy interactions such as steric clash.
The force field (see above discussion) and the integration method are chosen
based upon the nature of the system, i.e. small molecule, DNA, protein, etc., and the
information desired from the simulation. Another consideration is how well the dynamics
program to be used can be parallelized. Parallelization is very important as large
biomolecular simulations must be run across multiple processors or on “clusters”
in order to be completed within a reasonable amount of time. Molecular Dynamics
packages available for commercial or academic use frequently incorporate their own
force field which has already been parameterized by the developers. Some commonly
used dynamics packages that include their own force fields are Amber, CHARMM, and
GROMACS.72,73,75 There are also a number of packages available for academic uses
that utilize other developed force fields. For example, LAMPPS121 is compatible with the
CHARMM, AMBER, OPLS, and GROMOS force fields; NAMD74 can be used with
CHARMM, AMBER, and OPLS; and GROMACS75 can be used with its native force field
GROMOS, CHARMM, or AMBER. There are a variety of integration methods currently
employed by dynamics software packages, including the Verlet algorithm,122 the ‘leapfrog’ algorithm,123 the velocity Verlet method,124 and Beeman’s algorithm.124 Factors that
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must be considered when choosing an integration method include computational effort
required, length of time steps required, energy conservation, and the ability of the
methods to deal with the ensemble method being used. The most widely employed
integration methods employed today are Verlet and velocity Verlet methods. The Amber
package employed in the Molecular Dynamics studies described in the next chapter
uses the velocity Verlet integration method by default.
Once the initial configuration of the system has been defined and the force field
and integration method (software package) selected, decisions must be made as to the
length of time and the time steps that will be required for the simulation. The length of
time will be determined by the nature of the system being studied, the process being
studied, and the computational resources available to the modeler. Currently, the time
length limitation for dynamics simulation is on the order of tens to hundreds of
nanoseconds, although microsecond simulations for smaller systems have been
reported. For example, protein folding, which occurs on a millisecond time scale, is not
currently observable using molecular dynamics methods, but small scale loop
movements and ligand binding can theoretically be observed on the nanosecond or low
microsecond time scales. The calculation time steps are another key consideration and
will depend on the integration method being used, the system studied, and the
computational resources available. Obviously, the smaller the time step chosen, the
more computational expensive will be the simulation and the resulting time required to
complete the simulation will increase. A standard recommendation is that the time step
chosen should be one-tenth the time of the shortest motion being studied. In
biomolecular systems this is usually the C-H bond vibration which occurs on a 10fs time
scale, thus 1fs time steps would typically be chosen. If C-H bonds are held constrained
during the simulation using a method known as the SHAKE algorithm, then this time step
can be doubled to 2fs.125
The next consideration is the type of ensemble to be studied and the types of
energy calculations that will be used. Molecular dynamics are traditionally performed
using the NVE or microcanonical ensemble, which holds constant the number of
particles (N), the volume (V) and the energy (E). Monte Carlo methods traditionally
utilize the NVT or canonical ensemble (constant N, V, and temperature, T). When
studying biomolecular systems, however, it is more practical to use the NTP, or
isothermal-isobaric ensemble, which holds constant the number of particles (N), the
temperature (T), and the pressure (P). This simulates physiological conditions more
closely than the other types of ensembles. Probably the most time consuming part of a
molecular dynamics simulation is the calculation of long range interactions and there are
a variety of methods for handling this. The use of distance cutoffs for energy
calculations is one popular way to address this problem. Cutoffs present a problem with
certain types long-range interactions, such as charge-charge interactions which can still
significantly contribute to the energy of the system beyond the standard cutoffs used in
most dynamics simulations. Special methods have been developed to address this
problem, including the Ewald summation, the reaction field method, and the cell multiple
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method. The Ewald summation method is probably the most popular, and a version
known as Particle-Mesh Ewald (PME) is currently deployed in the Amber simulations
package.126
Finally, boundary conditions and choice of solvation methods must be decided
upon. Because interactions at the boundaries of the system being studied (i.e. vacuum,
wall, etc.) can influence the energy calculations, the boundaries must be defined or
taken into account in some manner. For biomolecular simulations, the most common
way to do this is to employ periodic boundary conditions. Periodic boundaries involve
placing the system in a cell, typically a cubic box or other geometric shape, and then
surrounding the cell with mirror cells containing replicas of the system (26 cells for a
cubic box). The interactions energies can then be calculated across cell boundaries
overcoming the boundary effect and essentially enabling the simulation of a much larger
system. If a particle leaves one side of the cell, it subsequently enters from the other
side; this keeps the number of particles in the system being studied constant. One
caveat that must be mentioned here is that the cell size chosen must be large enough so
that the actual biomolecule being studied does not “see” itself and affect its own energy
calculations. Usually, it is desirable only for solvent molecules to cross the periodic
boundary.
This brings us to the final consideration, the choice of solvation method. There
are currently three different ways to take into account solvation: the first is to simulate
the system in vacuo using only a distance dependent dielectric screening term in the
force field to simulate the solvent screening effects on electrostatic charge calculations.
This method is the least rigorous, eliminates the need for periodic boundary conditions,
and is the fastest in terms of computational expense; however it is also the least reliable
and should be reserved only for simulations where solvent effects are not expected to
play a key role. The second method is to model solvation in a dynamics simulation is
known as ‘implicit solvation’, or continuum solvation. This method uses special energy
terms in the force field to represent the solvent as a continuous medium. Two commonly
used algorithms are used to approximate the solvent electrostatic effects: the PoissonBoltzmann equation, and the Generalized Born model, which is a linear approximation of
the Poisson-Boltzmann equation that is less computationally expensive. Both of these
equations are often combined with a hydrophobic solvent accessible surface area (SA)
term. Implicit solvation models, while more reliable than in simple dielectric terms, still
have limitations. Entropic effects are not accounted for in these models, which can be a
major factor in loop movements, ligand binding, and protein folding. The effect of
solvent viscosity on the motion of solutes is also not accounted for when using implicit
models, although in some cases this can be desirable. Finally, although H-bonding can
be generally accounted for with implicit solvation algorithms, the directionality of H-bonds
cannot. The final solvation method is known as explicit solvation. In this method the
solvent molecules are explicitly treated by surrounding the solute or biomolecule by
solvent molecules. This method is the most accurate but also the most computationally
expensive as all energy calculations must now include the many solvent molecules,
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typically on the order of 50,000 or more, needed to solvate the biomolecule. For
biomolecular simulations, there are several water models that have been designed for
use, the most commonly used is the TIP3P water model, a 3-site model where the water
is represented by a molecule with 3 interaction sites and a rigid shape.127 4, 5 and 6 site
models have been developed but they increase the computational expense of the
simulation and are rarely used except for simulations modeling water dynamics.
Once the molecular dynamics methods have been determined and the system
has been set up, the simulation can be run. A typical dynamics simulation of a
biomolecular system under explicit solvation is a multi-step process. An initial solvent
minimization is required, where the solvent is minimized while the solute is held under
constraint. This is followed by a solvent dynamics step, where the solvent (and any
counter ions added to balance the solute charge) are allowed to equilibrate; typically 10
to 100ps are sufficient. The next step would be allowing the entire system to minimize
while slowly loosening the constraints on the solute, or biomolecule. This is followed by
the dynamics simulation itself which occurs in two phases, an equilibrium phase and a
production phase. The equilibrium phase brings the system to equilibrium from the
starting configuration, often while raising the temperature slowly to the desired
simulation temperature. Equilibration is reached when the calculated average
temperature, pressure, and energies have stabilized. Finally, the production phase of
the simulation can begin, where the system is allowed to fully evolve for the desired time
period. Typically only data obtained from the production phase is used to calculate the
desired properties.

1.4 Contemporary Structure-Based Drug Design
Over the last decade, a number of new drug design techniques have emerged
that are gaining wide acceptance in industry and academia. This section will introduce
several contemporary design techniques that can be incorporated into a structure-based
drug design program, discuss methods involved with these techniques and examples of
their successful application. The focus of this section will be fragment-based drug
design with a brief introduction to click chemistry, tethering and dynamic combinatorial
diversity.
1.4.1 Principles of Fragment-Based Drug Design
In 1997, Lipinski et al. proposed the “Rule of Fives” for drug-likeness, solubility
and oral bioavailability.23 The model proposed that an ideal oral drug candidate should
have a molecular weight of no more than 500 Daltons, no more than 5 hydrogen bond
donors and 10 hydrogen bond acceptors, and a ClogP no greater than 5. This model
was readily adopted by both the pharmaceutical industry and academia and is
commonly used to filter corporate libraries and large compound collections prior to highthroughput screening. In fact, many drug companies have fashioned their corporate
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libraries to be in compliance with the Rule of Fives. However, a study published in 1999
by Teague, et al. which examined the lead compounds for a large number of
commercially available drugs demonstrated that the molecular weight, logP, rotatable
bonds, and hydrogen bond donor and acceptor counts were significantly lower than the
final marketed compounds.128 They concluded that the lead optimization process almost
always leads to more complex compounds, and advanced the concept of lead-likeness
versus drug-likeness. The authors went on to propose that screening programs should
focus on lead-like or fragment compounds rather than drug-like compounds.
Since that time, many other studies have been performed investigating the
concept of fragment-based screening, and many groups have reported the discovery of
novel compounds with low nanomolar potency utilizing this methodology.129 There are
now definite criteria for defining lead-like or fragment compounds, the most commonly
used being Congreve’s “Rule of Three” which states that most fragment hits have a
molecular weight of ≤ 300, ≤ 3 hydrogen bond acceptors, ≤ 3 hydrogen bond donors,
and have a ClogP of ≤3. Additionally, the rotatable bond count should be ≤ 3 and the
polar surface area should be ≤ 60 Å.128,130
There are several advantages to screening fragments over drug-like compounds,
the most notable being the likelihood that the lead optimization process will result in a
drug-like compound which has a greater chance of having good oral bioavailability and
favorable ADME properties. Compare this with the drug-like screening process, where
the optimization of a drug-like hit, which again is most likely to increase molecular size
and complexity, could very possibly result in a compound falling outside the desirable
range of physicochemical properties for an oral drug candidate. Additionally, because
fragments-based methods have the potential to sample higher chemical diversity, a
much smaller number of compounds are generally needed for fragment-based
screening, usually on the order of hundreds to a few thousand. This concept is best
explained using an example. Two fragment libraries each containing 1000 fragments
would contain 1,000,000 compounds when combined using a single linker. Screening
this number of compounds would be a significant undertaking. However, if one were to
test the fragments first, then take the 5 most active from each set and combine them in a
similar manner, the result would be only 2025 compounds that required testing (1000
fragments + 1000 fragments +25 linked compounds), a significantly easier undertaking,
while still covering the same chemical space. The advantage of fragment screening is
obvious when compared to a standard high-throughput screen that would involve
hundreds of thousands to millions of compounds.
Another advantage is that fragment-based screening can lead to higher hit rates.
This is because compounds of lower complexity have a greater chance of matching the
target receptor site.131 As the complexity of the compounds being screened increases,
the probability of binding (hit rate) decreases. Finally, dealing with fragments rather than
larger, drug-like compounds, is advantageous from a technical perspective in that data
management, compound acquisition, and synthesis are all simplified.
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1.4.2 Fragment-Based Drug Design Methods
As previously discussed, during the lead optimization process, a fragment hit of
low potency can be developed into a drug-like compound of very high potency. There
are several optimization techniques which have been used with success that deserve
special mention: fragment evolution, fragment linking, and fragment self-assembly. In
fragment evolution, additional functional groups are added to the fragment hit to optimize
binding and increase potency. This process is generally guided by X-ray or NMR
structural information. One requirement to using this optimization procedure is that the
original hit fragment must act as an ‘anchor’ and not alter its binding position during the
evolution process. This method is most useful for smaller active sites that can afford
multiple fragment binding sites.
If the targets active site can accommodate multiple fragment binding sites, then
the fragment linking optimization method can be employed. Fragment linking involves
the addition of a linking group (which may or may not form receptor site binding
interactions of its own) to join two fragment hits that bind into two separate sites on the
target receptor. This linking frequently results in compounds whose potency is much
greater than that of the two starting fragments, mostly due to entropic considerations.
The key point here is that the expected free energy of binding of the linked molecule is
greater than the sum of the binding energy of the two individual fragments. This is
because with the two separate fragments, there are two entropic penalties to binding,
whereas only one with the linked compound. One important consideration when using
the fragment linking method is that the two fragments must remain in their original
binding positions after being linked. This factor can determine the choice of linking
group to be used.
Fragment self-assembly involves the use of chemically reactive fragments that
are able to bind into the active site and react with each other, forming a larger inhibitor.
The active site acts as a template for the reactive compounds, aligning them for their
reaction and filtering out fragments not able to match the active site characteristics.132
This is an example of “click chemistry” as it applies to fragment-based design.
1.4.3 Fragment Activity and Binding Analysis
Fragment-based screening is not without its disadvantages. Because of the
lower molecular weight and complexity of the fragment compounds, they are expected to
be less potent than a drug-like compound. This means that specialized screening
methods need to be employed to identify hit compounds. Several methods have been
used with success, including high concentration screening,133 X-ray crystallographic
screening,134 NMR screening135, affinity detection by mass spectrometry136, surface
plasmon resonance137, and isothermal titration calorimetry (ITC).138 It should be noted
that although the fragment hits typically show a much lower potency, often high
micromolar to low millimolar, in terms of binding efficiency (binding affinity normalized by
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molecular weight or heavy atom count), they are often on par with or exceed the
efficiency of drug like compounds.139 Binding efficiency is a key concept of fragmentbased drug design.
Typical high-throughput screening experiments assay the compounds being
tested at 10 μM concentration. In fragment-based drug design, because of the lower
binding affinity of the fragment ‘hit’ compounds, a 10 μM concentration is not sufficient to
detect activity. Concentrations up to low millimolar must be used to detect active
fragments; typical high-concentration fragment screens will use 250 or 500 μM. This
presents special problems associated with this high concentration screening. At higher
concentrations, solubility of the screening compounds can become an issue and
compounds can precipitate out of the screening solution which can interfere with assays
and activity detection. Therefore, if high-concentration screening is to be used for
activity detection, it is advisable to build the fragment screening library using only very
soluble compounds.
With the advent of high-throughput crystallography techniques, x-ray
crystallography has evolved into a screening technique that can identify fragment
binding. Fragment compounds are typically screened by soaking cocktails of 4 to 10
compounds, which have been selected for optimum diversity, into protein crystals.
There are several advantages to screening using this method. First, the binding mode of
the fragment can be directly visualized, which facilitates the subsequent lead
optimization process. Also, multiple binding fragment binding sites can visualized, which
can facilitate the fragment linking approach to lead optimization. And finally, unlike
traditional screening methods, high fragment concentrations are not normally necessary
when using x-ray crystallography methods. This method has gained considerable
acceptance with drug companies in recent years and several have developed
crystallography platforms for use specifically with fragment screening, including Astex’
Pyramid,140 Stuctural GenomiX’ FAST, Plexxikon’s Scaffold-Based Drug Design,141 and
Abbott’s CrystaLEAD process.134
Nuclear magnetic resonance (NMR) is another sensitive method that can be
used to detect fragment binding. There are two general methods that can be employed
to detect fragment binding: detection by receptor (protein) resonances and detection by
ligand (fragment) resonances. When detection is done by observing receptor
resonances, and initial map or “fingerprint” of the receptor amide or methyl protons is
obtained in a non-bound state which can then be compared to resonances obtained with
cocktails of fragments compounds present. Chemical shifts of 1H-15N or 1H-13C
resonances in the active site can indicate bound ligands. It is even possible to localize
the binding site if sequence-specific resonance assignments are available. Ligand
based methods take advantage of the differences in ligand resonances between bound
and unbound states and typically use one of two methods: Saturation Transfer
Difference (STD)142 and WaterLOGSY.143 Receptor and ligand based NMR detection
methods each have their advantages and disadvantages. A key advantage to using the
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receptor-based method over the ligand based method is that high affinity compounds
can be detected by analyzing the resonance peaks obtained. Also, because the protein
has been assigned, it is possible to identify binding to target and non-target sites on the
protein. Disadvantages to receptor-based NMR methods include molecular weight
limitations for the proteins (>30 kDa is typically beyond the practical range for protein
sequence assignments), requirements for large amounts (milligrams quantities) of
protein, and long sample stability requirements. Finally, a key disadvantage of ligandbased detection methods is that tight-binding ligands can show as false negatives
because they do not disassociate from the receptor frequently enough to distinguish
between bound and unbound ligand resonances. SAR by NMR144 is a specialized
fragment linking technique that allows for the design of high affinity ligands by linking
lower affinity fragments that have been detected by 2D NMR methods. The key to the
SAR by NMR method is that two separate binding sites and ligands have to be identified
and linked using fragment linking methods.
The last three methods of binding and activity analysis are mass spectrometry
(MS), Surface Plasmon Resonance (SPR), and isothermal titration calorimetry (ITC).
Electrospray ionization is typically used in MS techniques to ionize protein/ligand
complexes. Mass identification can then be used to identify fragment binding, even from
mixtures of fragments. This can be a sensitive detection method, but relies on the ability
of the protein/ligand complex to remain together in a gas phase ionized state.
Disadvantages include the requirements for relatively large quantities of protein and an
unclear understanding of the effect ligand binding forces between ligand/receptor on
going from solution to gas phase. In the SPR detection method, the protein is typically
immobilized onto the surface of a solid support after which screening compounds are
introduced. Binding is detected by analyzing changes in the refractive index at the
surface caused by co-localization of the ligand and protein.145 This method has
advantages in that it is possible to measure kinetic binding data and there are no affinity
limitations. However, because the protein is immobilized the measurements do not take
place in solution. Also, a method of immobilizing the protein in its active state must be
utilized. Finally, isothermal titration calorimetry has shown utility in the identification of
low-affinity compounds in recent fragment-based design studies.138 ITC has been widely
used to measure the thermodynamic properties of ligand binding by measuring heats of
association for receptor-ligand complexation at a given temperature as one component
is titrated into the other for complexes involving high-affinity ligands. Using this method
the enthalpy of binding (ΔH°), Gibbs free energy of binding (ΔG°), and the disassociation
constant (Kd) can be determined. From these values one can determine the entropy of
binding (ΔS°), by using the following equation:
∆ °

∆ °

∆ °

Equation 1.7

One major disadvantage of ITC measurements is that they have been reported to
be reliable for low-affinity systems, such as fragment-based studies. However, it has
recently been suggested that with ITC measurements can accurately predict Kd values
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for low-affinity ligands (~ mM) using improved sensitivity measurements and carefully
designed guidelines.146

1.5 The Design of Antimicrobial Agents: Special Challenges to
Computer-Aided Drug Design
The design of pharmaceutical agents with activity against bacterial targets
presents some unique challenges and opportunities that will be discussed in this section.
Because bacteria are prokaryotic organisms, there are significant differences in these
cells when compared to the eukaryotic cells of their mammalian hosts. The metabolic
pathways, structural features, and cell components commonly targeted in drug design
programs are often unique to bacteria. While this provides an excellent opportunity in
terms of selectivity and decreased toxicity, there are also special factors that must be
considered, including distribution to the target, bacterial cell penetration, metabolism,
elimination, and bacterial resistance. These factors can play a key role in the design of
a compound library for screening against bacterial targets.
1.5.1 Penetration of Cell Wall
One of the most significant differences between bacterial cells and the cells of
their human hosts is the presence of a cell wall. Bacteria can be generally classified by
their cell wall dye staining characteristics as either Gram positive or Gram negative.
Gram positive bacteria have a simple cell wall located externally to the bacterial
cytoplasmic lipid membrane that is primarily composed of a thick layer of peptidoglycan,
a series of peptide cross-linked polysaccharide chains. Gram negative bacteria have a
more complex cell wall that is composed of a thinner peptidoglycan layer which is
covered by a second lipid membrane which contains channels known as ‘porins’. Aside
from their functional purpose of maintaining cell stability and structure, the cell wall can
present a significant barrier to the penetration of the antibacterial compound in to the
cell. Fortunately, the cell wall also presents an attractive antibacterial drug target.
Because of the significant structural differences between Gram positive and
Gram negative cell walls, the drug compounds that target Gram positive bacteria are
often very different in terms of structure and physical properties from those that target
Gram negative bacteria. Gram positive cell walls do not contain the porin channels that
are found in Gram negative cells, necessitating the passive diffusion of drug compounds
targeting these bacteria across the cell wall. Due to this need for cell wall diffusion,
gram positive agents are usually more lipophilic than antibacterial compounds that target
Gram negative bacteria. Agents targeting Gram negative bacteria typically enter the cell
by crossing through the porins. Because of this these compounds are often more
hydrophilic to increase their solubility and facilitate passage through the porin channel.
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1.5.2. Special Pharmacokinetic Issues to Consider
Figure 1.7 shows the cLogP and molecular weight distribution of the most
common antibacterial drug classes. Note the low cLogP of the carbapenems and
aminoglycoside antibiotics, two classes commonly used in the treatment of Gram
negative infections. This indicates that these classes are very highly water soluble. The
penicillin and macrolide antibacterial classes, both commonly used to treat Gram
positive infections, are generally distributed into a higher cLogP range, indicating that
these compounds are much more lipophilic. Some key general features of antibacterial
agents can be seen from Figure 1.7 as well. Unlike drugs for mammalian targets, the
antibacterial agents generally have a molecular weights and cLogP values that fall
outside of the normally accepted range for “good” oral drug candidates.23 There are two
reasons for this, the first is that many of these classes of drugs have been derived from
natural products, which tends to yield compounds with higher molecular weights. The
second reason, as has been discussed above, has to do with the unique cell penetration
requirements of antibacterial agents.
The trend toward higher molecular weight and decreased lipophilicity seen with
several of the antibacterial drug classes has resulted in special pharmacokinetic issues
that must be considered. First, oral absorption of the classes with very high MW and low
cLogP is significantly decreased, resulting in many agents that can only be given by the
intravenous route, such as the carbapenem β-lactams and the aminoglycosides. The
route and mechanism of elimination for these compounds is also affected by their
molecular weight and lipophilicity. Compounds with high solubility (low cLogP) are
primarily eliminated by the kidneys without first being metabolized, while compounds
with low solubility (high cLogP) are primarily metabolized prior to elimination. The
distribution of these agents to the target tissue is also affected by their high molecular
weight and low cLogP. The combination of poor oral absorption and low distribution for
several antibacterial drug classes has necessitated the use of large doses, often on the
gram scale, in order to the required therapeutic concentrations for efficacy.
1.5.3 Screening Library Design for Antimicrobial Targets
The issues discussed in the previous section can strongly influence the design of
a screening library to be used against bacterial targets. Special consideration must be
give to the nature of the target as well as the classification and cell wall characteristics of
the bacteria. As discussed in section 1.2.3, when building a virtual screening library it is
often necessary to use filters to focus the screening library so that it contains only
compounds that fall within “drug-like” or “lead-like” ranges for molecular weight,
lipophilicity, etc. These ranges have been defined by Lipinski, Veber, Congreve, and
others for drugs to be delivered by the oral route.23,24,130 It must be considered, however,
that the ranges specified in these studies have predominately been defined by marketed
orally available drugs that interact with human targets. As mentioned above, the nature
of the bacterial cell and targets that lie within have resulted in average molecular weights
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Figure 1.7. Molecular Weight and cLogP Distribution for Common Antibacterial
Drug Classes
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that fall above the “drug-like” range of Lipinski, et al, and cLogP values that fall below
these ranges for the drugs that bind these targets. Therefore, when creating a drug-like
library for screening against bacterial targets, it is advisable to use higher molecular
weight and lower cLogP restrictions. For example, a molecular weight restriction of 650
or 700 daltons rather than 500 is not unreasonable. Similarly, a lead-like library should
have slightly higher molecular weight restrictions, on the order of 350 or 400 daltons.
1.5.4 Resistance Development
The last issue that will be discussed here is bacterial resistance. It seems that
almost as soon as a new class of antibacterials reaches the market, bacteria are isolated
that have become resistant. Take for example, the drug linezolid (Zyvox®), which was
approved in the U.S. in April, 2000 for the treatment of resistant staphylococcal
infections. The first case of clinical linezolid resistance was reported just two years
later.147 This is not a new phenomenon; bacteria have been developing resistance to
antibacterials for as long as we have been designing them, as can be seen from the data
presented in Table 1.6.
There are several reasons for the rapid emergence of resistance in bacterial
organisms, the first is evolutionary. The rapid replication rate of bacteria and the
selective pressure applied when treated with antibacterial agents result in the selection
of organisms with resistance to these agents. Complicating this is the misuse and
overuse of antibiotics and antibacterials, both in the treatment of human infection and
use in the environment. Finally, noncompliance on the part of patient for whom
antibacterial agents are prescribed also contributes to the rapid emergence of
Table 1.6. Introduction and Development of Resistance Timeline for Common
Antibacterial Drug Classes
Antibacterial Class

Mechanism of Action

Sulfonamides
β-lactams (i.e. penicillins)
Aminoglycosides
Tetracyclines & Related
Macrolides & Related
Vancomycin
Fluoroquinolones
Streptogramins
Oxazolidinones
Daptomycin

Inhibit Folate Production
Inhibit Cell Wall Synthesis
Inhibit Protein Synthesis
Inhibit Protein Synthesis
Inhibit Protein Synthesis
Inhibits Cell Wall Synthesis
Inhibit DNA Replication
Inhibit Protein Synthesis
Inhibit Protein Synthesis
Disrupts Cell Membrane

Introduced
1935
1942
1944
1948
1954
1956
1985
1999
2000
2003

Resistancea
1940
1945
1959
1953
1988
1985
1991
2001
2001
2004

a. Unless otherwise cited, resistance emergence dates are approximate estimates
based upon anecdotal reports.
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resistance. Bacteria acquire their resistance in one of two ways, either by spontaneous
genetic mutation, or by transfer of genetic material from one organism to another.
Bacteria have developed a variety of mechanisms to survive exposure to
antibacterial agents. Some common mechanisms of bacterial resistance include:
deactivation of the antibacterial agent by enzymatic modification of the compounds
structure, decreased permeability of the bacterial cell by altering the cell wall or
decreasing porin expression, export of the antibacterial agents by efflux pumps before
they can affect their target, alteration of the target’s active site such that it maintains
activity but no longer affinity for the antibacterial agent, protection of the target by
producing biomolecules that interfere with binding, overproduction of the target
biomolecule or the natural substrate for the target, and finally utilization of alternate
pathways that bypass the inhibited process or pathway. Table 1.7 lists the most
common antibiotic drug classes and the most frequent mechanism of bacterial
resistance to each class.
A number of mechanisms have been developed that can aid in bypassing the
resistance mechanisms mentioned above. In the case of enzymatic inactivation of the
antibacterial, compounds can be utilized in conjunction with the antibacterial that inhibit
the deactivating enzyme, allowing the antibacterial agent to produce its effect. A classic
example of this case is the use of β-lactamase inhibitors with β-lactam antibiotics. The
use of two antibacterial agents that inhibit successive steps in a pathway that is being
targeted is known as sequential blocking. The best example of this is the use of the
antifolate compounds sulfamethoxazole and trimethoprim, the former targeting
dihydropteroate synthase and the latter dihydrofolate reductase, sequential steps in the
bacterial folate pathway. Efflux pump inhibitors are being investigated for use with
antibacterial classes such as the tetracyclines and fluoroquinolones, for which efflux is a
major resistance mechanism. Finally, the use of multiple agents that bind to the same
target can bypass the altered target resistance mechanism and delay the development
of bacterial resistance in some cases.
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Table 1.7. Common Bacterial Resistance Mechanisms Affecting Antibiotic Classes
Resistance Mechanism

βLa

AGb

Enzymatic Inactivation
Decreased Cell
Permeability
Efflux
Altered Target Site
Protection of Target
Overproduction of Target
Bypass of Inhibited Process

+++
+

+++
+

+
++

-

+
+

+
++
-

+
++
-

++
+++
-

++
++
+

+++
+
++
-

a. β-lactams
b. Aminoglycosides
c. Macrolides
d. Sulfonamides
e. Tetracyclines
f. Fluoroquinolones
g. Streptogramins
h. Glycopeptides

Macc Sulfd TCNe FQf

SGg

GPh

+

+

+

+
+++
+
-

+++
-

+++
+
-

+++ Most Common
++
Common
+ Less Common

Adapted with permission from Opal, S. M. and Medeirus, A. A. Molecular

Mechanisms of Antibiotic Resistance in Bacteria. In Principles and Practice of
Infectious Disease, 6th ed.; Mandell, G. L.; Bennett, J. C.; Dolin, R., Eds.
Elsevier: Philadelphia, 2005; Vol. 1, pp. 253-270.148
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CHAPTER 2. STRUCTURAL AND MECHANISTIC STUDIES ON
DIHYDROPTEROATE SYNTHASE
2.1 Introduction
This chapter and the following two chapters will discuss our efforts in the design
of novel molecular agents with activity against the enzyme dihydropteroate synthase.
Our work toward this goal followed an approach very similar to that shown in Figure 1.5
in Chapter 1, using a combination of pharmacophore searching and docking using the
known crystal structures and known inhibitors of the target enzyme. The target enzyme
of these studies is from Bacillus anthracis, the causative agent of the disease anthrax,
and several crystal structures of the B. anthracis DHPS were utilized in this work. This
chapter will discuss a series of molecular dynamics simulations that were performed to
map the positions of two flexible loops from DHPS, which were unclear in our crystal
structures. This was done primarily to build a model that could be used for virtual
screening studies, with additional goals of gaining insight into the structure of the
transition state and the mechanism of the reaction that DHPS catalyzes. Chapter 3
follows this with a discussion of the docking validation studies which were performed to
select the best docking and scoring algorithms for use in virtual screening against
DHPS, and finally Chapter 4 discusses the virtual screening studies that were performed
and presents the results of those studies.
2.1.1 DHPS: New Approaches for an Old Target
The rapid emergence of bacterial drug resistance has led to a decrease in the
clinical utility of virtually all marketed antibacterial agents and an increased interest in the
design and synthesis of new antibacterial agents with novel targets. An alternative
approach to antibacterial drug design is to identify the mechanism of bacterial resistance
and utilize this knowledge to develop new inhibitors of established bacterial targets. The
sulfonamide class of antibiotics was one of the first classes of fully synthetic compounds
successfully used for the treatment of bacterial infections. Sulfonamides act by
interrupting the folate biosynthetic pathway in lower organisms by targeting the enzyme
dihydropteroate synthase, DHPS. These antibiotics mimic the natural substrate, pABA,
and act either by competitive inhibition or by the formation of “dead-end” sulfonamidepterin products. The key steps of the bacterial folate pathway are shown in Figure 2.1
with the antibacterial inhibition steps highlighted. DHPS catalyzes the addition of pABA
to 7,8-dihydropterin-pyrophosphate (DHPP), to form 7,8-dihydropteroate, shown below.
Historically, the sulfonamide antibiotics have been used extensively for a variety
of gram-positive and gram-negative bacterial infections. Sulfonamides and
combinations with DHFR inhibitors such as co-trimoxazole, a sulfamethoxazoletrimethoprim combo, have been used for the treatment of infections by Neisseria,
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Figure 2.1. Key Steps in the Folate Biosynthetic Pathway of Prokaryotes
Streptococci, Staphylococci, Pneumococci, E. coli, Mycobacterium leprae (leprosy),
Plasmodium falciparum, and Pneumocystis jiroveci. However, drug resistance has
emerged as an important factor that severely limits the clinical use of sulfonamide drugs,
and resistance mutations in the gene that encodes DHPS, folP, have now been
characterized in clinical isolates of many pathogenic organisms. This emerging
resistance has led to a decrease in the clinical utility of these agents for the treatment of
several types of infection, such as upper respiratory tract infections and gastrointestinal
infections. Previously considered to be a first-line agent, co-trimoxazole has been
relegated to a 2nd or 3rd line option.
Co-trimoxazole is still considered a first line treatment for uncomplicated urinary
tract infections and certain types of skin and soft tissue infections, but local resistance
patterns often preclude its use. For example, E. coli, the most commonly isolated
pathogen in urinary tract infections, remains mostly susceptible to co-trimoxazole with a
resistance rate of 15-20%, however some urban areas have reported rates as high as
80%.149 While resistance has certainly caused a dramatic decline in the use of
sulfonamide drugs, it should be noted that several emerging pathogens have shown
universal susceptibility to co-trimoxazole, lending validity to the further investigation of
DHPS and DHFR as drug targets. In fact co-trimoxazole is the recommended agent for
treatment of community acquired MRSA, which is rapidly reaching epidemic proportions,
and the 7 known clinical isolates of vancomycin resistant S. aureus (VRSA) were all
shown to be susceptible as well.150
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2.1.2 A History of Sulfonamide Drug Development
Figure 2.2 shows a timeline of the key developments and discoveries in the
history of sulfonamide drug use and development. The discovery of the sulfonamide
class of antibacterial agents is credited to Gerhard Domagk, of I. G. Farben Industrie in
Germany, who was testing the antibacterial properties of several organic dyes. Domagk
noted that the agent Prontosil, shown in Figure 2.3, protected mice against streptococcal
infection. Interestingly, Prontosil was only effective when injected directly into mice and
had no antibacterial properties when studied in vitro against streptococcal species. This
was not appreciated until 1935, the same year that Prontosil began to see significant
clinical utilization, when Trefouёl and coworkers were able to show that Prontosil was
metabolized in the body to sulfanilamide (Figure 2.4), and that sulfanilamide was the
actual active component. The success of sulfanilamide in the treatment of various
streptococcal and staphylococcal infections led to great interest in the development of
sulfonamides as antibacterial agents and led to the discovery and utilization of a variety
of sulfonamide agents. The actual mechanism of bacterial inhibition was not elucidated
until 1940, when Woods and coworkers showed the competitive action of pABA on the
effect of the sulfonamides and pABA was subsequently shown to be a key component of
folic acid, incorporated during bacterial folate synthesis. This proposed mechanism was
not confirmed until 1969, when Richey and Brown were able to purify DHPS and
demonstrate the inhibition of DHPS by sulfanilamide.
The picture seemed clear until 1974 when Weisman, Brown, and Bock showed
that in some types of bacteria, the sulfonamide agents were actually combined with the
pterin substrate to form “dead-end” products, which they theorized went on to inhibit
subsequent steps in the folate pathway. However, in 1979 Roland and coworkers
showed that a pterin-sulfamethoxazole compound was not able to inhibit DHPS or any
other enzyme in the bacterial folate biosynthesis pathway. One possible answer to this
conundrum was provided by Swedberg, who proposed that the mechanism of inhibition
of bacterial growth by the sulfonamide agents was actually “enzymatic trapping” of the
pterin-pyrophosphate substrate in a sulfonamide complex. Swedberg was able to
demonstrate a decrease in the effectiveness of these agents when additional pterinpyrophosphate was added.
2.1.3 The DHPS Crystal Structures
The first crystal structure of DHPS (from E. coli) was not solved until 1997; a full
36 years after the last sulfonamide agent entered the market. Since that time, crystal
structures have been published for six bacterial species (E. coli, S. aureus, M.
tuberculosis, B. anthracis, T. thermophilus, and S. pneumonia) and one fungal species
(S. cerevisiae).151-157 The DHPS enzyme’s overall structure is a (β/α)8 TIM barrel of
repeating β/α units which create the classic β barrel composed of eight β strands
surrounded by eight α helices. The β strands and α helices are connected by eight
flexible loops which fold over the active site in the center of the barrel. Figure 2.5 shows
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1932

Domagk at I.G. Farben observed that Prontosil, an azo dye, protected mice
against streptococcal infections. The first patient to be treated was his
daughter, Hildegarde Domagk.158

1935

Trefouёl, et al demonstrated that Prontosil is converted to sulfanilamide in
the body and that sulfanilamide was the active component.159

1936

Colebrook and Kenny demonstrated the efficacy of Prontosil in the treatment
of puerperal fever in human beings.160

1939

Domagk was awarded the Nobel Prize. President Roosevelt’s son was
treated with sulfa drugs, overcoming early reservations.

1940

The isolation of penicillin reduced interest in sulfa drugs, but the emergence
of penicillin resistance renewed interest after WWII.

1940

Woods, et al demonstrated competition by para-amino benzoic acid (pABA)
and the discovery that pABA is part of folic acid pointed to the folate
pathway as the target of sulfa drugs.161,162

1961

The last sulfonamide new molecular entity (NME) to be released onto the
U.S. market (sulfamethoxazole). The mechanism of bacterial folate
biosynthesis was elucidated by Brown, Weisman and Molnar.163

1969

Richey and Brown purified dihydropteroate synthase (DHPS) in the folate
pathway, and potent inhibition by sulfanilamide was demonstrated.164,165

1974

Wiesman/Brown and Bock demonstrated the incorporation of sulfonamides
into “dead-end’ sulfo-pterin products in certain bacteria.166,167

1979

Roland, et al showed that dihydropterin-sulfonamide products do not inhibit
DHPS or other folate enzymes. Swedberg theorized that the mechanism of
growth inhibition by sulfonamides is enzymatic trapping of pterinpyrophosphate in a sulfonamide complex.168,169

1997

First x-ray crystal structure of DHPS published, E. coli.151

1999

Vinnicombe, et al, demonstrated that the target for sulfonamide inhibition (of
S. pneumoniae) is the enzyme-DHPP binary complex, rather than the apo
form of the enzyme.170

2004

Babaoglu and co-workers solved a crystal structure of B. anthracis DHPS
with a pterin site inhibitor bound, the basis for the work described here.154

Figure 2.2. History and Key Insights into Sulfonamide Drug Development and
Chemotherapy
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Figure 2.3. Prontosil

Figure 2.4. Sulfanilamide
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Figure 2.5. B. anthracis DHPS Shown with Product and Substrate Analogs
Overlaid
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the crystal structure of B. anthracis DHPS with a pteroate product analog and DHPP
substrate analog overlaid in the active site. The product analog gives an approximate
location for the pterin binding site as well as the pABA binding site, while the substrate
analog shows the approximate position of the diphosphate group. The active site of
DHPS can be actually divided into 4 distinct subsites: the pterin binding site, the
diphosphate binding site, the pABA binding site, and a conserved water binding site,
each of which is visible in Figure 2.5. A magnesium cofactor is known to coordinate the
diphosphate group and several residues, including His256 and Asn27, and is theorized
to play a role in the catalytic mechanism of DHPS. The magnesium ion has not been
observed in any of our B. anthracis crystal structures to date.
Unfortunately, even with the known structural information, several pieces of the
puzzle are still missing and the catalytic mechanism of DHPS remains unclear. The
flexible loops that fold over the active site during catalysis enclosing pABA and
completing the pABA binding subsite are unresolved or occupy incorrect positions in
many of the crystal structures that have been solved. Two key flexible regions in
particular, loops 1 and 2, are believed to play a key role in catalysis but are only visible
in a few of the structures available and even those positions are uncertain or unreliable.
Additionally, as discussed below, the majority of the mutations known to confer
resistance to the sulfonamides are found in these two loops. This missing information
contributes to our lack of understanding not only of the reaction mechanism, but also the
mechanism of sulfonamide resistance. Additionally, the magnesium cofactor mentioned
above has only been resolved in 2 of the 17 DHPS crystal structures that have been
published to date, and in once case it was replaced by manganese. Table 2.1 gives a
listing of the published DHPS crystal structures by species as well as the presence or
absence of the key structural features just mentioned for each crystal structure. In some
cases, as in our B. anthracis structures, it can be seen that although the position of a
flexible loop has been solved, it may not be in the transition state or correct binding
position, and thus does not contribute to our knowledge of the mechanisms in question.
2.1.4 The DHPS Molecular Mechanism: Current Knowledge
Although there is still much uncertainty regarding the exact mechanism of the
reaction catalyzed by DHPS, some information is known and some credible theories
have been put forth. In their paper presenting the E. coli DHPS structure, Achari and
coworkers stated their inability to generate a structure with sulfonamide bound by
soaking the drug into unliganded DHPS crystals.151 They were only able to generate a
structure when sulfanilamide was soaked along with dihydropterin and pyrophosphate.
This result seems to indicate a need for pterin, pyrophosphate, or both to be present in
order for the sulfonamide (and presumably pABA) to bind. However, the position of the
sulfanilamide in their structure has been called into question by the mechanism
proposed by Baca, et al as well as the pteroate product structure by Babaoglu.154,171 In
this latter structure, the position of the pteroate gives an indication of a possible
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Table 2.1. Features of the Known DHPS Crystal Structures
Species

PDB Code

Present in Active Site

Loop 1

Loop2

Mg2+

Notes

E. coli

1aj0

Artifactual

Present

Missing

2.0 Å Resolution

1aj2
1ajz

Sulfanilamide, SO4,
Pterin Analog
Pterin-PP Analog, SO4
SO4

Artifactual
Artifactual

Present
Present

Missing
Missing

2.0 Å Resolution
2.0 Å Apo Structure

S. aureus

1ad1
1ad4

Nothing
Pterin-PP Analog

Artifactual
Missing

Present
Present

Missing
Mn2+

2.2 Å Apo Structure
2.4 Å Resolution

M. tuberculosis

1eye

Pterin-P Analog

Present

Missing

Present

1.7 Å Resolution

B. anthracis

1tws
1tww
1twz
1tx0
1tx2

SO4
Pterin-PP Analog, SO4
Pterin-P Analog, SO4
Pteroate Analog, SO4
MANIC Inhibitor

Artifactual
Artifactual
Artifactual
Artifactual
Artifactual

Presenta
Missing
Missing
Missing
Missing

Missing
Missing
Missing
Missing
Missing

2.0 Å Apo Structure
2.5 Å Resolution
2.75 Å Resolution
2.15 Å Resolution
1.83 Å Resolution

S. cerevisiae

2bmb

Pterin-P Analog

Artifactual

Present

Missing

2.3 Å Resolution

T. thermophilus

2dqw
2dza
2dzb

Nothing
pABA
Pterin-PP Analog

Missing
Missing
Missing

Missing
Missing
Missing

Missing
Missing
Missing

1.65 Å Apo Structure
1.90 Å Resolution
1.90 Å Resolution

S. pneumoniae

2vef
2veg

Nothing
Pterin-P Analog

Missing
Missing

Missing
Missing

Missing
Missing

1.80 Å Apo Structure
2.4 Å Resolution

a. In the B. anthracis apo structure, loop 2 extends into the pterin binding site replacing the pterin substrate.
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transition state in which the pABA group occupies a position significantly different from
the position proposed by Achari, et al.
In their paper describing the S. aureus DHPS structure, Hampele and coworkers
proposed a random, single-displacement reaction mechanism in which the reaction
proceeds through a ternary complex of DHPS, DHPP, and pABA. They proposed a
random order of addition of substrates based upon their S. aureus Vmax measurements.
Vinnecombe and Derrick countered this with their theory that the target for sulfonamide
inhibition of DHPS is actually the enzyme-DHPP binary complex.170 They based this
theory on their studies of S. pneumoniae and the observation that the pABA substrate
binding was absolutely dependent on the presence of pyrophosphate in the active site,
which they believed acted as an analog of the DHPP substrate. Additionally, they
showed that the sulfonamides displaced pABA in a competitive manner and,
interestingly, they also showed that the product of the reaction, dihydropteroate, was
also able to bind to the DHPS active site.
In their paper presenting the structure of DHPS from M. tuberculosis Baca and
coworkers proposed a detailed mechanism and transition state geometry based upon
their observations of the Pterin-monophosphate analog in the pterin subsite and the
position of the magnesium co-factor. They proposed a trigonal bipyramidal transition
state geometry where the C9 carbon of DHPP would develop a partial positive charge
which would be stabilized by the electron-rich conjugated pterin ring system. The amino
group of pABA would attack the carbon position from the opposite side of the
pyrophosphate, as shown in Figure 2.6. The pyrophosphate interacts with a His, Asp,
and Asn residue in addition to the stabilizing effect of the magnesium ion, which
facilitates the removal of the pyrophosphate during catalysis. Other key binding residues
are shown in Figure 2.6. They went on to propose a possible role for a key serine and
arginine residue in loop 2 in stabilizing the pyrophosphate during catalysis and
facilitating pyrophosphoryl transfer.
Babaoglu and coworkers confirmed the position of the pABA compound
proposed by Baca, et al. in their transition state theory with their product analog crystal
structure. Additionally, they confirmed the proposed position of the diphosphate group.
They proposed that the catalytic mechanism took place in 4 steps. In its unliganded
state, a side chain of a key arginine (Arg68 in B. anthracis) in loop 2 occupies the pterin
binding subsite. In the first step of catalysis the pterin substrate binds and its terminal
phosphate group occupies the anion pocket (phosphate subsite). The magnesium
cation coordinates the diphosphate group and the Mg2+ binding residues mentioned
above as loop 2 shifts the arginine residue out of the pterin site. The second step is the
formation of the pABA binding subsite by movements of both loop 1 and loop 2. A key
part of Babaoglu’s theory is the proposed ionic interaction of Arg68 with the pABA
substrate, which Babaoglu proposed stabilized the position of pABA. This is in contrast
to the arginine position described by Baca, who proposed that the arginine interacted
with the terminal phosphate of DHPP during catalysis. The third step would be the
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Figure 2.6. Proposed DHPS Transition State for M. tuberculosis
Adapted with permission from Baca, A. M.; Sirawaraporn, R.; Turley, S.; Sirawaraporn,
W.; Hol, W. G. Crystal structure of Mycobacterium tuberculosis 7,8-dihydropteroate
synthase in complex with pterin monophosphate: new insight into the enzymatic
mechanism and sulfa-drug action. J Mol Biol 2000, 302, 1193-212.
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nucleophilic attack of the pABA nitrogen on the C9 carbon of DHPP and subsequent loss
of a pyrophosphate (facilitated by the magnesium cation), which they proposed took
place using an SN2 mechanism, similar to Baca’s transition state theory. Finally, the
pteroate and pyrophosphate products are expelled from the active site and loop 2 moves
back to its position occupying the pterin binding subsite.
There are several questions that have yet to be answered regarding the structure
of the transition state and the catalytic mechanism of the reaction. Although key binding
residues and several residues believed to be involved in catalysis have been proposed,
none of the structures that have been solved to date have shown the positions of both
loops 1 and 2 (the location of many of these residues) in their catalytic conformation.
The position of pABA during the transition state and even the type of nucleophilic attack
are still points of debate as is the function of the arginine residue in loop 2 during
catalysis. Does it bind to the terminal phosphate and facilitate its removal or does it bind
to the carboxylate of pABA, facilitating the correct alignment of pABA for nucleophilic
attack? This remains to be determined. Additionally, the positions and roles of several
residues that when mutated confer sulfonamide resistance remain to be determined.
This last point is discussed further in the following section.
2.1.5 Sulfonamide Resistance Mechanisms
Bacterial resistance to sulfonamide drugs can be caused by a variety of the
mechanisms discussed in section 1.5.4, but predominately resistance is caused by
chromosomal mutations of the DHPS gene, folP, or by the acquisition by the bacteria of
plasmids bearing the drug resistant DHPS variants, sul1, sul2 or sul3. In the first case,
spontaneous mutations of the folP gene result in a DHPS enzyme that is no longer
capable of binding to sulfonamide agents, but can still bind to the native substrate pABA,
albeit usually with decreased efficiency. In the latter case, bacteria have acquired
plasmids carrying alternate forms of DHPS which are significantly different from the
native enzyme, still capable of binding pABA and catalyzing the reaction with DHPP, but
showing markedly decreased affinity for the sulfonamide agents. Notably, with the
plasmid variants, the efficiency of pABA binding is not as impaired as in the
chromosomally mutated DHPS. Plasmid-borne resistance has only been characterized
in Gram-negative enteric bacteria thus far, while chromosomal mutations have been
characterized in both Gram-positive and Gram-negative bacteria.172,173
Mutations of folP conferring resistance that have been characterized in several
bacterial species are shown in Table 2.2 along with their corresponding B. anthracis
positions. The structural positions of these mutations are highlighted in Figure 2.7,
which shows B. anthracis DHPS with a known pterin inhibitor bound in the active site. It
should be noted from Table 2.2 and Figure 2.7 that the mutation sites predominately fall
on the flexible loops of the DHPS enzyme with the majority of mutations occurring on
loops 1 and 2. Table 2.2 highlights 3 specific mutations that have been observed across
several species. In B. anthracis these mutations are Phe33Leu(Ile), Thr67Ala(Ile), and
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Table 2.2. Sulfonamide Resistance Mutations Observed from Six Organisms

Orgamisms

Mutaton Observed

E. coli
N. meningititis
P. carinii
M. leprae
P. carinii
P. falciparum
P. falciparum
S. pneumoniae
M. leprae
P. carinii
E. coli
S. pneumoniae
S. pneumoniae
P. carinii
S. pneumoniae
P. carinii
P. falciparum

Phe28Leu, Ile
Phe31Leu
Phe23Leu
Thr53Ile, Ala
Thr55Ala
Ser436Ala, Phe
Ala437Gly
Arg58-Pro59 duplication
Pro55Leu
Pro57Ser
Pro64Ser
Arg insertion after Gly60
Ser61 duplication
His60Asp
Ile66-Glu67 duplication
Ile111Thr
Lys540Glu
Gly194Cys, Ser193-Gly194
duplic.
Ala581Gly
Ala613Ser, Thr
Val248Gly

N. menignitidis
P. falciparum
P. falciparum
P. carinii

Point Mutations Conserved Across Species
Adapted with permission from Baca, et al.153
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Corresponding
B. anthracis Residue

Structure

Phe33
Phe33
Ser34
Thr67
Thr67
Thr67
Arg68
Arg68-Pro69
Pro69
Pro69
Pro69
Gly70
Phe71
Ala72
Val74-Ser75
Ile122
Asn147

Loop1
Loop1
Loop1
Loop2
Loop2
Loop2
Loop2
Loop2
Loop2
Loop2
Loop2
Loop2
Loop2
Loop2
Loop2
Loop4
Loop5

Gly188
Ala190
Gly224
Ile246

Loop6
Loop6
a7’
a7’

Figure 2.7. B. anthracis Crystal Structure with Known Pterin Site Inhibitor and Key
Mutation Residues Shown
MANIC, a known inhibitor of DHPS, is shown here occupying the pterin binding site in a
high resolution X-ray crystal structure. Residues that when mutated are associated with
sulfonamide resistance are shown in yellow. It should be noted that Phe33 is pushed far
away from the active site due to a crystal lattice interaction with a neighbouring
monomer.
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Pro69Ser(Leu). Again, all three of these conserved mutations sites fall on either loop 1
or loop2, whose positions remain unresolved or unclear in most of the crystal structures
published to date. Thus, the exact mechanism of these mutations in decreasing the
binding affinity of the sulfonamide agents has not been determined.
Although the effect of the resistance mutations on the binding of the DHPP
substrate (and consequently on the binding of pterin site inhibitors) is uncertain, due to
the location of the mutations on flexible loops that fall near the pABA binding site, it is
unlikely that they would affect the binding of DHPP or any other compounds with affinity
for this site. This has direct ramifications on the design of a new class of DHPS inhibitors
with affinity for the pterin subsite. Theoretically, agents that inhibit DHPS by binding to
this subsite would bypass the resistance mechanisms that have rendered sulfonamide
drugs useless for many types of infections. Additionally, the highly conserved nature of
the pterin subsite (see section 4.1.1) indicates a possible requirement for many of the
pterin subsite residues in catalysis, which may mean that the pterin site would be less
likely to undergo resistance conferring mutation.
2.1.6 Molecular Dynamics Simulations: Goals and Objectives
In order to gain insight into the catalytic mechanism of DHPS and the
conformation of the flexible loops 1 and 2 during catalysis, we performed several series
of large scale (2 to 4 nanosecond) molecular dynamics simulations under various
solvation conditions using the program AMBER v9 from UCSF.72,174 The general goals
of these simulations were to enable us to visualize the structure of the transition state,
deduce the catalytic mechanism of the enzyme, and shed light on the mechanisms of
sulfonamide drug resistance. The intent is to use the structures and information
obtained from the dynamics simulations to facilitate our design of transition state analogs
with strong inhibition of DHPS. A secondary goal of this project was to develop a
working model of the DHPS active site, including pABA and DHPP subsites which could
be used in subsequent virtual screening experiments.
In this study we performed three series of simulations. The first series of
simulations were the substrate/product simulations. This series involved simulations of
the apo structure; a ternary complex (Michaelis complex) involving the DHPS enzyme,
DHPP, and pABA; and a binary complex involving the pteroate product analog and the
DHPS enzyme. The intent of this series of simulations was to allow us to visualize the
attack of the nucleophilic nitrogen in pABA on the electrophilic allylic carbon in DHPP
and the correct orientation of the attacking pABA as it approaches DHPP, with a purpose
of further aiding our design of transition state inhibitors.
The second series of simulations were the inhibitor complex simulations which
replaced pABA in the first series with sulfamethoxazole in a ternary complex simulation.
Additionally, in this series we ran multiple simulations with a sulfamethoxazole-pterin
(pterin-SMX) hybrid in the active site with either pyrophosphate or sulfate. The pterin-
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SMX compound, Figure 2.8, was synthesized in our lab and crystal structures of the
compound in complex with DHPS has been solved but not published. The intent of this
series was to gain insight into the unique interactions of sulfonamide drugs with the
pABA site and the flexible loops. Of particular interest are the interactions of loop
residues with the oxazole ring in sulfamethoxazole, which is very mobile in our crystal
structures, and the position of Arg68, whose function during the transition state remains
a matter of debate. The goal was to identify these interactions and facilitate the
development of tightly binding transition state analogs with potent inhibition of DHPS.
Additional insight into the nature of the interaction of the resistance mutation residues
was sought during these simulations.
The third and final series of simulations were the resistance mutation simulations. This
involved the use of both pABA and sulfamethoxazole ternary complexes with DHPS and
DHPP in conditions similar to series 1 and series 3 except that the residues known to
cause sulfonamide drug resistance were mutated in these simulations to investigate the
mechanism by which they confer sulfonamide resistance. The goal of this final series
was to shed light on the mechanisms of resistance and will assist us in our structurebased drug design efforts.

2.2 Molecular Dynamics Studies: Materials and Methods
2.2.1 Structure Preparation
Several different crystal structures were used as starting points for the
simulations described above. For the first series of substrate/product simulations, the
pteroate crystal structure, pdb code 1tx0, was utilized. The pteroate product analog
present in the crystal structure was replaced with the pABA and DHPP substrates for
those simulations, or removed completely for the apo structure simulations. It was left in
place for the product simulations. To prepare the structure for the dynamics simulations
it was necessary to first generate the initial starting positions for the missing or incorrect
residues of loops 1 and 2. This was done by homology modeling the positions of these
two loops based upon their known positions in the M. tuberculosis and E. coli crystal

Figure 2.8. Pterin-SMX Hybrid Compound
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structures. As discussed above, loop 1 is present in the M. tuberculosis structure while
loop 2 is present in the E. coli structure. Both of these loop positions fall near the active
site and are theorized to be close to their transition state positions. For loop 1, residues
Ile25 through Glu41 were replaced with the corresponding sequence from M.
tuberculosis and mutated to match the B. anthracis sequence. For loop 2, we modeled
the positions of residues Gly64 through Val74 on the E. coli loop 2 position. This placed
the key Arg68 side chain near the anionic binding pocket and allowed it to make an ionic
interaction with the sulfate or phosphate substrates. Following this, hydrogens were
added to the structure and atoms were typed with Amber atom types. Gasteiger-Huckel
charges were used for the substrate and product analogs. A 1000 iteration minimization
of the hydrogen atoms was followed by a brief 250 iteration minimization of the flexible
loops only to eliminate any steric clash occurring after loop placement. It should be
noted that a key active site water was retained in the active site in all dynamics
simulations. At this point the structure was ready to take into the simulations phase.
Series 3 simulations involving the resistance mutations utilized the same structure, the
pteroate analog was replaced with the sulfamethoxazole, pABA, and DHPP structures
and the resistance site in question was mutated using the Biopolymer tool of Sybyl.
Simulations involving the sulfamethoxazole-pterin hybrid compound used the
pterin-smx crystal structures that had been solved in our previous studies (unpublished
data). Two different pterin-smx crystal structures were utilized in these studies. The first
structure, like the 1tx0 structure discussed above, was missing much of loop 2, including
the position of the key Arg68 residue, and loop 1 was in the incorrect position seen with
our previous structures. This structure was prepared in a similar manner as the 1tx0
structure described above. The position of the oxazole ring of the sulfamethoxazole
hybrid was not clear in the this crystal structure and it appeared to be able to rotate to an
“up” position, tucked between loops 6 and 7, and a “down” in which it is solvent exposed
and closer to loops 1 and 2, shown in Figure 2.9, right and left. In the first several
simulations that involved the pterin-smx hybrid, the position of the oxazole ring was in
the “down” position in the starting structure and the Arg68 side chain occupied the E. coli
position placing it near the phosphate or sulfate group in the anionic subsite (Figure 2.9,
left). During the course of these dynamics simulations a new pterin-smx crystal structure
became available that contained more detail regarding the position of the oxazole
system as well as more residues in loop 2, including the position of the Arg68 side chain.
The remainder of the simulations utilized this starting position (Figure 2.9, right). Only 3
residues from loop 2 were missing from this new pterin-smx crystal structure (Pro69 to
Phe71), and they were easily placed and minimized. Importantly, the Arg68 side chain
in the newer structure was visualized and appeared to be interacting with the negatively
charged sulfonamide group of the pterin-smx ligand. It should be noted, however, that
there was no phosphate or sulfate bound in the anionic pocket of this new structure,
which may have influenced the position of the Arg68 side chain.
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Figure 2.9. Two Starting Positions for the Pterin-SMX Dynamics Simulations
2.2.2 Force Field and Parameterization
All simulations performed in this study utilized the Amber 2003 force field.175
Parameters for the standard protein residues in the simulations were generated using
the Leap program available in the Amber v9 suite of programs. These parameters have
been tested and validated by the Amber developers. It was necessary to develop and
load parameters for the non-standard residues in our simulations, including pABA,
DHPP, sulfamethoxazole, pterin-smx, pterin-pABA, sulfate, and pyrophosphate. The
parameters for the Na+ and Mg2+ cations were already available in the Leap program.
Parameters for the non-standard residues were generated using the Antechamber
program and the General Amber Force Field (GAFF) of Amber v9.176,177
Antechamber and the GAFF were specifically designed to develop parameters
for organic molecules that are compatible with the traditional Amber force fields and that
can be utilized in biomolecular dynamics simulations. Similar to the Amber FF03 (used
to load protein parameters), the GAFF uses a simple harmonic function for bonds and
angles (see the discussion in Chapter 1 on force field implementation). However, GAFF
is much more general than FF03 and covers significantly more organic chemical space.
It currently consists of 33 basic and 22 special atom types. The HF/6-31G*, RESP, or
AM1-BCC charge methods can be used with the GAFF. In our studies, we used input
.mol2 files for each non-standard residue and the AM1-BCC charge method (due to
speed and efficiency). Antechamber typed the atoms and bonds, calculated the total
number of electrons and net charge, and generated a parameter file for each compound
that could be used with the Leap program when developing parameters for the entire
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system. Parameters not specifically defined in the GAFF for our non-standard residues
were loaded by antechamber based on analogy to similar parameters (after close
inspection by the modeler). Appendix A contains the parameter files for each nonstandard residue
2.2.3 Simulation Methods
A variety of simulation methods were utilized in these studies for each series of
simulations. In addition to varying the duration of the simulation, we investigated the
effects of implicit versus explicit solvation, presence or absence of cationic cofactor, and
presence or absence of the anionic sulfate or phosphate groups. Table 2.3 gives a
complete list of every simulation and the simulation design for each series of
simulations.
The following general procedure was used to set up a dynamics simulation:
First, the program Leap was used to load the parameters for the non-standard residues
that had been previously generated as well as all the standard residues in the protein.
As mentioned previously, we utilized the Amber 2003 FF for all simulations performed in
these studies. The next step was to balance the charge of the system by adding Na+
counter-ions. This was done using Leap for all simulations, both implicit and explicitly
solvated. In the case of implicit simulations, the topology and parameter files were then
generated. In explicitly solvated simulations, the Leap program was used to generate a
10 Å octahedral solvent box around the system using the TIP3 water model.127
Topology and parameter files were then saved for these systems.
The Amber module Sander was used to run all minimizations and molecular
dynamics simulations. The general procedure for implicitly solvated simulations involved
performing a 500 iteration minimization of the system prior to starting the dynamics run
(250 iterations using the steepest descent method, followed by 250 iterations using the
conjugate gradient method). A non-bonded cutoff of 16 angstroms was used for long
range electrostatic interaction calculations in all cases, and the Hawkins, Cramer,
Truhlar pairwise generalized Born solvation model was utilized for all implicit
simulations.178 The dynamics simulations that followed were allowed to evolve from 2 to
4 nanoseconds, depending on the simulation. The Langevin thermostat was used to
maintain the temperature of the system at 300°K. SHAKE bond length constraints were
applied to the bonds involving hydrogen to allow a 2 femtosecond simulation time
step.125 Periodic boundary conditions were not necessary for implicitly solvated
systems.
The general procedure for explicitly solvated systems involved an initial 1000
iteration (500 steepest descent, 500 conjugate gradient) minimization of the solvent
holding the protein constrained, followed by a 2500 iteration (1000 steepest descent,
1500 conjugate gradient) of the entire system. Non-bonded energy cutoffs of
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Table 2.3. DHPS Molecular Simulations Design Summary
SeriesNumber

PDBa

Active Site

Duration

Solvationb

Cofactor
Cationc

Anionic
Groupd

1-2

1tx0

4 ns

Explicit

None

None

1-5
1-14
1-16
2-1a
2-1b
2-1c
2-4
2-6
2-13
2-15
2-17

1tx0
1tx0
1tx0
n/p
n/p
n/p
n/p
1tx0
n/p
n/p
n/p

4 ns
4 ns
4 ns
2 ns
2 ns
2 ns
3.6 ns
4 ns
4 ns
4 ns
4 ns

Implicit
Explicit
Explicit
Implicit
Implicit
Explicit
Explicit
Implicit
Explicit
Explicit
Explicit

Na+
Mg2+
None
Mg2+
none
Mg2+
none
Na+
Mg2+
Mg2+
Mg2+

DHPP
SO4
None
SO4
none
SO4
SO4
none
SO4
none
PPi

2-18

n/p

4 ns

Explicit

Mg2+

PPi

3-3

n/p

4 ns

Explicit

none

SO4

3-7

1tx0

4 ns

Implicit

Na+

DHPP

3-8

1tx0

4 ns

Implicit

Na+

DHPP

3-9

1tx0

4 ns

Implicit

Na+

DHPP

3-10

1tx0

4 ns

Implicit

Na+

DHPP

3-11

1tx0

4 ns

Implicit

Na+

DHPP

3-12

1tx0

None (Apo
Structure)
pABA, DHPP
pteroate product
pteroate product
pterin-SMX
pterin-SMX
pterin-SMX
pterin-SMX
SMX, DHPP
pterin-SMX
pterin-SMX
pterin-SMX
(oxazole ring in,
Arg68 down)
pterin-SMX
(oxazole ring
out, Arg68 up)
pterin-SMX,
F33L
pABA, DHPP,
F33L
SMX, DHPP,
F33L
pABA, DHPP,
T67A
SMX, DHPP,
T67A
pABA, DHPP,
P69S
SMX, DHPP,
P69S

4 ns

Implicit

Na+

DHPP

a. The published pdb code used is indicated when relevant. Non-published, internal
crystal structures are indicated by n/p.
b. Explicit solvation used the TIP3 water model in all cases; implicit solvation utilized a
Generalized-Born Surface Area Model.
c. The Na+ cation was placed into the anionic site during the charge neutralization step
of protein and left in place during simulations. Mg2+ atoms, when used, were
positioned based upon the 1eye M. tuberculosis crystal structure.
d. When DHPP or another pterin-diphosphate analog was simulated in the active site,
the diphosphate chain occupied the anionic binding subsite.
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10 angstroms were used in all minimization and dynamics steps involving explicitly
solvated systems. Periodic boundary conditions were applied during the minimization
steps to maintain a constant volume. The Particle Mesh Ewald (PME) summation
method was used to calculate long range electrostatic energies in both minimization and
dynamics steps for explicitly solvated systems. The minimization steps were followed by
a 20 picosecond dynamics simulation which kept weak restraints on the protein while the
solvent was allowed to evolve. During this step the temperature was slowly raised from
0 to 300°K using the Langevin thermostat. A constant volume was maintained during
this step using the periodic boundary condition. The following step is the full dynamics
evolution phase, usually between 2 and 4 nanoseconds in durations. During this step all
restraints were removed from the protein and the system was allowed to fully evolve.
The temperature was held at 300°K and the pressure was maintained at 1 atomsphere
using isotropic position scaling of the periodic boundary. The SHAKE algorithm was
employed in all explicitly solvated dynamics simulations to allow for 2 femtosecond time
steps.
All dynamics simulations were carried out in parallel using the Linux Cluster at
the Hartwell Center of St. Jude Children’s Research Hospital. Amber simulations scaled
most efficiently to sixteen processors, and this was typically used for a molecular
dynamics simulations. Analysis of the completed dynamics simulations was performed
using the programs VMD and Chimera.179,180
2.2.4 Molecular Simulations Analysis
The ptraj analysis tool available in the Amber v9 package was used to perform
trajectory analysis in these studies. It should be first noted that full trajectory analysis
was only performed against models determined to be stable from visual analysis of the
trajectory. Simulations in which the ligands or cofactors were expelled (discussed
below) were not considered stable and trajectory analysis was not performed, although
observations are made in the discussion regarding key events at specific time points (i.e.
ligand expulsion).
Kinetic, potential, and total energy plots were calculated to demonstrate
equilibration and stability of the simulation (see Appendix B). Additionally, temperature,
pressure, and density plots were used for further demonstration of model stability (data
not shown). Dihedral analyses were performed for 4 key binding and mutation residues:
Phe33, Thr67, Arg68, and Pro69 (Appendix B). Dihedral analysis was used to
determine the degree of conformational sampling for the loop 1 and 2 residues as well
as the stability of the residues during the portion of the production phase that was used
to determine average structures.
Average and minimum energy structures were calculated and RMSD plots were
generated based upon these structures to determine the degree of structural variation
and model stability (Appendix B). Average structures discussed below were calculated

59

from the final 1 nanosecond for simulations extending to 4 nanoseconds and the final
500 picoseconds for simulations extending to 2 nanoseconds. Minimum energy
structures were determined from the entire production phase (excluding heating and
minimization steps). RMSD values were calculated referenced to the starting structure,
the average structure, and the minimum energy structure for the entire protein using
backbone atoms, and for both loop 1 and loop2 using backbone atoms and all atoms
(Appendix B).
Energy plots, RMSD plots, and dihedral plots determined from dynamics
simulation 2-17 (the simulation used to determine the active site model used in our
subsequent studies) can be found in Appendix B.

2.3 Molecular Dynamics Studies: Results and Discussion
2.3.1 Substrate/Product Simulations
The simulations in this series included the DHPS apo structure, a
pABA/DHPP/DHPS ternary structure, and a pABA-pterin/DHPS binary structure. The
first simulation was a 4ns explicitly solvated simulation of the DHPS apo structure. The
starting position for this simulation was essentially the 1tx0 structure with loops 1 and 2
placed as described above, but lacking the pteroate product analog, or any other
cofactor. Our anticipation was that during the course of this simulation that the Arg68
residue would insert into the active site and engage in a pi-stacking interaction with the
pterin side residue Arg254, as is seen in our apo crystal structure. However, this was
not the case. Instead, Arg254 was observed to fold back upon itself and engage in ionic
interactions with two Aspartate residues (Asp61 and Asp101) while Arg68 engaged in
and maintained ionic interactions with Asp35 on loop1. Figure 2.10 shows the initial
configuration of these residues in the starting structure (left) and the interactions that are
seen in the final, average structure (right). Although it remains to be determined why the
loop positions of the apo crystal structure weren’t reproduced in this simulation, one
possible explanation is that the simulation did not contain a ligand in the anionic binding
subsite, while a sulfate anion was present in this site in the apo crystal structure. As will
be discussed below, we have noted in many of our simulations the effect of this
negatively charged group on stabilizing the loop positions near the active site.
Additionally, we have observed in our crystal structures that Arg254 engages the sulfate
(and terminal phosphate of DHPP) in ionic interactions that may stabilize its position in
the active site as well.
The second simulation of merit in this series was the pABA, DHPP, DHPS
ternary structure. This was a 4 nanosecond implicitly solvated simulation. Of note here
is the use of a Na+ cation in the Mg2+ site interacting with the diphosphate group of
simulation prior to ligand expulsion. The Arg68 residue is engaged in an ionic interaction
with the α phosphate of DHPP while Pro69 (a known resistance mutation site)
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Figure 2.10. DHPS Apo Simulation Starting and Final Structure
participates in van der Waals interactions with the pABA substrate. The Pro69 and
Lys220 residues facilitate the placement of pABA by forming vdW interactions on both
duration of the simulation. In this simulation loop 2 folds completely over the active site
and engages in interactions with both the pABA and DHPP substrate. The pABA
substrate was ejected from its binding site at 3.2 ns into the simulation, but we were able
to note several key interactions prior to this event and gain a clearer understanding of
positions of loop 2 during pABA binding. Figure 2.11 depicts the active site of DHPS
seen during this simulation with several key interactions highlighted, as determined by
calculating an average structure from the 500 ps period of the production phase of the
DHPP. This cation was placed by Leap during the charge balancing step of structure
preparation and because of its fortuitous position, was left to occupy the site for the
sides of the pABA ring. Thr67 (another resistance mutation site) appears to engage in
charge-dipole interaction with Lys73 stabilizes possibly helping to stabilize the position of
loop 2. Finally, in this simulation we followed Phe33, the third of the conserved
resistance sites, and did not observe any direct interaction with the pABA substrate at
any time point.
The next two simulations in this series were a set of related, explicitly solvated
simulations of the pteroate product analog lasting 4 nanoseconds. The only difference
between the two simulations was the lack of a sulfate anion and magnesium cofactor in
the second of the two. The purpose of these simulations was to investigate the
importance of the anion and cation cofactor in the stabilization of the enzyme-product
state and the positions of loops 1 and 2. The differences in these two simulations were
dramatic. In the first case (sulfate and cation present) the pteroate product analog
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Figure 2.11. Key pABA and DHPP Active Site Interactions
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maintained its position for the full 4 nanosecond simulation. Arg68 on loop 2 was
observed to engage in ionic interactions with the terminal carboxylate of the pteroate
compound for the majority of the simulation. In the second case (no sulfate or cation),
the pteroate product analog quickly destabilized in the active site and by .6 nanoseconds
had begun to be expelled from the active site. Arg254 folded back upon itself in the
active site to make ionic interactions with Asp61, similar to what was seen in the apo
structure simulations. These results seem to indicate that the position of both loop2 and
the active site Arg254 are dependent on the presence of a negatively charged group
(sulfate or phosphate), in the anionic binding subsite.
2.3.2 Inhibitor Complex Simulations
The next series of simulations involved complexes with the known sulfonamide
inhibitor, sulfamethoxazole. The first simulation that we performed was with the ternary
sulfamethoxazole, DHPP, DHPS structure, similar to the pABA, DHPP, DHPS ternary
complex simulation performed in the first series. Like its corresponding pABA simulation
in series 1, this simulation utilized a Na+ ion in the anionic site as the cationic cofactor.
Unlike the corresponding pABA simulation, however, in this simulation the
sulfamethoxazole was promptly ejected from the active site. This occurred very quickly,
by 0.1 ns the sulfamethoxazole was completely removed from the pABA binding site.
Interestingly, the DHPP substrate remained in the pterin site for the duration of the
simulation. The Arg68 side chain formed and maintained ionic interactions with the
terminal phosphate of DHPP for the entire simulation. No interactions with any of the
resistance conferring mutations were noted with the sulfamethoxazole ligand in this
simulation. The reason for the prompt ejection of sulfamethoxazole from the pABA
binding site is unclear as this simulation was set up in exactly the same manner as the
corresponding pABA simulation from series 1. Whether this indicates a decreased
affinity of sulfamethoxazole for the pABA binding site of the pABA substrate remains to
be determined.
Following this we performed a series of simulations involving the pterin-smx
hybrid compound that had been developed in our lab (Figure 2.8). The first set of
simulations was very similar to the pteroate simulations discussed previously for series
1. These simulations involved a 2 nanosecond implicit simulation of the pterin-smx
compound both with and without the Mg2+ and sulfate bound in the anionic site. As in
the corresponding pteroate simulations, the structure lacking magnesium and sulfate in
the anionic pocket was unable to maintain cohesiveness and the pterin-smx compound
began to fall out of the active site halfway through the simulation. Again the Arg254
folded back to make ionic interactions with Asp101 and Asp61. The presence of an
anionic sulfate or phosphate in this subsite seems crucial to stabilizing the Arg254
residue in its extended form, which appears necessary to keep any pterin substrate in
the active site. The structure with the sulfate and magnesium present maintained the
pterin-smx in the active site for the duration of the simulation. Arg68 was observed to
interact with the negatively charged sulfonamide group for nearly the entire simulation.
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The oxazole ring rotated between the “up” and “down” conformations several times
during the course of this simulation.
To compare the differences between implicit and explicit solvation and their
effects on loop and substrate movements, we designed and ran a pterin-smx simulation,
explicitly solvated, for 2 nanoseconds. This simulation included both the magnesium
and sulfate groups in the anionic site and corresponded to the 2 ns implicit simulation
just discussed. Two key differences were noted with this simulation. First, the oxazole
ring did not move between the two positions as quickly as in the implicit solvation
simulation. This is likely due to the effect known as “solvent drag”, where the viscosity of
the explicit solvent slows small scale movements such as this. The second interesting
difference that was noted was that the side chain of Arg68 maintained contact with the
sulfate group in the anionic pocket for the duration of the simulation, whereas in the
implicitly solvated simulation, the arginine side chain interacted with the sulfonamide
group of the pterin-smx hybrid. Figure 2.12 shows the average positions of the pterinsmx, sulfate, cation, and close side chains for the implicit simulation (left) and the explicit
simulation (right). The reason for the preference of the arginine for the sulfate in the
explicitly solvated simulation is not readily clear, although the altered conformation of
Asn27 and the result on the position of the cation is noted and may have played a role in
the placement of the arginine side chain.
The final set of simulations that were performed using the pterin-smx hybrid was
a set of 4ns, explicitly solvated simulations with pyrophosphate and magnesium in the
anionic pocket. We had two goals with this set of simulations. First, to more accurately
simulate the “dead-end” product stage of the DHPS reaction by using the pyrophosphate
product rather than a sulfate anion in the anionic pocket. Up to this point, difficulties with
the parameterization of pyrophosphate had precluded our use of this compound in our

Figure 2.12. DHPS Pterin-SMX Final Simulation Structures; Implicit Left, Explicit
Right
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simulations, but by strengthening the force constants predicted by the Antechamber
program, we were able to use pyrophosphate in these simulations. The second goal
was to investigate the position of the oxazole ring and the Arg68 side chain. To this end,
we utilized the both of the pterin-smx crystal structures that had been solved in our
group (discussed above in section 2.2.1). In the first simulation, we utilized the first
pterin-smx crystal structure that was solved and placed the oxazole in the “down”
position and the arginine side chain interacting with the pyrophosphate. In the second
simulation we utilized the second pterin-smx crystal structure as the starting position,
with the oxazole ring placed in the “up” position and the arginine side chain interacting
with the sulfonamide group. Figure 2.9 shows the starting structure of the active site for
both these simulations, oxazole “down” on the left and oxazole “up” on the right. In
addition to monitoring the positions of the Arg68 side chain and the oxazole, we also
followed the positions of the three conserved resistance conferring mutation sites,
Phe33, Pro69, and Thr67, in an attempt to identify any interactions that these residues
made with the pterin-smx compound that might be disrupted following a mutation and
decrease the binding affinity of the sulfamethoxazole.
In the oxazole “down” simulation the pterin-smx compound remained in the active
site for the duration of the simulation, although large movements and loss of some key
binding interactions in the pterin subsite were noted midway through the simulation.
This corresponded with the loss of the pyrophosphate group from the anionic site at 1.8
ns. The Arg68 side chain maintained an ionic interaction with the pyrophosphate group
for the duration of the simulation. In fact, the Arg68 side chain was observed to almost
“pull” out the pyrophosphate from the anionic site. Whether this is the normal
mechanism for the enzyme’s substrate removal or an artifact from the starting position of
the simulation remains to be determined. Phe33 and Thr67 were observed to make
interactions with the pterin-smx compound and the pyrophosphate, respectively, but
Pro69 made no observable interaction with the pterin-smx compound during the
simulation period. Although not observed in the average structure calculated, Phe33
was observed to make aromatic stacking interactions with the oxazole ring of the pterinsmx compound at several points during the production phase of the trajectory and
seemed to alternate between this position and another stacking interaction with Phe71 in
loop 2 (seen in our average structure). The interaction with the oxazole ring may
contribute to the stabilization of the sulfamethoxazole compound in the pABA site, while
the interaction with Phe71 possibly contributes to the stabilization of loops 1 and 2 in
their “active” configurations. The hydroxyl group of Thr67 made hydrogen bonding
interactions with the pyrophosphate group and maintained this bond as the
pyrophosphate left the anionic site. Figure 2.13 shows the stacking interaction between
the oxazole ring and the Phe33 side chain that was observed in this simulation. Also
visible is the interaction between the pyrophosphate group and Arg68 and Thr67 as it
leaves the anionic subsite (note this is image was not obtained from the average
structure).
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Figure 2.13. Pterin-SMX Down, 4ns Explicit Simulation
The matching simulation was performed starting with the oxazole ring in the up
position and the arginine side chain interacting with the sulfonamide group of the pterinsmx compound (shown in Figure 2.9). In this simulation the pterin-smx compound
stayed tightly bound to the active site and maintained all key binding interactions for the
duration of the simulation. The oxazole ring stayed in the up position tucked between
loop 6 and loop 7 and was not observed to interact with the Phe33 side chain or any of
the other conserved resistance mutation residues. The pyrophosphate group stayed in
the anionic subsite for the duration of the simulation. The side chain of Arg68 initially
formed an ionic interaction with the negatively charged sulfonamide group of the
pterin-smx, but this was quickly lost as the side chain migrated to interact with loop 1
residues, particularly Phe33, shown in Figure 2.14 (average structure).
2.3.3 Resistance Mutation Simulations
The final series of simulations that were performed in these studies involved
analyzing the effects of the three key mutations, F33L, T67A, and P69S, that have been
observed to confer sulfonamide resistance in several bacterial species. In six
simulations of 4ns each, under implicit solvation, both pABA and SMX were analyzed in
their ternary complex with DHPP with one each of the three mutations applied. In these
simulations, a Na+ occupied the anionic subsite along with the diphosphate group of
DHPP. These simulations were compared with the corresponding native enzyme
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Figure 2.14. Pterin-SMX Up, 4ns Explicit Simulation
simulations from series 1 and series 2.
The first set of simulations involved the F33L mutation. In the pABA simulation,
the pABA compound was quickly expelled from the active site, by 0.2 ns, no interactions
with Leu33 were noted. Arg68 made contact with the terminal phosphate of DHPP,
which remained in the pterin site for the duration of the simulation. Loop 1 was observed
to lose its position and fold away from the active site. By 2 nanoseconds, loop 1 had
begun to form into a helical structure. The reason for the quick loss of the pABA group
down position, the sulfamethoxazole compound stayed in the pABA site for the duration
of the simulation. Arg68 alternated contact between the negatively charged sulfonamide
group and the terminal phosphate of DHPP, at some time points it was able to make a
bridging interaction between the two groups. As in the pABA simulation, loop 1 quickly
folded out of place and the Leu33 side chain was not observed to interact with
sulfamethoxazole at any time. The helix formation of loop 1 was not observed in this
simulation. Although the reason for the retention of sulfamethoxazole and the quick
expulsion of the pABA compound are not clear, the effects of the F33L mutation on the
position of loop 1 over the active site seemed to reinforce our observation from series 2
that the Phe33 residue plays an important role in the stabilization of loop1 during
catalysis.
The second set of resistance simulations was the Thr67Ala simulations. In this
set of simulations both the pABA and the sulfamethoxazole compounds were
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immediately expelled from the active site. No interaction between Ala67 was noted with
either pABA, sulfamethoxazole, or DHPP in either simulation. Again, Arg68 made and
kept an ionic interaction with the diphosphate group and the DHPP compound remained
in the pterin site for the duration of the simulation. Interestingly, in this set of
simulations, loop1 was not observed to withdraw from the active site and kept its
approximate starting position for the duration of the simulation in both cases.
The final set of simulations was the Pro69Ser mutation. The results of this set of
simulations were similar to those seen with the two previous sets. Both pABA and
sulfamethoxazole were expelled from the active site early on in the simulations. Arg68
and DHPP behaved in the same manner as that seen in the first two sets of resistance
simulations, and loop 1 maintained its position near the active site. Ser69 was observed
to make hydrogen bonds to both the pABA and the sulfonamide compounds during and
after these compounds were leaving the active site, however the significance of these
interactions is not clear as they did not involve the binding of either compound in the
pABA subsite.

2.4 Summary
The simulations described in this chapter have contributed, at least in part, to our
understanding of the binding of both the normal substrates and sulfonamide inhibitors of
DHPS. Additionally, we have gained insights into the roles during binding and catalysis
of several key residues, whose positions were unclear in our crystal structures as well as
the overall positions of loops 1 and 2 during binding and catalysis. In particular the role
and position of Arg68, Phe33, Thr67, and Pro69 were closely followed during these
simulations. A summary of our findings follows below.
Arg68 has been proposed (and observed in 1 of our crystal structures) to make
ionic contact with the negatively charged carboxylate in pABA or the negatively charged
sulfonamide group in that class is antibacterials. The majority of our simulations seemed
to indicate a preference of the Arg68 side chain for the negatively charged sulfate or
phosphate in the anionic binding pocket rather than pABA or sulfonamide group.
Although this may be due in part to the starting position of the arginine group, we noted
that even when the Arg68 side chain was started in a position where it interacted with
the sulfonamide group (as in our “oxazole up” pterin-smx simulations), the contact was
not maintained. We noted in one simulation that the Arg68 side chain appeared to
facilitate the removal of the pyrophosphate substrate from the anionic pocket, possibly
assisted in this by hydrogen bonding interactions made by Thr67.
Phe33 is a key residue that confers resistance to sulfonamide agents when
mutated to leucine. We followed this residue closely in all of our simulations and noted
an inability of the Phe33 side chain to interact directly with pABA due to distance
constraints. However, the aromatic side chain of Phe33 was able to interact with the
oxazole side chain of sulfamethoxazole when the simulation was started with this group
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out and down. We note the presence of an aromatic group at this position in the majority
of the sulfonamide agents that have been marketed. It is possible that this interaction
facilitates sulfonamide binding and that the loss of this interaction upon Phe33 mutation
decreases the binding affinity of sulfonamide groups for the pABA binding site. This
observation can be confirmed by performing activity assessments with a DHPS mutant,
sulfamethoxazole (or other aromatic side chain containing sulfonamide), and
sulfanilamide (a sulfonamide drug without an aromatic side chain). If this theory is
correct, the Phe33 mutation will lower the activity of sulfamethoxazole, but not affect the
activity of sulfanilamide. Another possible explanation for the role of Phe33 is the
stabilization of loop 1 in a position near the active site during catalysis. We noted in our
F33L mutation simulations that loop 1 moved quickly out of position when this residue
was mutated, but stayed in position otherwise (as long as a pterin substrate and anion
were present in the active site). This phenomenon has been observed by another
group, performing similar studies with S. pneumoniae.181
Our simulations provided us with some insight into the role and function of Thr67
in binding, loop position, and resistance. In the product/substrate simulations Thr67 was
observed to make a hydrogen bond with Lys73, also in loop 2, and possibly play a role in
the stabilization of loop 2 during catalysis. We also noted, in our pterin-smx simulations,
that the Thr67 made hydrogen bond interactions with the pyrophosphate group as it left
the anionic pocket, possibly facilitating the removal of this group. We note that the
Thr67 side chain is normally not able to interact with the anionic substrate when it
occupies its normal position in the anionic pocket. Unfortunately, we did not observe
any interactions with Ala67 in the T67A mutation simulations that could provide any
insight into the mechanism of this sulfonamide resistance conferring mutation.
The Pro69 residue was observed to play a key role in pABA binding during our
product/substrate simulations by making vdW interactions with one face of the pABA ring
structure. Presumably, this interaction is disrupted upon mutation to a serine residue
such that the sulfonamide agents can no longer bind. However, our mutations
simulations with P69S did not reveal the mechanism of this resistance as both
compounds were expelled from the active site rather quickly.
In addition to following the residues mentioned above, we were keenly interested
in the position of the oxazole ring of sulfamethoxazole during binding and performed
simulations with this group in the two positions we observed in our crystal structures.
Although, when the oxazole ring was in the “up” position, tucked into a small pocket
between loops 6 and 7 it was not able to make the Phe33 stacking interaction, we noted
that this position in the pterin-smx simulations was very stable (more so than the “down”
position). Another known resistance mutation may lend credence to the oxazole in this
position. In N. meningitides, a glycine to cysteine residue has been shown to confer
resistance to sulfonamide drugs. This glycine corresponds to Gly188, which resides in
the small pocket the oxazole ring fills while in the “up” position. A mutation to cysteine
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would presumably block the oxazole ring from occupying this pocket, theoretically
leading to a decreased affinity of the sulfonamide drugs for the pABA binding site.
Finally, the role and position of the Arg254 residue and the terminal phosphate of
DHPP (or sulfate in several of our studies) deserves mention. This arginine side chain is
known (and can be seen in our crystal structures) to play a key role in pterin binding.
Our simulations showed in several cases that the position of the Arg254 side chain was
dependent on the negatively charged group in the anionic subsite. An extended position
was only maintained when the negatively charged group was present. Additionally, even
in the presence of a pterin substrate, if the anionic group was absent, the Arg254 side
chain withdrew from the pterin site and folded back to make ionic interactions at the back
of the pocket. The direct result of this was the destabilization of the pterin substrate in
the pterin subsite. This seems to imply that the pyrophosphate product leaves the active
site first (perhaps facilitated by Arg68), followed by the pteroate product after Arg254
withdraws from the active site. This observation may have ramification on the design of
pterin site binding inhibitors of DHPS.
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CHAPTER 3. MOLECULAR DOCKING VALIDATION STUDIES ON
DHPS
3.1 Introduction
The overall goal of the research presented in Chapters 2, 3 and 4 is the
discovery of novel compounds with significant binding affinities for the pterin pocket of B.
anthracis DHPS using virtual screening approaches. The pterin binding pocket in DHPS
represents an attractive alternative target for the design of novel antibacterial agents.
There is a high degree of conservation in the residues that comprise this pocket, and no
resistance mutations have been documented in or adjacent to this site, as can be seen
from Figure 3.1. To date, a variety of DHPS apo- and holo- crystal structures have been
deposited in the Protein Data Bank from six bacterial species (E. coli, S. aureus, M.
tuberculosis, B. anthracis, T. thermophilus, and S. pneumonia) as well as one fungal
species (S. cerevisiae).151-157 However, prior to embarking on a large virtual screening
project against the pterin site of DHPS, it was necessary to investigate different docking
and scoring programs and validate their performance. The work presented in this
chapter details our extensive docking validation studies against the DHPS pterin site.
3.1.1 Why Validate?
Large-scale virtual screening or high-throughput molecular docking (HTD) of inhouse or commercial databases has become a common lead discovery technique in
drug design. It has been shown to be a complementary tool to traditional, highthroughput screening, with hit rates that can be orders of magnitude higher than those
from the latter.11 In this study, we specifically address the problem of selecting an
appropriate docking and scoring combination for virtual screening against a specific
target and accurately rank-ordering the virtual hits for further analysis. A review of the
literature reveals that there are many docking programs and scoring functions which
have been investigated in numerous docking validation studies since 2000.182-196 It is
clear from these studies that, given the large number of docking and scoring functions
available, and the variability in their performance with different targets, it is crucial to
perform a docking validation study prior to embarking on any virtual screening
experiment.184,185,187,192,193,196 Ideally, the identification of the optimal docking and scoring
combination will decrease the number of false positives and false negatives while
ensuring optimal hit rates.
3.1.2 Docking Validation: Current Methods and Metrics
A number of methods have been reported for validating docking programs and
scoring functions.197,198 One commonly used method is pose selection whereby docking
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Figure 3.1. DHPS Structure with Resistance Mutation Sites Highlighted
Proposed transition state analog shown in active site. Residues conferring sulfonamide
resistances are shown in yellow (see Table 2.2).
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programs are used to re-dock into the target’s active site a compound with a known
conformation and orientation, typically from a co-crystal structure. Programs that are
able to return poses below a preselected Root Mean Square Deviation (RMSD) value
from the known conformation (usually 1.5 or 2 Å depending on ligand size) are
considered to have performed successfully. Pose selection is then followed by scoring
and ranking to study which of the available scoring functions most accurately ranks the
poses with respect to their RMSD values.
Another validation method is to dock a so-called decoy set of inactive, or
presumed inactive, compounds that has been ‘seeded’ with compounds with known
activity against the target in question. After ranking the docked decoy set by score,
enrichment can be calculated and enrichment plots or Receiver Operating Characteristic
(ROC) curves plotted.199-201 ROC curves plot the sensitivity (Se) of a given
docking/scoring combination against specificity (Sp), and Area’s Under the Curve (AUC)
can be calculated for comparison. There are two reported advantages of ROC curves
over enrichment plots; they are independent of the number of actives in the decoy set
and they include information on sensitivity as well as specificity.198,202 However, the
former advantage has recently been challenged.203
3.1.3 DHPS Validation: Research Project Goals
In this study of the B. anthracis DHPS pterin-binding pocket, five docking
programs and nine scoring functions were evaluated using pose selection/scoring and
enrichment studies. Pose selection and scoring used the 7-amino-3-(1-carboxyethyl)-1methyl-pyrimido (4,5-c)-pyridazine-4,5(1H; 6H)-dione (AMPPD) co-crystal structure,
shown in Figure 3.2, as the source structure. AMPPD was first described as a pterinbased DHPS inhibitor by researchers at Burroughs Wellcome Co.204-207 We have been
able to re-synthesize AMPPD and obtain a 2.3 Å resolution co-crystal structure using B.
anthracis DHPS. RMSD calculations were used to determine how well specific
docking/scoring combinations pose and score the ligand in the pterin site. Enrichment
studies were performed using 10 compounds also identified in the Burroughs Wellcome
efforts, with measured inhibitory activity against E. coli DHPS that are known to bind to
the pterin-binding site.206,207 These active compounds were seeded into three separate
decoy sets, each of which has been used in previously reported docking validation
studies. Enrichment at 1% and 2%, and ROC curves were used to compare
docking/scoring combinations, and results across decoy set were also compared.
The work reported here seeks to address eight questions. (1) How useful is
simple pose selection and scoring for determining the optimal docking/ scoring
combinations for use against a specific target? (2) How do enrichment calculations at
1% and 2% compare with Areas under ROC curves in evaluating the docking/scoring
combinations? (3) How important is decoy set selection? (4) How do docking failures
affect results and how should these be accounted for? (5) How does post-docking
relaxation affect enrichment results? (6) Can the use of consensus scoring improve

73

Figure 3.2. 7-amino-3-(1-carboxyethyl)-1-methyl-pyrimido (4,5-c)-pyridazine-4,5(1H;
6H)-dione, AMPPD
enrichment results? (7) Is it possible to incorporate the known inhibitory activities of the
seeded active compounds to more accurately distinguish between the docking/scoring
combinations? Finally, and most importantly for our project, (8) which is the best
docking/scoring combination for use in virtual screening against the pterin-binding
pocket of the B. anthracis DHPS enzyme?

3.2 Molecular Docking Validation against DHPS: Methods
3.2.1 Docking Programs and Scoring Functions
Five docking programs were evaluated in this study, FlexX, DOCK, Glide, GOLD,
and Surflex. FlexX52 v1.20.1 and Surflex65 v2.0.1 are included in the Sybyl 7.3 molecular
modelling suite of Tripos, Inc.208 GOLD57 v3.1.1 was obtained from Cambridge
Crystallographic Data Centre (CCDC)209, Glide56,210 v4.0 is available from Schrodinger,
Inc.211, and DOCK49,212,213 v6.0 is freely available to academic institutions from the
University of California, San Francisco. FlexX, Surflex, and DOCK use incremental
construction algorithms to select compound poses. GOLD uses a genetic algorithm, and
Glide is a hybrid method that uses a torsional energy optimization and Monte Carlo
sampling214 for refinement. Nine Scoring functions were investigated. F-Score52,
Surflex-Score58, ChemScore63, and GlideScore56 are empirical scoring functions, PMFScore82 is knowledge-based, and D-Score212, G-Score57, GOLD-Score and Grid-Score
are force-field scoring functions. F-Score, D-Score, G-Score, ChemScore, and PMFScore are included in the Cscore module of Sybyl 7.3, while Surflex-Score, GOLDScore, and GlideScore are the native scoring functions for Surflex, GOLD, and Glide,
respectively. F-Score is also the native scoring function for FlexX, and Grid scoring was
selected for use with the DOCK program.
3.2.2 DHPS Target Structure
The crystal structure of AMPPD in complex with B. anthracis DHPS, shown in
Figure 3.3, was used for all the molecular docking exercises performed in this study. We
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Figure 3.3. AMPPD Shown Bound into the Pterin Binding Pocket
Key hydrogen bonds are indicated by spherical ellipsoids.
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have determined the structures of B. anthracis DHPS in complex with several ligands
including pterin site binders and product analogs.154 The AMPPD structure was chosen
for use in this study for three reasons; it binds solely within the pterin binding pocket and
does not interact with the adjacent pABA, it has two rotatable bonds which adds an
additional degree of complexity to the docking problem compared to the rigid pterin site
binders available to us, and its complex with DHPS is one of the highest resolution
structures that we have determined. The structure was prepared using the Biopolymer
tool of Sybyl 7.3. Missing residues within mobile loops 1 and 2 were modelled using the
closely similar E. coli and M. tuberculosis DHPS structures previously reported and
discussed in section.151,153 Loops 1 and 2 are believed to participate in pABA binding
and catalysis, but appear to play little or no role in pterin binding to the enzyme.
Hydrogen atoms were added and AMBER FF99 charges were calculated for the protein.
A structurally conserved water molecule (WAT1) that interacts with residues Ile187 and
Gly216 directly adjacent to the pterin site was included as part of the receptor. A 1000
iteration minimization of the hydrogen atoms was followed by a 100 ps molecular
dynamics simulation to refine the positions of the mobile loops 1 and 2. The simulation
was performed with the Dynamics tool of Sybyl7.3 using the NTP ensemble, standard
temperature and pressure, and 2 fs steps. All residues and ligands with the exception of
those in loops 1 and 2 were held under tight constraints. The average structure from the
last 20 ps of the simulation was calculated, and a 100 iteration minimization was applied
to the entire structure to obtain the final receptor structure.
3.2.3 Docking Methodology
General. For consistency, site description files for all docking programs were
generated using the AMPPD ligand and an 8 Å spherical radius. WAT1 was included in
all docking runs for all programs. FlexX v1.20.1. A receptor description file was built
using the saved .pdb file. Ligands were docked as mol2 files and prepared as discussed
below. All other parameters accepted default settings for docking runs. GOLD v3.1.1.
Default speed settings were accepted for both pose selection and enrichment studies.
The input structure was the mol2 file with ligand extracted. WAT1 was set ‘on’ with spin
orientation enabled, and the set atom types function was ‘on’ for ligand and ‘off’ for the
protein. The fitness function was set to GOLD-Score (ChemScore disabled) with default
input and annealing parameters. The Genetic Algorithm default settings were accepted
as population size 100, selection pressure 1.1, number of operations 100,000, number of
islands 5, niche size 2, migrate 10, mutate 95, and crossover 95. All other parameters
accepted the default settings. Surflex v2.0.1. The SFXC file was built using the mol2
prepared protein structure. The protomol was generated using the AMPPD ligand with a
threshold of 0.50 and bloat set to 0 (default settings). Ligands were prepared as
described below and docked as mol2 files. Cscore calculations were enabled on all
Surflex docking runs. All other parameters accepted the default settings. Glide v4.0.
The receptor grid was generated using the mol2 file and was based upon the AMPPD
ligand and an 8 Å enclosing box. Default values were accepted for van der Waals
scaling and input partial charges were used. Standard precision docking was used for
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all Glide docking runs, with default settings for all other parameters and no constraints or
similarity scoring applied. DOCK v6.0. The structure and ligand were prepared as
discussed above and saved as mol2 files. The molecular surface was generated with
the dms tool, included in the DOCK v6.0 package, with a default probe radius of 1.4 Å.
Sphgen was used to generate spheres using the dms output and default settings. The
active site was defined using the sphere selector tool and an 8 Å radius about the
AMPPD ligand, and a corresponding 8 Å grid was generated for scoring using the
showbox and grid tools. Flexible ligand docking was utilized with grid scoring as
primary and secondary scoring and ligand minimization was enabled. All other docking
parameters accepted default settings for docking runs.
3.2.4 Ligand Preparation
Ligands were prepared for docking using the Sybyl 7.3 Molecular Modelling Suite
of Tripos, Inc. 3D conformations were generated using Concord 4.0215, hydrogen atoms
were added and charges were loaded using the Gasteiger and Marsili charge calculation
method.105 Basic amines were protonated and acidic carboxyl groups were deprotonated prior to charge calculation. The AMPPD ligand was minimized with the
Tripos Force Field prior to docking using the Powell method with an initial Simplex216
optimization and 1000 iterations or gradient termination at 0.01 kcal/(mol*A). Input
ligand file format was mol2 for all docking programs investigated.
3.2.5 Pose Selection and Scoring
The AMPPD compound was prepared for docking as described above. It was
then docked into the DHPS active site of the AMPPD co-crystal structure with each
docking program using the methods described above. The number of poses returned by
each docking program was determined by the default settings, and the poses were
scored using that program’s native scoring function. Using the five scoring functions
available in the Cscore module of Sybyl, the poses were scored once again in a process
that we define as ‘rescoring’. The rms analysis tool in the GOLD utilities was used to
calculate non-hydrogen RMSD of the docked and scored poses relative to the crystal
structure conformation of the AMPPD compound. We used an RMSD of 1.5 Å as our
threshold for determining success or failure as opposed to the commonly used 2 Å
because of the relatively low number of freely rotatable bonds in the AMPPD compound.
For pose selection, the pose with the lowest RMSD was determined from all poses
returned by the docking program, regardless of rank. For scoring utility, the RMSD of
the best scoring compound was calculated.
3.2.6 Enrichment Studies
Decoy Sets. In this study, three compound sets that had been used in previous
validation studies were chosen as the decoy sets. The Schrodinger decoy set was used
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to validate the Glide docking program.56,210 It consists of 1000 drug-like compounds with
an average molecular weight of 400 D and was downloaded as a 3D SD file from the
Schrodinger website. The ZINC decoy set of 1000 compounds was used by Pham &
Jain in a validation study of the Surflex scoring function.217 The Available Chemicals
Directory (ACD) decoy set of 861 compounds was used by Bissantz and co-workers in a
large docking/scoring validation study.196 Both the ZINC and ACD decoy sets are
available in the Sybyl demo material as 3D SLN files. Active Compounds. The active
compounds that were seeded into each of the decoy sets are shown in Figure 3.4. They
were chosen from a previously published series of 65 DHPS inhibitors that are known to
bind to the virtually identical pterin site of E. coli DHPS.206,207 The compounds were
chosen to reflect as broad a range of binding affinities and structural differences as
possible, with the requirement that the activity of the compounds is below an IC50 of 20
μM. The compounds were built using the Sketch tool of Sybyl 7.3 and prepared for
docking as described above. Rescoring. The highest scoring pose of each compound
in the enrichment sets (both active and decoy) was saved for each docking program and
imported into a Sybyl Molecular Spreadsheet for rescoring using the Cscore functions FScore, ChemScore, PMF-Score, D-Score, and G-Score. The effect of relaxing the
compounds in the active site using the Cscore relaxation option was investigating by
scoring before and after the relaxation. Additionally, a composite score was calculated
using the 5 Cscore functions for both the relaxed and unrelaxed scores calculated.
3.2.7 Statistical Analysis
We have developed a non parametric statistic, sum of the sum of log rank
(SSLR), to test whether a scoring function performs better than random ordering and to
compare the docking performances of two scoring functions. The SSLR statistic
considers both the ranks of known active compounds relative to the decoy compounds
and also the orders of the rank indicated by the IC50 values. For a virtual screening
experiment, assuming a total of m decoy compounds and n active compounds, the
SSLR statistic is defined as:
∑

∑

log

Equation 3.1

where is the rank of the jth active compound among all N = m+n compounds; n active
compounds are arranged in the order according to their IC50 values. By default, the
smaller the IC50 is the more active is the compound; small SSLR favors early detection
of active compounds. Test if a scoring function performs better than random
scoring. The exact distribution of SSLR under null hypothesis is difficult to derive
mathematically but can be easily obtained numerically by simulations. The null
hypothesis assumes that the ranks of the active compounds are assigned completely at
random. We simulate this random scoring study 1 million times and record all their SSLR
values. The empirical distribution of the simulated values represents an estimate to the
exact distribution. We believe that 1 million simulations should be sufficient enough to
produce a reasonably good estimate. The p value of the test is simply the proportion of
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Figure 3.4. DHPS Active Compounds Used in Enrichment Studies Shown with
Activity against E. coli DHPS
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the times that the simulated SSLRs are less than the observed SSLR. Compare the
performances of two scoring functions. We have developed a permutation test to
compare the performance of two scoring functions. Under the null hypothesis that two
0, the ranks of the active compounds of
scoring function are equal, i.e.
the two scoring functions are interchangeable. Assuming and are ranks of the ith
active compound for the two scoring functions, the permuted rank is given by:
1

Equation 3.2

1

Equation 3.3

and

where
is from Bernoulli distribution with success probability 0.5. Empirical distribution
of the difference of SSLR is obtained based on the permuted data and the p value of the
test is given by the proportion of the times that the permuted differences are greater or
less than the observed difference, depending on the direction of alternative hypothesis.
Missing values. In situations where the docking and scoring combination failed to
return poses (failed docking), we have penalized the docking/scoring combination by
giving those compounds with missing scores the worst score returned by that particular
scoring function for a compound in the decoy set (see our discussion on docking failures
below).

3.3 Molecular Docking Validation against DHPS: Results
3.3.1 Pose Selection and Scoring
Table 3.1 shows the results of the pose selection and scoring validation trials.
The number of poses returned by the five individual docking programs is listed in
parentheses below the docking program name. The best pose, as determined by lowest
RMSD, and the rank of that pose by the docking program’s native scoring function is
given in column 2. Column 3 lists the RMSD of the top scored pose by the native
scoring function of each docking program. Scored poses with an RMSD of less than or
equal to 1.5 Å are considered to be successful. Each of the five docking programs
successfully returned a correct pose, and four of the five native scoring functions ranked
a correct pose as the highest. The one exception was the GOLD and Gold-Score
function combination which ranked a pose with a 3.29 Å RMSD as the highest. Columns
4 through 8 in Table 1 give the rescoring results with the Cscore scoring functions; the
RMSD of the top ranked pose after rescoring is presented together with the rank of that
pose by the native scoring function in parentheses. In most cases, the Cscore scoring
functions were able to rank successful poses, and the failures are shown in red in Table
3.1. Three of the scoring functions were not able to rank the FlexX poses, and D-Score
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Table 3.1. Pose Selection and Scoring Results

Docking
Program

FlexX
(30
Poses)
Surflex
(10
Poses)
Glide
(30
Poses)
GOLD
(5
Poses)
DOCK
(10
Poses)

Best
Pose
(Pose
Rank)

Native
Scoring
Function
(1st)

0.56 Å
(3rd)

F-Score
(Pose
Rank)

G-Score
(Pose
Rank)

D-Score
(Pose
Rank)

ChemScore
(Pose
Rank)

PMFScore
(Pose
Rank)

1.19 Å

1.19 Å
(1st)

1.87 Å
(10th)

17.22 Å
(21st)

1.87 Å
(10th)

1.03 Å
(2nd)

1.48 Å
(3rd)

1.49 Å

1.50 Å
(10th)

1.50 Å
(10th)

1.49 Å
(6th)

1.49 Å
(1st)

1.48 Å
(4th)

0.37 Å
(10th)

1.13 Å

0.40 Å
(11th)

0.43 Å
(15th)

1.13 Å
(1st)

0.37 Å
(10th)

0.40 Å
(12th)

1.30 Å
(4th)

3.29 Å

1.30 Å
(4th)

3.37 Å
(3rd)

1.30 Å
(4th)

1.30 Å
(4th)

1.30 Å
(4th)

0.38 Å
(10th)

0.85 Å

0.85 Å
(1st)

1.00 Å
(4th)

0.52 Å
(10th)

0.85 Å
(1st)

1.00 Å
(5th)

Non-hydrogen RMSD values are shown; RMSD values less than 1.5 Angstroms are
considered correct poses, greater than 1.5 Angstroms are considered failed.
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performed particularly poorly in this respect, ranking a failed docking pose (outside the
pterin site) as the highest. However, D Score was able to correctly rank a successful GScore and ChemScore were not able to correctly rank poses generated by FlexX, and
G-Score also failed with the poses generated by GOLD. Overall, F-Score and PMFScore correctly rescored the poses generated by all the docking programs and were the
best performing functions in this respect. We also note that the poses returned by the
Surflex, Glide, and DOCK programs were always successfully scored by both the native
functions and the Cscore functions.
3.3.2 Enrichment Studies
Figures 3.5, 3.6, and 3.7 show the calculated enrichment at 1% for each docking
program/scoring function combination when used with each of the three decoy sets used
in this study. It should be noted that we were not able to complete the GOLD docking of
the ACD decoy set due to licensing issues, but the ZINC and Schrödinger decoy sets
were successfully docked by the GOLD docking program. Enrichment is defined as the
number of active compounds detected at a given percent of total decoy set by score
ranked pose. Enrichment was calculated at 1% and 2% of the total decoy set rather
than 1% and 2% of compounds successfully docked. This requires further explanation.
Table 3.2 displays the number of poses (1 pose per compound) returned by the docking
programs investigated in this validation study. It is apparent that some programs were
able to return more poses than other programs, and this must be taken into account so
as not to unfairly penalize programs that failed to dock some of the decoy compounds.
Several observations can be made from the data presented in Figures 3.5 to 3.7.
First, the two force field based functions, D-Score and G-Score, and the empirical
function ChemScore all performed poorly for each decoy set. Second, the Glide and
Surflex docking programs with their native scoring functions performed well (4 or more
actives detected at 1%) against each of the three decoy sets. Finally, when used as the
FlexX native scoring function, F-Score performed poorly against all three decoy sets, but
when used to rescore for the other four docking programs F-Score returned modest to
good results. Most notably, F-Score detected 5 of the 10 active compounds when used
with DOCK against the ZINC validation set.
Enrichment was also calculated at 2% of the total decoy set docked for
comparison (see supplementary material). D-Score, G-Score and ChemScore
continued to perform poorly. The scoring functions F-Score and PMF-Score were able
to detect on average 1 or 2 more active compounds at 2%. Notably, the top performers
at 1%, GlideScore and SurflexScore, continued to show excellent results at 2%,
detecting between 6 and 8 of the 10 active compounds.
When comparing the enrichment results with respect to the choice of decoy set,
there was a clear difference in performance for the various docking/scoring
combinations. Overall, the ZINC decoy set returned the best enrichment results, while
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Figure 3.5. Enrichment Factors at 1% of Total Validation Set Docked, ZINC Decoy
Set
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Figure 3.6. Enrichment Factors at 1% of Total Validation Set Docked, Schrödinger
Decoy Set
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Figure 3.7. Enrichment Factors at 1% of Total Validation Set Docked, ACD Decoy
Set
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Table 3.2. Number of Compounds Docked by Validation Set
Docking Tool
Full Set
DOCK
FlexX
Surflex
GOLD
Glide

ACD
871
749
811
870
n/d
579

Schrödinger
1010
752
991
1010
1010
607

ZINC
1010
852
1004
1010
991
819

the ACD decoy set returned the worst results. It might be expected that the docking
programs would have the most difficulty in distinguishing the active compounds from the
decoy set when they are close in size and lipophilicity, but this trend was not seen in our
enrichment studies. The Schrödinger decoy set differed most from the active
compounds with respect to these two parameters but returned the worst enrichment
results, while the ZINC and ACD sets, which have the closest parameters, yielded better
enrichment results.
3.3.3 Receiver-Operating Characteristic Curves
Figures 3.8, 3.9 and 3.10 show representative ROC plots for three of the five
docking programs evaluated in this study (see Appendix C for additional ROC plots).
The results from the native scoring functions and from rescoring with the five Cscore
scoring functions are shown. The calculated areas under the receiver-operating
characteristic curves (AU-ROC) values for each docking program with its native scoring
function and the five Cscore functions are given in Table 3.3, and are color coded
according to performance; green - excellent (above 0.9), black – moderately well (0.9 to
0.6), red – poor (less than 0.6). Calculated p values are shown in parentheses in Table
3.3. At a significance level (α) of 0.05, p values less than 0.05 indicate significant
improvement over random selection while p values greater than 0.05 indicate no
significant difference over random selection. It should be noted that, when creating the
ROC curves, we used the total number of compounds in the validation set rather than
total number of docked compounds to enable a more direct comparison of the
performance of the docking and scoring algorithms. This point has been discussed
earlier with respect to enrichment values, but it is also relevant here. As can be seen
from Figure 3.11, when calculating the area under the ROC for Glide using both the total
Schrödinger decoy set versus the total successfully docked, there is a small but
noticeable difference. This presents a problem when comparing results with a docking
program such as Surflex that was able to dock the complete Schrödinger decoy set.
Four observations can be made from these results. First, unlike the enrichment
results at 1% and 2%, there is little difference in the ROC results for docking programs
when compared across decoy sets. Generally, when a docking/scoring combination
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Figure 3.8. Selected ROC Plots: Glide Docking of ZINC Decoy Set
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Figure 3.9. Selected ROC Plots: Surflex Docking of Schrodinger Decoy Set
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Figure 3.10. Selected ROC Plots: GOLD Docking of Schrodinger Decoy Set
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Table 3.3. Calculated AU-ROC with p Values from ROC Curves for 5 Docking Programs, Native Score and Cscore Functions
(Unrelaxed)
Docking Program /
Validation Set
DOCK - ZINC
DOCK - Schrödinger
DOCK - ACD
FlexX - ZINC
FlexX - Schrödinger
FlexX - ACD
Glide - ZINC
Glide - Schrödinger
Glide - ACD
Surflex - ZINC
Surflex - Schrödinger
Surflex - ACD
GOLD - ZINC
GOLD - Schrödinger

Native Scorea
0.835 (<.001)
0.770 (<.001)
0.902 (<.001)
F-Score
F-Score
F-Score
0.971 (<.001)
0.982 (<.001)
0.977 (<001)
0.985 (<.001)
0.978 (<.001)
0.975 (<.001)
0.763 (.002)
0.778 (<.001)

F-Score
0.804 (.001)
0.793 (.001)
0.860 (<.001)
0.813 (<.001)
0.746 (<.001)
0.891 (<.001)
0.941 (<.001)
0.947 (<.001)
0.975 (<.001)
0.980 (<.001)
0.963 (<.001)
0.975 (<.001)
0.923 (<.001)
0.846 (<.001)

PMF-Score
0.962 (<.001)
0.932 (<.001)
0.958 (<.001)
0.932 (<.001)
0.889 (<.001)
0.915 (<.001)
0.939 (<.001)
0.889 (<.001)
0.936 (<.001)
0.956 (<.001)
0.880 (<.001)
0.926 (<.001)
0.930 (<.001)
0.827 (<.001)

G-Score
0.533 (.338)
0.584 (.110)
0.652 (.021)
0.394 (.854)
0.386 (.887)
0.491 (.534)
0.558 (.182)
0.709 (<.001)
0.588 (.029)
0.189 (>.999)
0.117 (>.999)
0.221 (>.999)
0.398 (.883)
0.345 (.993)

D-Score
0.721 (.007)
0.689 (.008)
0.794 (<.001)
0.588 (.183)
0.528 (.376)
0.701 (.006)
0.666 (.039)
0.654 (.004)
0.738 (<.001)
0.436 (.755)
0.251 (.999)
0.467 (.661)
0.401 (.862)
0.197 (>.999)

ChemScore
0.540 (.297)
0.538 (.271)
0.633 (.010)
0.317 (.998)
0.289 ( .999)
0.506 (.461)
0.547 (.267)
0.651 (.010)
0.728 (<.001)
0.506 (.472)
0.360 (.966)
0.508 (.448)
0.237 (>.999)
0.185 (>.999)

a. p values <.05 for AU-ROC values >.5 indicate statistically significant improvement over random selection, p values <.05 for AUROC values <.5 indicate statistically significant decrement over random selection.
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Figure 3.11. ROC Comparison of Docked versus Total Set, Schrodinger Decoy Set
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performed well, it did so against all three decoy sets. The opposite is also true, with
poorly performing docking/scoring combinations consistent with all three decoy sets.
One exception to this is the noticeable (although not statistically significant) decrease in
performance of PMF-Score when rescoring docking output for the Schrödinger decoy
set. We also noted the improvement in performance of the D-Score function when
rescoring DOCK output and attribute this to the fact that the D-Score function is based
on the original DOCK scoring function by Kuntz, et al.212 Second, docking programs
generally performed moderately to very well when paired with their own native scoring
functions. Glide with Glide-Score and Surflex with Surflex-Score performed
exceptionally well, and no improvement to the AU-ROC values was seen when rescoring
these poses. DOCK, FlexX, and GOLD performed moderately well when scored with
their native scoring functions, Grid-Score, F-Score, and GOLD-Score, respectively, but
these showed significant improvement upon rescoring. Specifically, AU-ROC values
were markedly improved when DOCK results were rescored with PMF-Score, FlexX
results with PMF-Score, and GOLD results with both F-Score and PMF-Score. Third, FScore and PMF-Score generally performed well in rescoring. Curiously, F-score only
performed moderately well with its partner FlexX, but performed exceptionally well when
used to re-score the outputs of Glide, Surflex, and GOLD. Finally, we note the moderate
to poor performance of G-Score, D-Score, and ChemScore when these functions were
used to re-score docking output from all five docking programs. Their performance
ranged from moderate with DOCK and Glide, to exceptionally poor with Surflex and
GOLD.
3.3.4 SSLR Calculations
The SSLR value reflects the ability of the docking and scoring combination to
detect active compounds early and also their ability to correctly rank the active
compounds according to their known inhibition constants. Table 3.4 shows the
calculated SSLR statistic and p values for each of the docking/scoring combinations
evaluated in this study. Lower values for SSLR are more desirable, and p values
(shown in parentheses) of less than 0.05 indicate that the particular combination showed
significant improvement over random selection and ordering. Like the AU-ROC values,
the SSLR values demonstrate a clear distinction between the performance of the native
scoring functions, F-Score, and PMF-Score over G-Score, D-Score, and ChemScore.
As was seen with the AU-ROC calculations, the latter three scoring functions performed
very poorly when rescoring the poses from all five docking programs, while the former
three functions generally performed well across the board. We note that in three
instances, D-Score was able to detect and rank the active compounds significantly better
than random, as demonstrated by the p values for DOCK docking of the ZINC and ACD
decoy sets and FlexX docking of the ACD decoy set. These results follow very closely
with the corresponding AU-ROC values. In all cases the native scoring functions were
able to detect and rank the actives significantly better than random selection and
ordering. Finally, when used to rescore docked poses, PMF-Score and F-Score each
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Table 3.4. Calculated SSLR Statistics with p Values for 5 Docking Programs, Native Score and Cscore Functions
(Unrelaxed)
Docking Program /
Validation Set
DOCK - ZINC
DOCK - Schrödinger
DOCK - ACD
FlexX - ZINC
FlexX - Schrödinger
FlexX - ACD
Glide - ZINC
Glide - Schrödinger
Glide - ACD
Surflex - ZINC
Surflex - Schrödinger
Surflex - ACD
GOLD - ZINC
GOLD - Schrödinger

Native Scorea
212.3 (<.001)
269.9 (.009)
183.2 (<.001)
F-Score
F-Score
F-Score
131.4 (<.001)
125.9 (<.001)
141.1 (<.001)
112.1 (<.001)
116.4 (<.001)
123.1 (<.001)
259.6 (.004)
254.6 (.002)

F-Score
164.1 (<.001)
211.9 (<.001)
134.5 (<.001)
244.1 (.001)
270.3 (.009)
213.7 (<.001)
152.3 (<.001)
166.7 (<.001)
141.3 (<.001)
121.1 (<.001)
134.4 (<.001)
132.9 (<.001)
169.5 (<.001)
203.0 (<.001)

PMF-Score
145.8 (<.001)
201.7 (<.001)
182.6 (<.001)
151.3 (<.001)
204.5 (<.001)
190.3 (<.001)
148.6 (<.001)
192.7 (<.001)
188.0 (<.001)
140.0 (<.001)
205.0 (<.001)
211.3 (<.001)
153.4 (<.001)
227.7 (<.001)

G-Score
312.2 (.220)
309.4 (.186)
281.8 (.025)
331.2 (.568)
335.4 (.661)
306.9 (.160)
312.1 (.220)
300.3 (.103)
312.0 (.219)
360.9 (.993)
370.0 (.999)
353.5 (.956)
349.6 (.916)
352.3 (.945)

D-Score
265.6 (.006)
292.9 (.061)
251.2 (.002)
298.0 (.088)
316.9 (.290)
273.3 (.012)
297.3 (.084)
310.2 (.196)
279.2 (.021)
342.9 (.813)
363.2 (.997)
333.0 (.607)
344.5 (.842)
365.2 (.999)

ChemScore
313.7 (.241)
322.2 (.382)
301.4 (.111)
354.1 (.960)
357.6 (.982)
326.7 (.470)
305.2 (.143)
305.5 (.145)
279.5 (.021)
324.1 (.417)
346.7 (.878)
325.4 (.443)
358.6 (.986)
360.1 (.991)

a. SSLR statistics with p values <.05 are considered to have significant improvement over randomselection and ordering.
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performed exceptionally well, matching their performance when gauged with the AUROC values.
In order to compare scoring functions to each other within docking
program/decoy set pairs, p values were calculated to detect statistically significant
differences in scoring function performance. Tables 3.5 through 3.7 show p value cross
comparisons both for AU-ROC’s and SSLR values for each of the three representative
pairs mentioned above. These results are helpful in determining which, if any, of the top
performing scoring functions significantly outperformed the other, or if there was no
statistically significant difference. For example, in Table 3.5 the results indicate that
between Glide Score, F-Score, and PMF-Score, there was no significant difference in
their performance when judged by either AU-ROC or SSLR. Additionally, there is not a
significant difference in the performance of D-Score, G-Score, and ChemScore when
judged by either metric. In contrast, the data shown in Table 3.6 indicates
that for Surflex docking of the Schrödinger decoy set, there was a significant difference
between the performance of Surflex Score and PMF-Score that was detected by both
metrics, with Surflex scoring significantly outperforming PMF-scoring. Additionally, it can
be seen from Table 3.6 that a significant difference between PMF- and F-Score could
not be detected from the AU-ROC values, but that a difference was detectable when
comparing the two scoring functions with SSLR values. The ability of the SSLR value to
detect a difference in performance of two scoring functions that was not detected by AUROC is also demonstrated in Table 3.7 when comparing PMF-Score and GOLD-Score,
with GOLD-Score showing clear superiority over PMF-Score when judged by SSLR
values. There are also instances where SSLR failed to detect a significant difference
that was detectable by the AU-ROC method, as can be seen from the ChemScore/GScore results in Table 3.7.
The results of a direct comparison of the native scoring functions to each other
for each decoy set studied are given in Tables 3.8 through 3.10. It can be seen from
the p values that Glide with its native Glide-Score and Surflex with its native SurflexScore demonstrated a significant superiority over FlexX, GOLD, and DOCK with their
own respective native scoring functions. Additionally, a direct comparison of GlideScore and Surflex-Score shows that there is no significant difference between the results
of the two scoring functions, both in terms of the AU-ROC and SSLR methods.
3.3.5 Post-Docking Relaxation
Several authors have recommended that, when rescoring poses with non-native
scoring functions as reported here, the poses should first be optimized using the native
scoring function before generating the score.183,197 This procedure was not applied to
the enrichment and AU-ROC data reported above, and it may explain the poor results
observed with the D-Score, G-Score, and ChemScore algorithms. To investigate the
effects of optimizing the ligand poses prior to rescoring, we applied the molecule
relaxation function of Cscore to the docking output prior to rescoring with the five Cscore
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Table 3.5. Glide Docking of the ZINC Decoy Set
Docking
Program /
Validation Set

Glide
Score

F-Score

PMF-Score

G-Score

D-Score

Chem
Score

Glide Score
F-Score
PMF-Score
G-Score
D-Score
ChemScore

--.674
.717
<.001
<.001
<.001

.364
--.957
<.001
.011
<.001

.377
.959
--<.001
<.001
<.001

<.001
<.001
<.001
--.496
.454

.001
.006
<.001
.281
--.743

<.001
<.001
<001
.712
.212
---

Table 3.6. Surflex Docking of the Schrödinger Decoy Set
Docking
Program /
Validation Set

Surflex
Score

F-Score

PMF-Score

G-Score

D-Score

Chem
Score

Surflex Score
F-Score
PMF-Score
G-Score
D-Score
ChemScore

--.319
<.001
<.001
<.001
<.001

.267
--.003
<.001
<.001
<.001

.018
.059
--<.001
<.001
<.001

<.001
<.001
<.001
--.042
<.001

<.001
<.001
<.001
.035
--.215

<.001
<.001
<.001
<.001
.084
---

Table 3.7. GOLD Docking of the Schrödinger Decoy Set
Docking
Program /
Validation Set

GOLD
Score

F-Score

PMF-Score

G-Score

D-Score

Chem
Score

GOLD Score
F-Score
PMF-Score
G-Score
D-Score
ChemScore

--.112
.036
<.001
<.001
<.001

.373
--.501
.003
.001
<.001

.297
.780
--<.001
<.001
<.001

<.001
<.001
<.001
--.038
.251

<.001
<.001
<.001
.001
--.916

<.001
<.001
<.001
.009
.829
---
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Table 3.8. Native Scoring Functions with the ZINC Decoy Set
Docking
Program /
Validation Set

Grid
Score

F-Score

Glide
Score

Surflex
Score

GOLD
Score

Grid Score
F-Score
Glide Score
Surflex Score
GOLD Score

--.306
.085
.050
.236

.822
--.030
.002
.647

.078
.019
--.676
.018

.042
.007
.503
--<.001

.015
.659
.031
.013
---

Table 3.9. Native Scoring Functions with the Schrödinger Decoy Set
Docking
Program /
Validation Set

Grid
Score

F-Score

Glide
Score

Surflex
Score

GOLD
Score

Grid Score
F-Score
Glide Score
Surflex Score
GOLD Score

--.988
<.001
.003
.603

.808
--<.001
.002
.714

.004
.001
--.829
<.001

.004
.001
.703
--<.001

.871
.689
.003
.001
---

Table 3.10. Native Scoring Functions with the ACD (Bissantz) Decoy Set
Docking
Program /
Validation Set

Grid
Score

F-Score

Glide
Score

Surflex
Score

Grid Score
F-Score
Glide Score
Surflex Score

--.277
.317
.160

.866
--.080
.017

.146
.043
--.707

.120
.048
.888
---
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scoring functions. This relaxation function uses the Tripos Force Field to perform a 100
iteration torsional minimization of the docked ligand. Figure 3.12 and Figure 3.13 show
the effects of this relaxation procedure on the rescored AU-ROC values for the poses
scoring functions. This relaxation function uses the Tripos Force Field to perform a 100
iteration torsional minimization of the docked ligand. Figure 3.12 and Figure 3.13 show
the effects of this relaxation procedure on the rescored AU-ROC values for the poses
generated by Surflex docking of the ZINC decoy set. There was little change in the
calculated AU-ROC values for D-Score, some improvement for G-Score, and
significantly decreased AU-ROC values for the F-Score, ChemScore, and PMF-Score
functions. Similar results were obtained for all the docking programs and decoy sets
investigated in this study (data not shown).
3.3.6 Consensus Scoring
Consensus scoring has received mixed reviews in recent validation studies, with
some authors reporting enhanced enrichment over single scoring functions85,86,92 and
others reporting little to no improvement.184,191 To further investigate this in the DHPS
system, we used the Cscore module of Sybyl 7.3 to generate consensus scores from the
five Cscore functions. We used the default settings, and investigated consensus score
values generated from both unrelaxed and relaxed scores. A score of 0 through 5 is
generated for each ligand pose depending on the number of “good” scores received
from each of the five C-score functions. Table 3.11 gives the results of consensus
scoring on enrichment (by calculated AU-ROC) for each of the five docking programs.
Only the data from the ZINC decoy set are shown in the table, but the results were
similar for the other two decoy sets. Table 3.11 gives the results from the unrelaxed and
relaxed poses for comparison. Ideally, the majority of the known active compounds
should give a high Cscore value of 4 or 5, while the majority of the decoy compounds
should have low Cscore values. However, consensus scoring resulted in only a modest
enrichment, and it failed to significantly improve the enrichment results obtained when
scoring with single scoring functions. We saw no significant difference in the results
when Cscore calculations were performed on the unrelaxed poses over the relaxed
poses. The best results (an AU-ROC value of 0.891) were seen with consensus scores
generated from unrelaxed poses from the Glide docking.

3.4 Discussion
Our high resolution crystallographic studies of DHPS from Bacillus anthracis that
includes substrate and inhibitor complexes has provided us with the opportunity of using
virtual screening methods to identify novel inhibitory compounds that specifically dock
into the well characterized binding determinants of the pterin pocket. However, an
to identify which compounds should be further pursued by in-depth biochemical, kinetic
and structural studies. We have therefore performed a thorough investigation of docking
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Figure 3.12. Effect of Molecule Relaxation of Docking Output Prior to Rescoring with Cscore Functions (Unrelaxed)
Surflex docking of the ZINC validation set is shown unrelaxed.
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Figure 3.13. Effect of Molecule Relaxation of Docking Output Prior to Rescoring with Cscore Functions (Relaxed)
Surflex docking of the ZINC validation set is shown relaxed.
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Table 3.11. Cscore AU-ROC Results for Docking of ZINC Decoy Set
Docking Program /
Validation Set

Unrelaxed

Relaxed

DOCK
FlexX
Glide
GOLD
Surflex

.730
.722
.891
.716
.622

.734
.679
.857
.658
.554

and scoring methodologies to identify which combination would be expected to yield the
best results when applied to this particular pocket in this particular enzyme. As
described in the introduction, we sought answers to eight specific questions and have
successfully provided key insights into each of them.
We first investigated pose selection and noted the overall good performance of
all five docking programs. Each program was able to generate a successful pose
(RMSD less than 1.5 Å), and four of the five native scoring functions were able to rank a
successful pose. Additionally, when the poses were rescored with the five Cscore
scoring functions, each one performed reasonably well. The majority of the docking and
scoring functions were able to generate and rank successful poses, and we therefore
conclude that this method of evaluating docking/scoring combinations is useful for
eliminating poorly performing combinations but not for selecting the optimal combination.
We then addressed the question of how two commonly-used metrics, enrichment
calculations at a given percent of decoy set screened (1% and 2%) and areas under
receiver-operating characteristic curves (AU-ROC), compare when used for validation.
Although both metrics were generated using the same data, it was easier to note a
difference in performance when analyzing the enrichment values. Using the AU- ROCs,
we classified combinations as performing either well, moderately well, or poor, but within
each classification, it was difficult to determine the best docking/scoring combination.
Similar to the pose selection study, the AU- ROCs were most useful for eliminating
poorly performing docking/scoring combinations rather than selecting the top performing
combination. In contrast, the enrichment calculations which reward early detection of
active compounds appear to be more successful in distinguishing the top performing
docking/scoring combinations for use against a specific target, based on our results.
We next sought to answer the question of how important is the selection of decoy
compounds for use in enrichment studies. A recent study stressed the importance of
selecting decoy set compounds that closely match the active compounds in terms of
physico-chemical properties in order to avoid artificial enrichment.218 We selected three
decoy sets that had previously been used to validate docking programs against a wide
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variety of enzyme targets. Each of the three decoy sets has slightly different
characteristics, and differs in physico-chemical properties from the active compounds to
varying degrees. We compared the enrichment and AU-ROC results across decoy sets,
and although there were detectable differences when comparing enrichment calculations
at 1 and 2%, we were unable to correlate this trend with the degree of difference in
physico-chemical properties of the active compounds from the decoy sets. Significantly
for our purposes, when comparing the AU-ROC calculations across decoy sets, we did
not detect a significant trend either favoring or disfavoring one decoy set over another,
and when a docking/scoring combination performed well, it generally did so against all
three decoy sets and vice versa. However, our results are not necessarily inconsistent
with the previous study where a trend was observed.218 More likely, while our active
compounds differed significantly in some physicochemical properties from the 3 decoy
sets we selected, the decoy sets themselves did not differ enough between each other
to make a clear distinction in performance. This can be seen in Table 3.12, which shows
the average molecular volume, atom count, cLogP, # of H-bond donors (HD), # of Hbond acceptors, and number of rotatable bonds (RB) for the active set and the three
decoy sets. It can be seen that the active compounds tend to be smaller and more
hydrophilic than the decoy compounds, but the decoy sets themselves are very similar.
The question of how to deal with docking failures was also specifically addressed
because this issue has received little attention in previous studies. In our study, the
docking programs were frequently unable to return poses for some decoy compounds,
and this led to a problem in directly comparing the programs. For example, the program
Glide in combination with the Schrödinger decoy set returned 607 successful poses
while the Surflex program returned the full quota of 1010 poses (1000 decoys plus 10
actives). In the calculation of enrichment, we believe that it would have been an unfair
penalty on programs that failed to dock decoy compounds had we selected %
compounds docked rather than the % of the total number of compounds, and similarly in
the calculation of AU-ROC and SSLR. We therefore used the total number of
compounds (decoy + active) to calculate enrichment at 1 and 2%, and assigned the
worst reported score to all docking failures when calculating the ROC plots, AU-ROC’s,
and SSLR values. We recognize that this method may over-compensate because the
failure of a program to dock an inactive compound may actually reflect superior
performance. Thus, in the event that the performance of two docking/scoring
Table 3.12. Active and Decoy Compounds Average Characteristics
Set

Volume

Atom Count

cLogP

HD

HA

RB

Actives
ACD
Schrödinger
ZINC

211
287
341
310

37
42
50
42

0.29
3.27
3.77
3.02

3
2
2
1

7
4
6
4

5
5
6
5
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combinations are indistinguishable, we believe it is reasonable to use the number of
docking failures for inactive compounds as a means for selecting one over the other.
We next addressed the abilities of post-docking relaxation and consensus
scoring to improve enrichment results by evaluating their effects on our AU-ROC
metrics. Cole and co-workers have stressed the importance of using scoring functions
to optimize docking output prior to rescoring with that function197 and we attributed the
poor performance of the D-Score, G-Score, and ChemScore functions to this deficiency
in our analyses. To test this, we performed molecule relaxation using a function that is
available in the C-Score module of Sybyl (Tripos) prior to rescoring, and compared these
results with the unrelaxed scores. The scoring results following relaxation were typically
worse in terms of AU-ROC, and this may be due to the function’s use of the Tripos Force
Field rather than the scoring functions themselves. This is consistent with the findings of
Cole and coworkers because the notable exception was the improved performance of GScore that actually uses the Tripos Force Field parameters. Consensus scoring failed to
improve upon the results we were able to obtain with single function scoring, and we
believe that this can also be attributed the fact that the Cscore functions were not
optimized with respect to the functions themselves. We conclude that, when rescoring
with non-native scoring functions, it is very important to optimize with respect to that
scoring function.
The known inhibitory constants of the active compounds seeded into the decoy
sets represents important information that can be used to further evaluate the
performance of docking and scoring combinations. Thus, ideally, the active compounds
should not only be identified early but also in the correct order according to inhibition
constants. In this study we have introduced a new method for interpreting enrichment
study results that simultaneously rewards early detection of active compounds and
correct ordering, the ‘sum of the sum of log rank’ or SSLR. Although several methods
have been reported that specifically reward early detection203,219, we believe that this is
the first method that takes this approach. The SSLR method was developed to help us
distinguish between the top performing docking and scoring combinations that were
statistically indistinguishable using traditional AU-ROC methods. In the three
representative examples given above, the SSLR method was able to distinguish
between scoring functions in two cases where the differences in AU-ROC were not
significant but, in general, the SSLR values closely correlated to the AU-ROC results in
terms of statistical significance. However, it is very straightforward to apply the SSLR
method when relevant data are available, and we consider this a valuable method with
potentially great utility for future virtual screening studies.
The ultimate goal of this study was to determine which of the docking and scoring
combinations evaluated would be expected to yield the best results in terms of
enrichment when used against the pterin binding site of DHPS in a large scale, virtual
screening study. We noted the excellent performance of the native scoring functions
when used with each of their respective docking programs in our enrichment studies.
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We also noted the poor performance of the Cscore scoring functions when used to
rescore docking output, and explained this by our inability to optimize the poses with
respect to the scoring functions themselves. While this may explain the poor
performance of G-Score, D-Score, and ChemScore, it does not explain the good to
excellent performance of F-Score and PMF-Score. We believe that the nature of the
pterin binding site may in part explain this observed phenomenon. Ligand binding into
the pterin binding site not only involves van der Waals packing interactions within the
tight pocket but also polar hydrogen bonding and ionic interactions.154 Additionally, as
can be seen from Figure 3.4, there is a clear preference for planar, aromatic compounds
that can accommodate π-stacking with the side chain of Arg254. Our results are
consistent with those of Bissantz and co-workers who found that FlexX scores and PMF
scores performed better against polar active sites, while DOCK scores were more
reliable against non-polar active sites.196 There is also an explicit aromatic stacking term
used in F-Score, unique to this scoring function, which may have also contributed to its
good performance.

3.5 Summary
In order to select the best performing docking/scoring combination for virtual
screening studies against the DHPS pterin binding site, we employed several validation
methods. Pose selection studies using a co-crystal structure with a known pterin-site
inhibitor bound were useful in identifying docking/scoring combinations that performed
poorly but were less helpful in selecting a top performing combination. Similarly, the AUROC values were also less helpful at selecting a specific top-performing docking/scoring
combination, but clearly identified poorly performing combinations. However,
enrichment calculations at 1 and 2% percent of the decoy set screened proved very
useful in identifying two top performing docking/scoring combinations, Glide with Glide
Score and Surflex with Surflex Score. Finally, we have developed a new metric that can
be used as a validation method that we term SSLR. The SSLR statistic not only takes
into account early detection of active compounds from decoy sets, but also rewards for
correctly ordering the active compounds by their known inhibitory constants. We found
that the results of the SSLR tests closely matched the AU-ROC results and in several
cases were able to help us distinguish between docking/scoring combinations for which
there was not a statistically significant difference using the latter method.
We investigated three separate decoy sets and found a dependence on the
decoy set used when calculating enrichment at 1% and 2%, with the ZINC decoy set
yielding the highest enrichment values. This dependence was not seen when comparing
AU-ROC’s from ROC plots, which were generally comparable across validation sets.
Our investigations also showed that relaxation of the poses prior to rescoring with the
Cscore functions using the relaxation function of the Cscore module implemented in
Sybyl 7.3 did not overall improve enrichment and in some cases was actually
detrimental. We believe this is due to the fact that the Cscore relaxation function does
not use the scoring function to minimize the poses, but instead uses a different force
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field. No improvement over the best results seen with single scoring functions was
observed when applying consensus scoring, with either the relaxed or non-relaxed
poses. Again, we postulate that this is due to the fact that the Consensus scoring
functions were not optimized with respect to each function prior to scoring.
We demonstrate considerable variability when using these various validation
methods and identify clear winners. Indeed, without these analyses, it would be virtually
impossible to successfully use virtual screening in our studies. Based upon the results
from the enrichment studies, AU-ROC and SSLR calculations, we found that, of the
docking programs and scoring functions we evaluated, the most appropriate combination
for use in high-throughput virtual screening against DHPS would be Glide with the native
Glide Score function or Surflex with the native Surflex Score function.
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CHAPTER 4. HIGH-THROUGHPUT VIRTUAL SCREENING
AGAINST DHPS
4.1 Introduction
The work presented in this chapter will complete my discussion of the DHPS
virtual screening project that began in Chapter 2 and continued in Chapter 3. Chapter 2
discussed the crystal structure of B. anthracis DHPS and the molecular simulation
studies that were performed to investigate the structure and function of the flexible loop
regions surrounding the DHPS active site as well as to develop a complete screening
structure for high-throughput virtual screening studies. In Chapter 3, I presented the
results of a large-scale, validation study that was performed to select the best docking
and scoring combination for use in high-throughput docking studies against the pterin
binding site of DHPS. This chapter will introduce the methods that were utilized to
screen several million compounds against the pterin site and the results of those
investigations.
4.1.1 The DHPS Pterin Binding Site
We have solved several crystal structures of the B. anthracis DHPS enzyme with
both substrate and product analogs as well as an inhibitor bound.154 These structures
have shown that the active site can be separated into sub-sites for the binding of the
pterin substrate and the pABA substrate, as shown in Figure 4.1. The sulfonamide
agents, as previously mentioned, bind to the pABA sub-site and inhibit product formation
or combine with the pterin substrate to form “dead-end” products. Mutations that confer
sulfonamide resistance have been mapped to the DHPS enzyme and fall near the pABA
binding site, as shown in Figure 4.2. Theoretically, agents that inhibit the DHPS enzyme
by binding to the pterin sub-site would be able to bypass the resistance mutations that
have rendered the sulfonamide agents less useful for the treatment of infection. Table
4.1 lists the key binding residues in the pterin site and their corresponding residues in
several common pathogenic bacterial organisms. It can be seen that that there is a high
degree of conservation among the key binding residues between these different species.
This implies that inhibitors of the pterin binding site of DHPS may have low species
specificity and could result in antibacterial agents with a broad spectrum of activity
against many Gram positive and Gram negative bacterial species.
4.1.2 Virtual Screening against DHPS
As discussed in Chapter 1, virtual screening has been shown to be
complementary to high-throughput screening as a method to identify lead compounds in
a drug design project.11 Structure-based virtual screening involves the use of a 3D
structure of the drug target, usually by X-ray crystallography or NMR studies, and
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A

Figure 4.1. DHPS with Pteroate Product Analog Shown Bound
DHPS with pABA and Pterin binding sites indicated using a pteroate product analog. A.
pABA binding site falls near the solvent exposed surface, enclosed by flexible loop
regions. B. Pterin binding site deep within enzyme in a highly conserved pocket.
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Figure 4.2. The DHPS/Pterin-SMX Structure with Sulfonamide Resistance
Conferring Mutation Sites Indicated
Residues that confer resistance to sulfonamide antibiotics in several species (see
discussion in Chapter 2) have been mapped to the B. anthracis DHPS structure and are
shown here in red. The mutation sites predominately fall on flexible loop regions near
the pABA (sulfonamide) binding pocket.
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Table 4.1. DHPS Pterin Binding Site Residues

B. anthracis

Interaction Type

E. coli

S. aureus

M. tuberculosis

S. pneumoniae

P. aeruginosa

Thr67a
Arg68a
Asp101
Asn120
Ile122
Ile143
Met145
Asp184
Phe189
Leu214
Gly216
Lys220
Arg254

n/a
n/a
vDw? no direct
H-Acceptor
vDw
vDw
Pi Electronic
H-Acceptor
Pi Electronic
vDw
no direct
H-donor
Pi Electronic

Thr62
Arg63
Asp96
Asn115
Ile117
Cys137
Met139
Asp185
Phe190
Leu215
Gly217
Lys221
Arg255

Thr51
Arg52
Asp84
Asn103
Gln105
Val126
Met128
Asp167
Phe172
Leu197
Ala199
Lys203
Arg239

Ser53
Arg54
Asp86
Asn105
Val107
Val128
Met130
Asp177
Phe182
Leu207
Gly209
Lys213
Arg253

Thr57
Arg58
Asp91
Asn110
Ile112
Val133
Met135
Asp201
Phe206
Phe231
Gly233
Lys237
Arg282

Ser49
His50
Asp82
Asn101
Ile103
Val123
Met125
Asp173
Phe178
Leu206
Ser208
Lys212
Arg246

a.

Residues which fall on mobile loop elements and have been modeled in to place. Their position is uncertain or unknown in several
species.
Residues differing from B. anthracis target are colored in red.
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molecular docking experiments in which corporate or commercial libraries are docked
and scored in the target’s active site to identify compounds with binding affinity.
Because commercial libraries of screening compounds can be quite large, on the order
of several million compounds for the larger libraries, the computational expense of
docking the entire library can be significant, even with the most efficient docking
programs. For this reason, often specific constraints are applied to screening libraries
prior to docking which may include 1D physicochemical property filters like the
commonly used “Rule of Five” proposed by Lipinski and co-workers, which describes
filters for oral, drug-like compounds.23 Another type of constraint that can be applied to
limit the size of the screening library to be docked is the pharmacophore constraint. This
requires specific knowledge of key binding interactions that should be conserved for
successful inhibitor binding, usually obtained from co-crystal structures with ligand or
inhibitor bound. Using this method, screening libraries can be filtered to only include
compounds with specific numbers and locations of key binding elements such as
hydrogen bond donors or acceptors, aromatic rings, lipophilic groups, etc. Finally,
fragment constraints can be applied using the “Rule of Three”, or a variation thereof,
which filters for smaller, more fragment-like compounds.130
The advantages of screening fragments over drug-like compounds were
discussed in Chapter 1; most notable is the likelihood that the lead optimization process
will result in a drug-like compound which has a greater chance of having good oral
bioavailability and favorable ADME properties. Additionally, a much smaller number of
compounds are generally needed for successful fragment-based screening, usually on
the order of a hundred to a few thousand. This is because compounds of lower
complexity have a greater chance of matching the target receptor site. Fragment-based
screening is not without its disadvantages. Because of the lower molecular weight and
complexity of the fragment compounds, they are expected to be less potent than a druglike compound. This means that specialized screening methods need to be employed to
identify hit compounds. Several methods have been used with success, including high
concentration screening133 (up to mM concentration), X-ray crystallography or NMR
screening,135 affinity detection by mass spectrometry,136 and surface plasmon
resonance,137 and ITC.138 It should be noted that although the fragment hits will show a
much lower potency, often high micromolar to low millimolar, in terms of binding
efficiency (binding affinity normalized by molecular weight or heavy atom count), they
are often on par with or exceed the efficiency of drug like compounds.139
4.1.3 Research Goals and Design
Utilizing an X-ray crystal structure from B. anthracis DHPS with an inhibitor
bound into the pterin site, we performed several large-scale, high-throughput virtual
screens using the docking methods validated in Chapter 3. The virtual screening
followed two strategies that we implemented in two successive rounds of highthroughput docking. In the first round, a pharmacophore filter based upon the key pterin
site binding elements was applied to compounds from the ZINC databases.220
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Compounds which passed the filter and a molecular weight cut-off were subsequently
docked into the DHPS pterin site using our validated docking method, as described
below. In the second round, we forewent the pharmacophore filter and applied a
molecular weight and rotatable bond constraint to a subset of the commercial libraries
used in the first round. The compounds passing this constraint were then docked into
the pterin site using the validated docking method.
The pharmacophore filter was removed from the second round of docking for
several reasons. First, we hoped that by removing the pharmacophore pre-docking step
we could identify compounds that were unlike the pterin substrate in appearance and
physical property. The goal was to discover novel scaffolds with improved solubility that
could be taken into subsequent lead optimization trials. Second, removing the
pharmacophore filter provided us with an opportunity to investigate the use of
pharmacophore pre-processing of screening libraries versus simple high-throughput
docking, in terms of hit rates, quality of hits, and computational expense. Finally, the
second round of docking allowed us to compare the two top performing docking
programs from our validation study (presented in Chapter 3) in actual screening studies
against the target enzyme.
Hit compounds from both rounds of virtual screening were selected for testing in
our enzyme assay. Fragment hits which displayed greater than 30% inhibition of DHPS
activity in our assay were selected for investigation in crystallography trials. The results
of the two rounds of virtual screening with hit compound inhibitory activities are
presented herein.

4.2 Computational and Experimental Methods
4.2.1 The DHPS Screening Structure
A crystal structure of the B. anthracis DHPS enzyme with an inhibitor known to
bind the pterin site, AMPPD (Figure 4.3), has been solved and was used for all the
molecular docking performed in this study. Flexible loops 1 and 2 are highly mobile
elements. It is believed that the loops close over the active site after PtPP binding,
forming the pABA binding pocket and facilitating enzymatic catalysis.153 As can be seen
from Figure 4.2, the majority of sulfonamide resistance mutation sites fall on loops 1 or
2. Although visible in our crystal structure, the position of loop 1 is believed to be a
crystallization artefact due to contact with a neighbouring monomer, rather than
occupying a functional position (Figure 4.4, left). The positions of several residues, 6674, in loop 2 are disordered and not visible in this crystal structure. The missing or
inaccurately positioned residues from loops 1 and 2 were investigated by homology
modelling and extensive molecular dynamics simulations as discussed in Chapter 2.
The initial positions for loops 1 and 2 for these docking studies were taken from the
average structure obtained in our MD simulation series 2-17, which was performed using
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Figure 4.3. AMPPD Structure
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Figure 4.4. B. anthracis DHPS Before and After Flexible Loop Placement
B. anthracis DHPS Structure is shown before and after preparation for docking. The positions of mobile loops 1 and 2 were
homology modeled from the M. tuberculosis and E. coli crystal structures and minimized by molecular dynamics and energy
minimization methods, as discussed in Chapter 2 methods section.
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our crystal structure with the most residues from loop 2 visible to date. Loops 1 and 2
fall near the pABA binding pocket during catalysis and are not believed to play a large
role in pterin substrate binding. To prepare the enzyme for docking, hydrogens were
added and AMBER FF99 charges were calculated for the protein. A water molecule
located near the pterin binding pocket is conserved in all the DHPS structures published
thus far is believed to be structurally required. Charges were loaded to the water and it
was left in the active site for all docking runs performed. Hydrogen positions were
refined by performing a 1000 iteration minimization with heavy atoms constrained using
the Powell method with initial Simplex optimization.221 Figure 4.4 shows the docking
structure before and after placement of the flexible loops.
4.2.2 The Docking Protocol
The docking validation study reported in Chapter 3 concluded that for highthroughput docking studies involving DHPS, Surflex-Dock and Glide-Dock perform
exceptionally well. In this study, 2 rounds of high-throughput docking were performed,
one using each docking function. The first round involved docking of the ZINC version 6
(2006) databases after pre-filtering with molecular weight and pharmacophore
constraints using the UNITY program available in Sybyl 7.3. The ZINC databases
contain over 4.6 million compounds, and include multiple tautomers and protonation
states for the screening compounds. In order to filter for fragment-like compounds and
decrease the number of compounds requiring docking to a more manageable number,
we used a molecular weight filter of 350 Daltons for the first round of screening and also
employed pharmacophore filters as described below. Compounds meeting the
pharmacophore criteria were then docked and scored in the DHPS pterin binding site
with the Surflex docking tool using the same docking methods described below. The top
2% of the Surflex-Score ranked compounds were selected for testing in the DHPS
enzyme assay.
Round 2 of the high-throughput virtual screening forewent the pharmacophore
filters in an attempt to identify scaffold compounds that were not “pterin-like”. Several
commercial vendors were identified based upon the ease of acquisition of their
compounds (from Round 1) as well as the availability of their screening sets in an easily
obtainable format for screening. The compound screening sets were obtained, filtered
by modified “Rule of Three” criteria, and docked using the Glide-Dock program of
Schrodinger, Inc. The highest scoring compounds were selected by score and diversity
for enzyme assay and crystallography using the methods described below.
4.2.3 UNITY Database Preparation
The screening compounds used in Round 1 were downloaded in .sdf format from
the vendors located in the ZINC version 6 libraries.220 The libraries contained over 4.6
million compounds including protonation variants and tautomers for the medium pH
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range of 5.75 to 8.25 in 26 different vendor sets. Additionally, these libraries have been
pre-filtered to remove reactive and cytotoxic compounds as discussed in Chapter 1 (the
ZINC database filtering rules can be found in Appendix D). The .sdf files were converted
to UNITY databases for pharmacophore screening using the UNITY program available in
the Sybyl 7.3 molecular modeling suite of Tripos, Inc.222,223 During preparation, 2D and
Macro fingerprints were created using Unity’s default settings. The Concord program
was used to generate 3D coordinates, when necessary.224 Default values were
accepted for all other UNITY database preparation settings.
4.2.4 Pharmacophore Filtering
The pharmacophore filters utilized in the first round of virtual screening are
shown in Figure 4.5. They were created and applied to the ZINC screening sets using
the UNITY program. A surface volume constraint (Figure 4.5, top) was created using all
pterin site residues falling within 8 Å of the AMPPD ligand with a VdW tolerance of 1 Å.
Macros were created for 1 donor and 4 acceptor positions based upon the H-bonding
patterns seen with the AMPPD ligand as well as the pterin substrate (Figure 4.5,
bottom). A spatial tolerance of 0.3 Å was used for each macro and 2 partial match
constraints were applied to loosen the filter and remove false carboxylate and ester hits.
The UNITY databases created from the ZINC screening libraries were screened
against this pharmacophore model using a Flex search with modified “Rule of Three”
search options specified. The maximum molecular weight was 350 Daltons and the
maximum number of rotatable bonds was five. Flex ring search option was also
enabled. All other settings retained their default values.
4.2.5 Docking Library Preparation
For the first round of virtual screening, hitlists from the pharmacophore filtering
stage were merged to eliminate duplicate compounds and then the converted to a multimol2 file for docking. Charges were loaded to the compounds using the GasteigerHuckel method.105 The compounds were docked using the Surflex docking function and
scored with the Surflex scoring function as described below.65 The experimental docking
methods for both Surflex and Glide docking (virtual screening round 2) were the same as
used in our validation study discussed in Chapter 3.
Compounds used in the second round of virtual screening were obtained directly
from the chemical suppliers as .sdf files of their most updated collections, rather than
downloaded as sets from the ZINC site. The following chemical suppliers were used
due to the ease of obtaining compounds, reliability (in terms of compound purity), or
ease in obtaining their screening library in electronic format: ASDI, ChemBridge,
ChemDiv, InterBioscreen, Key Organics, Life Chemicals, MayBridge Ro3 screening set,
Maybridge complete set, Nanosyn, Peakdale, Pharmeks, Ryan Scientific, Sigma Aldrich,
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Figure 4.5. UNITY Pharmacophore Filters Applied to DHPS
Top: Active site surface
Bottom: Hydrogen Bond donor and acceptor macro filters.
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Specs, SynChem, Synthonix, and TimTec. The .sdf files were converted to .mae files for
Glide docking using the LigPrep program of Schrodinger, Inc. Fragment filters included
rotatable bond count of 5 and molecular weight of 300 Daltons. Ionization states were
built using Epik for a target pH range of 7.2 to 7.6. The desalter function was employed
to remove waters and counter ions and tautomers were generated. Stereoisomerism
was retained if specified and varied when not specified. Low energy ring conformations
were obtained, hydrogens added and 3D conformations generated using the OPLS 2005
force field.
4.2.6 Docking, Scoring, and Processing
Surflex docking in the first round utilized the multi-mol2 files generated as
described above and a protomol generated using a threshold of 0.50 and bloat of zero
(default values). These settings are the same as those used in the docking validation
study discussed in Chapter 3. An active site water (Figure 4.4, right) was retained for all
docking runs. The ring flexibility function was enabled; all other docking settings
retained their default values. Compounds docked with Surflex were scored with the
native Surflex scoring function; the Cscore option was disabled. The top 2% of the
Surflex scored compounds were selected for procurement and testing in the enzyme
assay described below.
Glide docking of the fragment compounds in the second round of virtual
screening utilized the .mae files generated for each supplier as described above. The
Glide receptor grid was generated using the B. anthracis DHPS structure described
above and an active site defined by an 8 angstrom box around the AMPPD ligand.
Default van der Waals radius scaling settings were employed for generation of the
receptor grid. No docking constraints were defined. Compounds were docked using the
standard precision setting with the flexible docking option enabled. All other Glide
docking settings used default values. These settings are the same as those utilized
during the validation of this docking method against the DHPS target. The top 1% of
docked compounds from each supplier were selected by Glide score and merged into a
single file, resulting in a set of 2845 compounds. Because the assay employed in this
study is not a high-throughput assay (see assay methods below), it was not feasible to
test all 2845 compounds in the assay within a reasonable amount of time. Therefore a
diversity filter was applied to the high-scoring compounds using the Selector program
available in the Sybyl 7.3 molecular modeling suite. The compounds were saved as a
multi-mol2 file and imported as a Sybyl Molecular Spreadsheet. The diversity metrics
employed were 2D fingerprints and Atom Pairs with equal weighting. The hierarchical
clustering method was used to generate 54 clusters. The highest scoring compound in
each cluster was then selected for testing in the enzyme assay.
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4.3 High-Throughput Virtual Screening: Results and Discussion
4.3.1 Pharmacophore-Based Virtual Screen
5,093 compounds from the ZINC screening libraries matched the pharmacophore
requirements of the first round of virtual screening. When the UNITY hitlists were
merged, the total number of unique compounds was 3104, indicating a large degree of
redundancy in the ZINC databases. All 3104 compounds were successfully docked and
scored by the Surflex docking tool and the top scoring 2%, 62 compounds, were
selected for procurement and testing. Of this number, 45 compounds have been
obtained and tested, the remaining 17 compounds were no longer available from any
supplier and have been slated for synthesis and testing in future studies. The
compounds were tested at 500 μM concentration (250 μM if very poorly soluble) and a
percentage inhibition was obtained. Compounds showing greater than 30% inhibition
were taken into crystallography trials. Although this level of activity is slight when
considering a standard high-throughput screen, it is an acceptable standard when
dealing with fragment-like compounds, as was the case in these studies. As discussed
in Chapter 1, with fragments it is more appropriate to consider binding efficiency rather
than absolute binding affinity when determining which compounds to advance to further
studies.
Twelve compounds met the activity requirement for further investigation and are
shown in Figure 4.6. This corresponds to a hit rate of 26%, which is above average for a
study of this nature. The addition of a pharmacophore filter prior to docking is most likely
responsible for the increased hit rate over standard high-throughput virtual screening
studies. All compounds shown in Figure 4.6 have been advanced to crystallography
trials, the results of which are pending. It is noted that the hit compounds from the first
round of virtual screening bear a close resemblance to the pterin substrate. Again, this
can almost certainly be attributed to the pharmacophore filter employed prior to
molecular docking. Figure 4.7 shows one of the pharmacophore hits docked into the
pterin binding site by Surflex. The key pterin binding interactions are closely matched by
the compound shown.
4.3.2 Fragment-Based Virtual Screen
Unfortunately, the hit compounds from the first round of virtual screening, most
likely due to their planar structure and aromatic stacking ability, are poorly soluble;
making testing in enzyme assay and crystallography studies difficult. The low solubility
of the hit compounds from round 1 was also felt to be a poor predictor for whole-cell
biological activity and in vivo activity (studies not yet performed). Additionally, the first
round of virtual screening did not yield the novel scaffolds for pterin site binding agents
that we had hoped to find, due to the high degree of similarity between these hit
compounds and the pterin substrate. For this reason, a second round of virtual
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Figure 4.6. Hits from Pharmacophore-Based Virtual Screening with Enzyme
Activity Shown
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Figure 4.7. Pharmacophore Hit Shown Docked into DHPS Pterin Site

119

screening was performed, with tighter fragment constraints and no pharmacophore
constraints.
Due to computational limitations, the complete ZINC screening set could not
feasibly be docked within a reasonable time frame. Therefore, for this round of virtual
screening, a subset of specific vendors was selected and their screening libraries were
obtained and docked (see methods above). The fragment constraints were tightened to
a maximum molecular weight of 300 and no more than 5 rotatable bonds. In an attempt
to improve the successful acquisition rate, the most updated screening libraries from
each vendor used were obtained directly from the vendors and built as described in the
methods section. The total number of compounds in the fragment sets docked was over
300,000. Using the Glide docking program, we successfully docked nearly 285,000
fragment compounds into the DHPS pterin site. A merged hit list of the top 1% of scored
compounds from each supplier contained 2845 fragment compounds. Diversity filtering
using the methods described above resulted in 54 clusters. The highest scoring
compound was selected from each cluster for testing in the enzyme assay.
31 of the 54 fragment compounds from the second round of virtual screening
have been successfully procured and tested to date. An additional 9 compounds are
available from the suppliers, but at significant expense and therefore have not yet been
ordered and tested. 8 compounds were rejected for ordering and testing due to close
similarity to compounds already tested, and 1 fragment compound was a duplicate hit
from the first round of virtual screening. 5 compounds were no longer available from any
supplier and have been slated for in-house synthesis and testing. This corresponds to a
10% acquisition failure rate for the second round of virtual screening, compared with the
27% failure rate (15 or 62 compounds) for the first round. This significant improvement
in successful acquisition of screening compounds is probably due to our use of the most
current screening libraries from each vendor as well as only screening libraries from
vendors with a proven track record from the first round of virtual screening.
Of the 31 fragment compounds tested for activity in the second round of virtual
screening, 3 compounds showed activity above the cut-off of 30% inhibition at 500μM
and have been advanced into crystallography trials. This corresponds to a 10% hit rate,
which is closer to the hit rates usually reported in high-throughput virtual screening
studies. The compounds with measured activity are shown in Figure 4.8. These
compounds bear much less resemblance to the pterin substrate and also have improved
solubility over the hit compounds from the first round of virtual screening.
4.3.3 Comparison of Screening Methods and Results
In this study we compared two separate methods for the virtual screening of a
large number of compounds, on the order of several million, against a target. To
compare the two methods we looked at several factors including: ease of use,
computational expense and time requirements, and quality and character of the hit
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Figure 4.8. Hits from Fragment-Based Virtual Screening with Enzyme Activity
compounds. The obvious advantage of the virtual screening method that employed
pharmacophore filtering (round 1) is that a much larger number of compounds, in this
case nearly 5 million, could be screened within a reasonable amount of time using the
computational resources available to our lab (4 processor batching capabilities on a
Linux workstation running RHEL v4). A reasonable amount of time, in our case, was 2
to 4 weeks. This does not include the several weeks it took to create the Unity
databases prior to the pharmacophore filtering step. Another advantage is that the hit
rate was greater with the pharmacophore filtering method over the full fragment library
docking method (26% versus 10%). The disadvantage, as mentioned above, to the
pharmacophore filtering method is that, due to the nature of the pharmacophore filter,
the hit compounds were all very similar to the pterin substrate. This similarity,
unfortunately, included poor solubility. Another obvious ramification of this similarity is in
terms of intellectual space and patentability.
In contrast to the pharmacophore filtering method, the fragment method, which
involved only the application of a molecular weight and rotatable bond filter, yielded hit
compounds that were significantly different that the pterin substrate with improved
solubility. However, the elimination of the pharmacophore filtering step made this
method more rigorous as we were required to explicitly dock and score all the
compounds passing the fragment filter. Even by eliminating unreliable overseas vendors
and employing a stricter fragment filter (300 Daltons versus 350 Daltons), it was still
necessary to dock nearly 300,000 compounds, nearly 2 orders of magnitude greater
than the number of compounds we explicitly docked in the pharmacophore filtering
method. Obviously, this method requires a much longer period of time to complete, in
our case nearly 8 weeks. As mentioned above, we also observed a significantly lower
hit rate with this method. Finally, after successfully docking the fragments in round 2,
the number of top scoring hits, even when selecting only 1% as opposed to 2% selected
in round 1, was unmanageable in terms of our assay abilities as well as our acquisition
budget, making it necessary to employ a further diversity filtering post-processing step.
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4.3.4 Structure-Activity Relationship Studies
An analysis of the hit compounds from the first round of virtual screening has
allowed us to develop a preliminary structure-activity relationship. The pharmacophore
map shown in Figure 4.9 shows the observations that have been made based upon the
activity of the pterin-like hits from the pharmacophore based search.

4.4 Summary
The results of two high-throughput fragment-based virtual screens against the
bacterial target dihydropteroate synthase (DHPS) from B. anthracis have been reported.
Molecular docking and scoring was performed in order to identify novel compounds and
potential scaffolds targeting the pterin binding sub-site of DHPS. Pharmacophore
filtering prior to docking was employed in the first round of virtual screening and
compared to hit results from the second round which did not involve pharmacophore
filtering. Although pre-filtering using pharmacophore constraints allowed the screening
of compounds on the order of several million, the hit results were all limited to pterin-like
compounds with limited solubility and little room for expansion into a novel scaffold area.
The second round of fragment-based virtual screening was much more
computationally intensive; having forewent the pharmacophore filter and limited the
number of compounds that were able to be screened to several hundred thousand.
However, the hit compounds were all unique when compared to the pterin scaffold and
displayed much greater solubility. Hit rates from the first round were much better than
the second round (27% versus 10%), due to the pharmacophore match constraint
applied in the first round. We also noted a lower successful compound acquisition rate
for the ZINC compounds used in the first round of virtual screening when compared to
building screening sets obtained directly from the supplier, as was done in the second
round of virtual screening. Ultimately, 15 compounds met our activity cut-off from the
enzyme assay employed in this study and were taken into crystallography trials.
A preliminary structure-activity analysis of the compounds from Round 1 of the
virtual screening has been presented. Utilizing the activity information gained from the
first round of virtual screening and the potentially novel scaffolds identified in the second
round, we hope to develop a series of unique, DHPS pterin-site binding agents with
potent activity against a broad range of gram-positive and gram-negative organisms.
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Figure 4.9. Pharmacophore Map Based upon DHPS Screening Hit Activity
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CHAPTER 5. LIGAND-BASED DESIGN OF NOVEL
ANTITUBERCULAR AGENTS1
5.1 Introduction
5.1.1 The Tuberculosis Bacilli as a Target for Antimicrobial Drug Design
There is an urgent need today for new anti-tuberculosis agents with novel
mechanisms of action. The global incidence of tuberculosis continues to rise, with a
third of the world’s population currently infected, yet there have been no new classes of
antimycobacterial agents approved for use in forty years.225 The efficacy of the currently
available agents used in standard Tuberculosis (TB) treatment regimens is severely
limited by several factors; including long treatment regimens, multiple drug treatment
regimens, drug interactions, and drug resistance. The emergence of resistance,
particularly Multi-Drug Resistant Tuberculosis (MDR-TB) and Extensively Drug Resistant
Tuberculosis (XDR-TB), is particularly concerning. A recent report released by the
World Health Organization estimated that the incidence of TB drug resistance
(resistance to one drug in standard TB regimen) was as high as 57% in some countries,
while multi-drug resistance was 14%.226 Novel agents are needed that can bypass
resistance mechanisms, that can treat the latent phase of infection shortening the
duration of tuberculosis treatment, and that are compatible with HIV co-therapy by
possessing low drug interaction rates.227,228
5.1.2 Nitrofuran Antituberculosis Agents
Toward these goals, our laboratory has been developing a series of nitrofuranyl
compounds with potent whole-cell activity against M. tuberculosis.229-235 Figure 5.1
shows the three major scaffolds in the nitrofuran series that have been examined so far.
The series originated from a screen for TB cell wall inhibitors that produced a nitrofuran
hit with a respectable MIC activity and low molecular weight.229 Subsequent lead
optimization efforts led to compounds with activity against the tuberculosis bacilli falling
into the nanomolar range. Importantly, these compounds exhibit activity against both
actively growing and latent bacilli, which is believed to be a beneficial attribute of
potential new anti-tuberculosis agents.234 Although the in vitro activity looks very
promising for this nitrofuran series, poor solubility and metabolic instability have
necessitated the development of further generations of nitrofuran agents that can
overcome these issues. Ligand-based drug design techniques were employed to guide
the synthesis of future generations of nitrofuran compounds, as described herein.
1

Adapted by permission. Hevener, K. E.; Ball, D. M.; Buolamwini, J. K.; Lee, R. E.
Quantitative structure-activity relationship studies on nitrofuranyl anti-tubercular agents.
Bioorg Med Chem 2008, 16, 8042-53.
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Figure 5.1. Major Scaffolds of the Nitrofuran Compounds
5.1.3 Nitrofuran QSAR Studies
Quantitative Structure-Activity Relationship (QSAR) techniques are methods
used to correlate physicochemical descriptors from a set of related compounds to their
known molecular activity or molecular property values.30 QSAR models are a useful
method of ligand-based drug design when the molecular target for the compounds being
investigated is either unknown or has not been structurally resolved. The descriptors
used to develop QSAR models can range from molecular descriptors for lipophilicity
(cLogP and LogD)31,32, steric bulk (Molar Refractivity, volume)33, and electrostatics (polar
surface area, Coulombic charges, dipole moments)34 to 3-dimensional descriptors that
involve alignment of the compounds, and calculating steric and electrostatic values using
charged probe atoms at grid lattice points (CoMFA)35 or 3-D similarity indices
(CoMSIA).36 Several quantitative structure-activity relationship models were developed
in this study. Different molecular alignment rules were investigated in order to obtain
models with high predictivity. Compounds with ionizable functional groups were
investigated in their charged and uncharged states. Descriptors including cLogP, LogD,
molar refractivity (CMR), polar surface area (PSA), and 3D CoMFA and CoMSIA
variables were investigated for their ability to predict and correctly rank whole cell MIC
activity using the method of Partial Least Squares, PLS.41
Since the activity data utilized in this 3D-QSAR study is whole cell activity
expressed as the Minimum Inhibitory Concentration (MIC, see experimental section), it is
assumed that the activity reflects several processes in addition to compound binding to
the biomolecular target. Compound solubility, mycobacterial cell entry (i.e. passive
diffusion or active transport), and stability to TB metabolism may all contribute to the
whole cell activity. Additionally, these nitro-aromatic compounds are pro-drugs and must
be metabolically activated by TB nitro reductase enzymes as already demonstrated for
nitroimidazole agents PA824 and OPC67683 that are currently in clinical
development.236-238 The activated form is then believed to interact with its ultimate
molecular target. Because of this multistep process, the development of reliable QSAR
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models using whole cell activity is considered to be a difficult undertaking. However,
several groups have reported success in the development of 3D-QSAR models using
whole cell antimicrobial and antitubercular activity recently.239-242 We have attempted to
account for some of the processes mentioned above by investigating the addition of
molecular descriptors that may be important factors for cell entry including lipophilicity
and steric bulk to our 3D-QSAR models and testing the effects of ionized versus neutral
compounds on the 3D-QSAR model’s validity and predictive power.

5.2 QSAR Methods
5.2.1 Training and Test Set Preparation
Figure 5.2 graphically illustrates the general method followed for the
development of the QSAR models in this study. We began with an initial set of 110
nitrofuran compounds with activity against M. tuberculosis (as determined by carefully
standardized micro broth dilution MIC determination method, see experimental section).
A test set of 15 compounds was selected from the remaining compounds for use in
external validation. These test set compounds were selected such that their activity and
physical properties (MW and cLogP) were broadly reflective of the training set
characteristics (see experimental section). Tables 5.1 and 5.2 list the training set and
test set nitrofuran compounds used in this study, respectively, along with their calculated
molecular descriptors and biological activity. MIC activity originally determined in μg/mL
were converted to micromolar values (μM/mL) and then converted to a pMIC value by
taking Log (1/MIC). The pMIC values were used as the dependent variable in all PLS
models subsequently developed. As a general rule, for a reliable 3D-QSAR model the
spread of activity should cover at least 3 log units and there ideally should be a minimum
of 15 to 20 compounds in the training set.243 The activity range of the nitrofuran
compounds ranged from 0.73 to 5.73 pMIC units (see Table 5.1), a full 5 log activity
distribution, and there were 95 compounds in the training set. Figure 5.3 shows the
training set and test set compounds distributed by their lipophilicity (cLogP) and
molecular weight. The compounds are colored by activity. Importantly, it should be
noted from this preliminary analysis that there is a correlation of increasing activity with
molecular weight but no correlation with increasing cLogP, which may be expected for
mycobacterial entry. We attribute the correlation with increasing molecular weight to the
non-random nature of the data set, as these compounds result from the systematic
medicinal chemistry development of the series from a low molecular weight, lower
potency screening hit to high potency, higher molecular weight optimized compounds.
When designing a 3D-QSAR model using Comparative Molecular Field Analysis
(CoMFA) or Comparative Molecular Similarity Indices Analysis (CoMSIA) the
compounds in the training and test sets must share a common alignment, assumed to
be the active conformation, and have the atomic charges loaded by a reliable method.244
The compounds used in this study were built using the Sybyl Molecular Modeling
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Figure 5.2. QSAR Project Flowchart
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Table 5.1. Physicochemical Properties and Activity of Training Set Compounds
Compound Molecular PSAa(A2) cLogPb
Weight
L1
L2
L3
L4
L5
L6
L7
L8
L9
L10
L11
L12
L13
L14
L15
L16
L17
L18
L19
L20
L21
L22
L23
L24
L25
L26
L27
L28
L29
L30
L31
L32
L33
L34
L35
L36
L37
L38

290.314
232.192
276.220
517.454
382.342
400.306
341.361
252.266
236.181
257.202
276.245
280.664
306.271
306.271
336.297
286.283
317.297
330.339
406.434
405.446
272.256
330.339
406.434
405.446
393.396
234.168
314.336
276.245
306.271
292.244
288.255
290.228
332.308
324.309
331.323
344.365
420.461
344.365

137.057
155.828
145.403
172.693
163.142
130.996
152.959
146.082
174.535
218.788
165.292
153.319
173.676
164.455
164.287
142.587
170.828
157.250
155.828
155.828
144.663
157.180
155.828
155.828
164.787
203.256
110.259
165.039
164.057
212.380
171.250
195.200
136.172
221.944
168.233
154.693
153.312
154.388

1.84
1.68
2.57
5.84
4.12
3.39
3.43
1.89
0.36
1.71
1.62
2.30
1.49
1.49
1.37
2.54
1.56
1.72
3.45
4.63
2.12
1.72
3.45
4.63
3.17
-0.28
2.82
1.62
1.84
1.23
1.17
1.53
2.06
0.45
1.63
1.79
3.52
1.79

LogD7.4c CMRb

MIC(μg/mL) pMICd

1.50
1.95
2.77
6.19
4.20
3.33
3.61
1.70
0.50
1.76
1.31
2.08
1.05
1.05
0.80
2.41
1.87
1.43
3.00
4.88
2.01
1.44
3.01
4.88
3.51
0.02
2.70
1.31
1.02
1.02
0.94
1.24
1.59
0.34
1.48
1.00
2.56
1.00

3.1
0.8
0.4
0.025
0.003
0.0008
0.00156
3.1
6.25
0.8
0.1
1.6
0.4
0.2
0.8
3.1
3.13
12.5
0.8
3.13
3.1
12.5
12.5
12.5
6.25
6.25
0.4
1.6
1.2
0.39
9.38
0.15
0.1
0.17
0.4
0.4
0.0125
6.25
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7.488
5.893
6.903
12.725
10.031
8.852
9.398
6.451
5.571
6.371
6.974
6.849
7.591
7.591
8.208
7.571
8.093
8.772
11.284
11.379
7.107
8.772
11.284
11.379
10.609
5.471
8.500
6.974
7.590
7.127
7.261
6.950
8.341
7.694
8.557
9.236
11.747
9.236

1.9715
2.4628
2.8392
4.3159
5.1053
5.6993
5.3401
1.9105
1.5774
2.5072
3.4413
2.2441
2.8840
3.1851
2.6236
1.9654
2.0059
1.4220
2.7059
2.1124
1.9436
1.4220
1.5121
1.5110
1.7989
1.5736
2.8953
2.2372
2.4069
2.8747
1.4876
3.2866
3.5215
3.2805
2.9182
2.9350
4.5268
1.7411

Table 5.1 (continued).

Compound Molecular PSAa(A2) cLogPb
Weight
L39
L40
L41
L42
L43
L44
L45
L46
L47
L48
L49
L50
L51
L52
L53
L54
L55
L56
L57
L58
L59
L60
L61
L62
L63
L64
L65
L66
L67
L68
L69
L70
L71
L72
L73
L74
L75
L76

419.473
260.245
266.637
419.473
420.461
331.323
260.245
289.287
280.664
320.297
314.217
264.209
264.209
347.389
379.388
330.339
384.429
438.452
362.356
365.379
319.292
349.314
437.463
359.333
248.192
402.401
415.443
415.443
293.255
267.236
325.382
446.498
388.375
430.454
430.454
414.412
444.481
311.088

153.312
155.967
155.828
153.312
153.310
172.571
146.467
153.314
153.346
166.871
153.346
153.346
153.346
181.002
222.205
185.480
153.312
153.345
155.962
180.785
117.883
168.194
153.312
158.130
211.631
176.891
183.540
175.337
239.058
196.771
106.482
119.369
178.977
176.288
176.353
177.426
160.475
155.835

4.70
2.03
2.24
4.7
3.52
1.35
2.07
2.03
2.30
1.77
2.67
1.90
1.90
2.35
0.45
1.41
2.51
3.68
1.95
2.51
2.16
1.79
4.86
1.24
1.29
1.98
1.79
1.62
2.56
2.94
3.62
3.73
1.64
2.89
2.87
2.34
2.62
2.51

LogD7.4c CMRb

MIC(μg/mL) pMICd

4.49
1.81
2.47
4.49
2.56
1.31
1.97
1.83
2.08
1.31
2.45
1.70
1.70
2.06
0.48
-0.23
1.08
3.17
1.55
2.20
2.13
1.62
4.63
0.62
1.64
1.90
1.71
1.67
1.92
2.38
4.25
2.81
1.55
2.76
2.77
2.29
2.44
2.74

1.56
1.6
0.8
0.8
0.05
1.56
3.1
0.4
0.2
0.4
0.05
1.56
0.8
1.56
50
0.8
0.05
0.1
1.56
1.56
0.2
1.56
0.4
1.6
0.2
0.0062
0.2
0.8
50
50
25
0.0125
0.05
0.025
0.025
0.05
0.1
1.6

129

11.843
6.821
6.385
11.843
11.747
8.557
6.821
7.654
6.849
8.055
6.868
6.373
6.373
9.210
9.276
8.772
10.490
11.763
9.252
9.226
7.960
8.572
11.858
9.060
6.047
10.353
11.032
11.032
6.870
6.293
9.216
12.498
9.889
11.280
11.280
10.791
11.744
6.670

2.4296
2.2113
2.5228
2.7196
3.9248
2.3271
1.9240
2.8593
3.1472
2.9035
3.7983
2.2288
2.5189
2.3477
0.8801
2.6159
3.8858
3.6419
2.3660
2.3696
3.2032
2.3501
3.0389
2.1907
3.2545
4.8123
3.3175
2.7154
0.7698
0.7296
1.1145
4.5529
3.8903
4.2360
4.2360
3.9185
3.6479
2.2888

Table 5.1 (continued).

Compound Molecular PSAa(A2) cLogPb
Weight
L77
L78
L79
L80
L81
L82
L83
L84
L85
L86
L87
L88
L89
L90
L91
L92
L93
L94
L95

338.314
389.359
431.442
357.380
434.488
416.428
429.470
421.449
403.389
250.183
262.218
262.218
373.426
238.240
246.219
276.245
258.229
233.180
233.180

156.451
156.162
171.924
141.100
153.312
170.810
171.300
162.679
183.649
155.747
164.178
168.069
146.915
145.856
114.858
126.760
115.575
179.275
179.120

3.28
0.92
1.90
2.41
3.63
2.09
1.73
2.90
1.36
1.84
1.55
1.55
2.57
1.56
1.91
1.79
1.89
0.34
0.34

LogD7.4c CMRb

MIC(μg/mL) pMICd

3.47
0.37
1.75
2.57
1.66
1.95
1.71
2.23
1.26
2.09
1.69
1.69
2.30
1.37
1.72
1.46
1.70
0.63
0.63

12.5
6.25
0.0008
6.25
0.8
0.1
0.4
0.0062
0.05
0.8
0.8
0.4
0.4
3.1
3.125
6.25
0.8
6.25
3.125

9.022
9.670
11.069
9.283
12.211
10.816
11.496
11.536
10.142
5.909
6.510
6.510
9.960
5.988
6.357
6.974
6.644
5.682
5.682

1.4324
1.7945
5.7318
1.7573
2.7349
3.6195
3.0309
4.8324
3.9068
2.4952
2.5156
2.8166
2.9701
1.8857
1.8965
1.6454
2.5089
1.5718
1.8728

a. Sybyl 8.0, Molecular Spreadsheet calculation, Tripos, Inc.245
b. ChemBioOffice Ultra 2008, CambridgeSoft, Inc.246
c. MarvinSketch, 4.1.13, ChemAxon, Inc.247
d. pMIC calculated as Log(1/MIC), where MIC values have been converted to μM/mL
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Table 5.2. Physicochemical Properties and Activity of Test Set Compounds
Test
Set

Molecular
Weight

PSAa(A2) cLogPb

LogD7.4c

CMRb

MIC(μg/mL) pMICd

T1
T2
T3
T4
T5
T6
T7
T8
T9
T10
T11
T12
T13
T14
T15

334.325
393.396
247.207
319.293
264.194
290.271
260.245
330.339
347.298
279.272
370.402
341.381
233.180
222.158
214.132

153.027
169.032
169.364
218.116
200.702
168.402
140.827
228.151
146.305
208.089
120.369
122.884
179.557
231.397
204.941

4.31
3.51
0.39
2.43
0.96
1.56
1.97
-1.41
1.01
1.99
1.24
2.28
1.33
0.97
-0.47

9.399
10.610
6.146
7.796
6.088
7.438
6.821
8.772
8.455
6.894
9.986
9.249
5.682
5.112
4.499

0.025
0.4
0.8
1.6
1.6
0.8
1.6
0.8
1.56
50
0.05
6.25
3.125
6.25
0.4

4.09
2.50
0.83
2.75
1.05
1.90
2.07
0.98
1.33
1.88
2.00
2.36
1.06
0.49
0.31

4.1262
2.9928
2.4900
2.3001
2.2178
2.5597
2.2113
2.6172
2.3476
0.7486
3.8697
1.7374
1.8728
1.5508
2.7286

a. Sybyl 8.0, Molecular Spreadsheet calculation, Tripos, Inc.245
b. ChemBioOffice Ultra 2008, CambridgeSoft, Inc.246
c. MarvinSketch, 4.1.13, ChemAxon, Inc.247
d. pMIC calculated as Log(1/MIC), where MIC values have been converted to M/mL.
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Figure 5.3. Nitrofuran Training and Test Set Compounds by Physical Property and Activity
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Package of Tripos, Inc.245 The charges were loaded on all compounds in the training
andtest sets using the PM3 semi-empirical method contained in the MOPAC suite.248
Several of the nitrofuran compounds contained ionizable functional groups that would be
expected to carry a charge at physiological pH. In order to account for this and to
investigate the effect of protonating or de-protonating these functional groups on model
predictivity, two sets of models were built for each alignment rule utilized. The first set of
PLS models used all nitrofuran compounds in their neutral state and the cLogP
molecular descriptor for lipophilicity (when a lipophilicity descriptor was used), the
second set of PLS models used ionized nitrofuran compounds, as determined by a
major microspecies calculation (discussed in the experimental section), and LogD as the
lipophilic descriptor. Because the molecular target of the nitrofuran compounds is
unknown and the active conformation remains unclear, multiple alignments for these
compounds were studied in an attempt to generate the optimal PLS model in terms of
activity prediction.
Alignment rules were determined by calculating energy minima using the Grid
Search function of Sybyl and 10 degree increments against the rotatable bonds in our
most active nitrofuran compounds from each representative scaffold. The first alignment
method specified all nitrofuran compounds be aligned in the same orientation: a
sterically unhindered trans-amide conformation shown in Figure 5.4, A. The second
alignment method specified that the compounds were aligned to the minimum energy
conformations of several of the more active nitrofuran compounds. Due to differences in
the side chains and steric hindrance factors, the second method actually consisted of
separate alignment rules for phenyl substituted, benzyl substituted, and hindered tertiary
amide nitrofurans. Figure 5.4, B and C show the alignment rules adopted for unhindered
phenyl and benzyl substituted nitrofurans. Sterically hindered tertiary amide nitrofurans
were aligned using the rules shown in Figure 5.4, A, which conform more closely to the
minimum energy conformation seen with these compounds and is the same rule
adopted for all compounds in the first alignment method. We note that the selected
conformation of our nitrofuran compounds in 5.4, B and C very closely aligns with the
structure of PA824 determined in a recently solved crystal structure.249
Global molecular and 3D physicochemical descriptors were calculated for all
compounds in the training and test set and used to develop the QSAR models (see
experimental section). Lipophilicity descriptors included cLogP, LogD, and Polar
Surface Area (PSA). Molecular volume and steric bulk were also investigated using
molar refractivity (CMR) as a molecular descriptor. 3D-QSAR methods utilized were
CoMFA and CoMSIA. The performance of the 3D models before and after the addition
of various combinations of molecular descriptors was investigated.
5.2.2 QSAR Model Development
The QSAR models investigated in this study were built using the Molecular
Spreadsheet tool in the Sybyl 8.0 suite of Tripos, Inc.245 3-dimensional descriptors were
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Figure 5.4. Nitrofuran Alignment Rules Used for QSAR Studies
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generated using both CoMFA and CoMSIA methods as described in the experimental
section below. The effect of outlier removal, number of components, and incorporation
of molecular descriptors in the 3D models were investigated for the CoMFA and CoMSIA
models generated. The program SAMPLS was used to gauge the optimum number of
components for each model during model development.250 In order to avoid over- fitting
the models, a higher component was only accepted and used if it resulted in an increase
of greater than 10% to the cross-validated r2 (q2) values. Progressive scrambling was
performed to confirm the optimum number of PLS components and dependent variable
scrambling was done to check for chance correlation within the models generated.251-253
The best model was obtained using the following methodology: First, models
were generated for each alignment and ionization rule using both CoMFA and CoMSIA
fields without the addition of molecular descriptors or the removal of any outlier
compounds. Next, the molecular descriptors cLogP, LogD, CMR, and PSA were
investigated for their ability to improve the best CoMFA and CoMSIA models. Following
this, the best performing CoMFA and CoMSIA models at this stage was optimized by the
successive removal of outlier compounds (see discussion below) and finally by region
focusing.254
5.2.3 QSAR Model Validation
The strength of all the models developed was evaluated by a number of
validation methods, including internal cross-validation, and external test set predictions.
The cross validation methods of Leave-One-Out (LOO) and Leave-Group-Out (10
compound groups) were chosen to generate cross validated r2 (q2) values and Standard
Errors of Prediction (SEP). Bootstrapping (10 runs) was utilized to calculate confidence
intervals for the r2 and Standard Errors of Estimate (SEE). The equations for q2 and
standard errors are given below. Models generated were used to predict activity for the
test set compounds and generate activity correlated r2 values. Coefficient of
determination, r2, values and standard errors were generated for the final models
developed. Models were considered questionable if the difference between crossvalidated r2 (q2) and non-validated r2 was > 0.3.255

q

1

∑ Y
∑ Y

Y
Y

Equation 5.1

where: Ypred = predicted activity, Yactual = experimental activity, and Ymean = the best
estimate of the mean

SEE, SEP

PRESS
n c 1

Equation 5.2

where: n = number of compounds, c = number of components, and:
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PRESS

Y

Y

Equation 5.3

5.2.4 Experimental Methods
Training and Test Set Preparation. All nitrofuranyl compounds investigated in
this QSAR study were originally synthesized and tested for activity in our lab.229-231
Compounds were built using the Sybyl 8.0 molecular modeling package and charges
were loaded using the PM3 semi-empirical method available in the MOPAC suite. The
compounds were minimized using the Powell method with an initial Simplex optimization
and gradient termination of 0.01 kcal/mol (500 maximum iterations). The global
molecular descriptors cLogP and CMR were calculated using ChemBioOffice 2008.246
Polar surface area was calculated using the molecular spreadsheet application in Sybyl
8.0.245 LogD was calculated for compounds at pH 7.4 using the calculator plugin tool in
Marvin 4.1.13.247 Ionized compounds were identified by performing a major
microspecies calculation on all compounds in the training and test set at pH 7.4 using
the calculator plugin tool of Marvin 4.1.13.247 All compounds were aligned manually as
discussed above. The 15 test set compounds were chosen from the 110 nitrofuran
compounds by selecting for diversity using the program, Selector.256 Selector is an
application available in the Sybyl 8.0 molecular modeling suite.245 Atom pairs and 2D
fingerprints were used to form 15 diversity clusters by hierarchical clustering. 1
compound was selected from each cluster, chosen to maximize the spread of activity
data.
QSAR Model Validation. SAMPLS was used to initially select the optimum
number of components used in the PLS models generated250; with the exception noted
above that a higher component was selected only if it resulted in an increase in q2 values
of at least 10%. Group cross-validation used 10 groups in all cases. Bootstrapped
results were obtained using 10 bootstrapping runs. The progressive scrambling stability
test was performed up to 10 components using 50 scramblings, 10 maximum bins, and 2
minimum bins. The critical point was 0.85 and the seed was 12080.
QSAR Model Development. 3-D CoMFA descriptors were generated using c.3
probe atom with a +1 charge and a grid spaced at 2 Å and extending 4 Å beyond the
compounds in all directions. Tripos Standard CoMFA steric and electrostatic fields were
generated using a distance dependent dielectric, no smoothing, and cutoffs of 30
kcal/mol for each. CoMSIA similarity fields were calculated for steric, electrostatic,
hydrophobic, h-bond donor, and h-bond acceptor using the default attenuation factor of
0.3. Partial Least Squares analysis was used to build models correlating descriptors to
the dependent variable, pMIC. Optimum number of components was determined by
SAMPLS, cross validation methods, and progressive scrambling. A column filtering
value of 0.5 and CoMFA standard scaling was used in all PLS analyses. Region
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focusing was performed by applying a discriminant power weighting factor of 0.3 and
new grid spacing equal to the original.
Antituberculosis Activity Testing. MIC values were determined using the
microbroth dilution method and were read by visual inspection. Two-fold serial dilutions
of test compound were prepared in 96-well round bottom microtiter plates (Nunc, USA)
in 100 µL of the 7H9 broth media (Difco Laboratories, MI, USA) supplemented with 10%
Albumin-Dextrose Complex and 0.05% (v/v) Tween80. An equivalent volume (100 µL)
of broth inocula containing approximately 105 CFU/mL of M. tuberculosis H37Rv was
added to each well to give final concentrations of test compound starting at 200 μg/mL.
The plates were incubated aerobically at 37°C for 7 days and the MIC was recorded as
the lowest concentration of drug which inhibited 90% of growth with respect to the nodrug control.

5.3. Results and Discussion
5.3.1 General Validation and Predictivity Results
Descriptions of the 3D-QSAR models built are given in Table 5.3; the validation
data and predictive ability are shown in Table 5.4. PLS models which used CoMFA
generated 3D descriptors generally outperformed models using CoMSIA 3D descriptors.
It should be noted that all 5 CoMSIA fields were used in the PLS (steric, electrostatic,
hydrophobic, h-bond donor, and h-bond acceptor) built in this study. The rules of
alignment and ionization had a strong influence on the final performance of the models
generated. Models using ionized nitrofuran compounds, Figure 5.5, generally performed
worse than the neutral compound models, with the exception of model 2 and 10, both of
which had higher test set r2 and non-validated r2 values, but lower internal validation, q2,
values. This may be reflective of the need for neutral compounds to passively diffuse
into the mycobacterial cell, or possibly the binding of the nitrofuran compounds to their
biomolecular target in a neutral state. Models generated using alignment 1, in which all
nitrofuran compounds adopted the sterically unhindered trans-amide conformation, also
performed significantly worse than those built using alignment 2, in which compounds
adopted one of three minimum energy conformations. Test set activity predictions were
particularly poor for the alignment 1 QSAR models, and the cross-validation also
demonstrated that these were much weaker models compared with alignment 2 models.
In light of this data, the decision was made to advance model 3 (CoMFA, alignment 2,
neutral compounds) and model 7 (CoMSIA, alignment 2, neutral compounds) into the
next stage of model development, which involved the investigation of molecular
descriptors ability to improve the model’s predictivity.
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Table 5.3. QSAR Model Descriptions

Model Description

Alignment Ionization # Components Outliers

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

1
1
2
2
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
No
No
No
No
No
No
No
No
No
No
No

1
2
3
3
2
2
3
2
3
4
3
3
3
3
4
4
3
3
5
5
5
3

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
6
7
8
6

2

No

5

6

23

CoMFA
CoMFA
CoMFA
CoMFA
CoMSIA
CoMSIA
CoMSIA
CoMSIA
CoMFA, cLogP
CoMFA, LogD
CoMFA, PSA
CoMFA, CMR
CoMFA, cLogP, CMR
CoMFA, cLogP, PSA
CoMFA, PSA, CMR
CoMFA, cLogP, PSA, CMR
CoMSIA, cLogP
CoMFA
CoMFA
CoMFA
CoMFA
CoMSIA
CoMFA (19) Region
Focused
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Table 5.4. QSAR Model Validation and Predictivity

Model

LOO Cross q2 /
SEP

Group Cross q2 /
SEP

Bootstrapped r2

Bootstrapped
SEE

Non-Validated r2 /
SEE

Test Set r2 /
SEE

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

.166 / 1.009
.139 / 1.030
.286 / .935
.235 / .968
.167 / 1.014
.153 / 1.022
.240 / .964
.205 / .981
.326 / .908
.264 / .954
.265 / .949
.311 / .918
.304 / .923
.296 / .928
.284 / .941
.308 / .925
.402 / .855
.448 / .732
.530 / .664
.559 / .643
.581 / .631
.573 / .668
.585 / .625

.162 / 1.012
.130 / 1.036
.279 / .930
.236 / .974
.187 / 1.001
.127 / 1.038
.215 / 1.004
.203 / .982
.320 / .913
.238 / .971
.261 / .951
.314 / .916
.295 / .929
.305 / .922
.288 / .938
.326 / .913
.358 / .887
.420 / .750
.537 / .660
.588 / .621
.600 / .616
.589 / .607
.587 / .623

.414 ± .079
.471 ± .047
.741 ± .041
.683 ± .050
.523 ± .044
.557 ± .044
.690 ± .030
.563 ± .071
.683 ± .059
.705 ± .065
.645 ± .043
.690 ± .034
.632 ± .030
.594 ± .048
.742 ± .034
.680 ± .045
.627 ± .051
.794 ± .023
.923 ± .016
.919 ± .015
.926 ± .020
.768 ± .041
.903 ± .024

.886 ± .393
.799 ± .326
.564 ± .279
.642 ± .340
.728 ± .298
.718 ± .301
.637 ± .313
.679 ± .285
.636 ± .227
.594 ± .293
.640 ± .232
.581 ± .204
.674 ± .202
.705 ± .242
.549 ± .240
.622 ± .242
.674 ± .278
.447 ± .175
.251 ± .097
.265 ± .116
.250 ± .116
.465 ± .149
.305 ± .127

.294 / .928
.355 / .842
.650 / .655
.580 / .717
.425 / .842
.451 / .823
.588 / .710
.451 / .816
.558 / .735
.588 / .714
.559 / .735
.633 / .670
.552 / .740
.486 / .793
.636 / .671
.578 / .723
.601 / .698
.725 / .516
.856 / .368
.884 / .330
.896 / .315
.708 / .512
.845 / .381

.118 / .831
.293 / .750
.769 / .456
.648 / .591
.567 / .611
.417 / .613
.786 / .497
.441 / .667
.528 / .746
.697 / .556
.609 / .601
.737 / .498
.514 / .781
.525 / .757
.717 / .533
.419 / .836
.559 / .618
.756 / .474
.781 / .561
.734 / .612
.754 / .584
.781 / .493
.769 / .524
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Figure 5.5. Nitrofuran Compounds with Predicted Charge at Physiological pHa,b
a. As determined by major microspecies calculation using MarvinSketch, v. 4.1.13. 247
b. Physiological pH, 7.4
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5.3.2 The Effects of Adding Global Molecular Descriptors
Global molecular descriptors were added to the 3D-QSAR models developed in
an attempt to account for factors contributing to the MIC including, solubility and cell
entry. The addition of cLogP to Model 3 led to a significant improvement in the crossvalidated r2 (internal validation), but a lower non-validated and bootstrapped r2 (model 9).
A similar result was seen when cLogP was added to CoMSIA fields in a reflective PLS
analysis (model 17); the cross validated r2 values were significantly higher, but the nonvalidated and test set r2 values were not an improvement over model 7. The addition of
LogD values to model 4 (in order to investigate ionization) had negligible effect on the
internal validity or test set prediction of that model. Polar Surface Area (PSA) values
added to model 3 had a negligible effect on internal validity of the model and worsened
the predictivity, as seen by the decreased performance against the test set. The
addition of CMR as a measure of steric bulk of the nitrofuran compounds led to slight
improvements in the cross-validated r2 values, but again, lower bootstrapped and testset
r2 values. Similarly, various combinations of the molecular descriptors, as shown in
models 13 through 16, did not improve model 3 to any significant extent Ultimately, the
models selected to proceed to step 3 (outlier investigation) were models 3 and 7, which
do not incorporate any global molecular descriptors.
5.3.3 Outlier Compounds
Figure 5.6 shows outlier nitrofuran compounds, the removal of which improved
the CoMFA and CoMSIA models discussed herein. Outlier compounds removed from
each model were determined by analysis of a QQ plot generated by the QSAR analysis
tool of Tripos, Inc. The QQ plot is essentially a normal probability plot of residuals,
which is a validated method specifically developed to detect outliers.255,257 Compounds
with residuals that did not follow normal distribution were removed sequentially from the
models developed, starting with the highest deviation from normal distribution. Model 18
was generated by removal of compounds L6, L64, and L79, all with under-predicted
activity. Model 19 was generated by removing 3 more compounds; L4, L53, and L49.
Subsequent outlier removal (model 20 and model 21) did not result in the improvement
of the CoMFA models to a significant extent. It can be seen from the data given in Table
5.4 that the removal of 6 outliers was optimal in terms of predictive ability of the CoMFA
models as demonstrated by the test set r2 values. Although there was modest
improvement in the internal validity (seen by cross-validated r2 values for CoMFA) by
removal of additional outlier compounds, there was negligible improvement to
bootstrapping and non-validated r2 values. CoMSIA model 22 was generated by
removal of six compounds from CoMSIA model 7 again based upon the residual
distribution. The CoMSIA outlier compounds are shown in Figure 5.6. Four of the six
outlier compounds removed to generate CoMSIA model 22 were also outlier compounds
from the CoMFA models (model 18 and model 19). CoMSIA model 22 showed
significant improvement to both cross-validated and non-validated r2 values but had little
effect on the test set r2 values, indicating an improvement in validity without affecting

141

Figure 5.6. Structures of Outlier Compounds
a. Outliers from CoMFA Model 19.
b. Outliers from CoMSIA Model 22.
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external predictivity. This model had comparable internal validity and test set predictivity
to our best CoMFA model (model 19), but the bootstrapped and non-validated r2 values
were significantly lower. For this reason, model 19 (CoMFA, 6 outliers) was chosen to
take to the final step in the 3D-QSAR development, region focusing.
The compounds in Figure 5.6 are sorted by whether their activity was overpredicted or under-predicted. Failure of these compounds to perform well in the QSAR
models can be due to several factors, including inability to align correctly with the
training set, inaccurate activity values, other processes not accounted for (i.e. active
transport, prodrug activation, alternate metabolic routes, increased metabolic stability).
Compounds with over-predicted activity may be subject to metabolic inactivation that
can’t be accounted for in the QSAR models. Further, we have demonstrated that L4 has
poor solubility that may account for its over-predicted activity.233 Additionally, as can be
seen from Figure 5.3, compound L4 has extreme values of molecular weight and
lipophilicity which may explain the inability of the generated QSAR models predict its
activity. The trifluoromethyl groups on compounds L49 and L6, both with under-predicted
activity, block metabolism at this site and also increase lipophilicity of these compounds.
This leads to enhanced metabolic stability and facilitated passive diffusion across the
lipophilic mycobacterial cell wall. These factors may have resulted in an improved MIC
for these compounds which the QSAR model was not able to predict. Compounds L64
and L79 (CoMFA and CoMSIA outliers) both contain a metabolically labile carbamic ester
functionality, cleavage of which could result in an active metabolite. This process may
account for the under-predicted activity of these two compounds. Compound L84 is
unique in that it had a high residual when activity predictions were performed using the
CoMSIA model (model 7), but residuals that did not result in outlier removal from any
CoMFA model. As can be seen from Figure 5.6, for the most part the CoMFA and
CoMSIA activity predictions were reasonably comparable; compounds L84 and L53 were
the notable exceptions. The reason for the poor activity prediction of this compound by
the CoMSIA model is not readily apparent.
5.3.4 Region Focusing
One method of 3D-QSAR optimization is known as region focusing.254 It involves
giving additional weight to the lattice points in a given CoMFA region to increase the
contribution of those points in a further analysis. Region focusing is used to suppress
PLS contributions from minor descriptors. The result is a new model with increased q2
(cross-validated r2), tighter grid spacing, and greater stability at a higher number of
components. In this study, discriminant power was used to weight the lattice points by
their contribution to the original model’s components (see experimental methods).
Figure 5.7 shows the CoMFA fields for one of the more active nitrofuran compounds
before and after region focusing. As can be seen from the data for Model 23 in Table
5.4, the application of region focusing to Model 19 resulted in a significant improvement
to the internal validity of the model, with small to negligible effect to the non-validated r2
and test set activity predictions. Relative steric and electrostatic contributions were
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Figure 5.7. QSAR Region Focusing
The CoMFA field calculations are shown for L7 before (upper) and after (lower) region
focusing. Electrostatic fields (Left): Blue fields indicate electropositive groups favored,
red fields indicate electronegative groups favored. Steric fields (Right): Green fields
indicate steric bulk favored, yellow fields indicate steric bulk disfavored.
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calculated from regression coefficients of the PLS models generated. Steric
contributions played a larger role than electrostatic in the final model (model 23). The
steric and electrostatic field contributions to the final model were 74% and 26%,
respectively. Model 23 was selected as the best performing model in this 3D-QSAR
study and will be used to predict the activity and guide future synthetic efforts on next
generation nitrofuranyl compounds. Figure 5.8 graphically represents the biological
activity predictions of Model 23. Figure 5.9 shows the CoMFA steric and electrostatic
contour fields for the final model with the active compound, L37, overlaid. Figure 5.10
displays the CoMSIA fields for our best performing CoMSIA model (model 22). The
CoMFA fields indicate that the steric effects are mostly limited to the side chain, with
clear areas seen where bulk is favored and disfavored. The CoMFA electrostatic fields
show regions where positive and negative charges are favored on both the nitrofuran
scaffold as well as the side chain. The blue field near the nitro group seems to indicate
that compounds with less negative charge near the one of the nitro oxygens are favored;
this is most likely due to the contribution of the aryl sulfone and aryl sulfoxide
substitutions at this position in our training set. There is also a clear preference for a
positively charged group at the terminal end of the side chain, which appears to
correspond to basic amine groups at this position in several of the more active
compounds in the training set. The CoMSIA fields (Figure 5.10) show steric regions and
electrostatic fields that correlate well with what is seen in the CoMFA fields. Additional
fields for hydrophobicity and H-bond donors and acceptors are shown; this information
will be used for optimization of further generations of nitrofuran compounds.
5.3.5 Progressive Scrambling and Dependent Variable Scrambling
Cross-validation values must be interpreted with caution when building 3D-QSAR
models with large training sets. This is because redundancy in the data sets can
confuse the Leave-One-Out and Leave-Group-Out validation techniques.252 The
Progressive Scrambling method was developed to overcome this problem.251-253 This
method checks the sensitivity of the PLS model developed to small changes in the
dependent variable. The values of Q2, cSDEP, and dq2/dr2yy’ are returned and can aid in
interpreting the predictivity of the model without the potentially confusing redundancy.
The Q2 statistic returned is an estimate of the predictivity of the model after removing the
effects of redundancy. It is calculated by fitting the correlation of scrambled to
unscrambled data (r2yy’) to the cross-validated correlation coefficient (q2) (calculated after
each scrambling performed) using a 3rd order polynomial equation. The cSDEP statistic
is an estimated crossvalidated standard error at a specific critical point (0.85 default
used in this study) for r2yy’, and is calculated from a 3rd order polynomial equation which
fits the scrambled results. The slope of q2 with respect to r2yy’ is reported as dq2/dr2yy’,
and is considered the critical statistic. It indicates to what extent the model changes with
small changes to the dependent variable. In a stable model, dq2/dr2yy’ should not exceed
1.2 (ideally 1). This method was employed against the final model to verify the number
of components used to build the model and to check the cross-validation against the
possibility of such a redundancy in our training set. Table 5.5 lists the results of the
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Figure 5.8. Model 23 Results: Actual versus Predicted Activity
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Figure 5.9. CoMFA Field Contour Maps for Model 23 with Active Compound, L37
Electrostatic fields (Left): Blue fields indicate electropositive groups favored, red fields indicate electronegative groups favored. Steric
fields (Right): Green fields indicate steric bulk favored, yellow fields indicate steric bulk disfavored.
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Figure 5.10. CoMSIA Field Contour Maps for Model 22 with Active Compound, L37
A. Steric Fields, Green indicates steric bulk favored, Yellow indicates bulk disfavored. B.
Electrostatic fields, blue indicates positive charge favored, red indicates disfavored. C.
Hydrophobic fields, Yellow indicates favored, gray indicates disfavored. D. H-bond donor
and acceptor fields, Cyan indicates donor favored, Magenta indicates acceptor favored,
and red indicates disfavored.a
a. H-bond donor disfavored fields were negligible at default energy values used for field
generation and are not shown here.
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Table 5.5. Progressive Scrambling Results, Model 23

Components

Q2

cSDEP

dq2’/dr2yy’

2
3
4
5
6
7
8

0.337
0.387
0.430
0.432
0.381
0.424
0.393

0.776
0.750
0.726
0.728
0.763
0.741
0.766

0.13
0.52
0.78
1.15
1.47
1.48
1.55

progressive scrambling of Model 23. For a valid model, as additional components are
added, values of Q2 should be increasing while cSDEP is decreasing, the slope should
fall near unity. While the value of the Q2 statistic may seem low in comparison to the
cross-validated r2 (q2) value, it must be noted that the introduced noise from scrambling
renders this statistic very conservative. Q2 values above 0.35 are reported to indicate
that the original, unperturbed model is robust.251 For Model 23, based on the
progressive scrambling results, 5 components was the optimum number for use.
Another validation method that was employed in this study was Dependent
Variable Scrambling (Y-scrambling). This method involves scrambling the dependent
data in the training set and then building a PLS model using this scrambled data. The
method is used to verify that the correlation in the original, unscrambled model is
accurate and not a chance correlation. Ideally, the cross-validated r2 (q2) values
returned from the scrambled PLS will be very low, even negatively correlated. Table 5.6
shows the results of the Y-scrambling test run against model 19. This model was
chosen because model 23 was built by region focusing model 19, which was been built
using unscrambled data. Therefore, Y-scrambling results against model 23 would not
have been easily interpreted.

5.4 Summary
Using a series of nitrofuranyl compounds with known anti-tuberculosis activity, a
predictive 3D-QSAR model has been developed. The effects of compound ionization,
multiple alignments, and the incorporation of global molecular descriptors for lipophilicity,
polar surface area, and steric bulk were investigated for their ability to improve QSAR
model predictivity. Our expectation was that the addition of a lipophilicity descriptor
(cLogP or LogD) and steric bulk descriptor could improve the model’s predictivity by
accounting for the cell entry contribution to the MIC of a given compound. We also
theorized that polar surface area and ionization could model the effects of solubility.
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Table 5.6. Dependent Variable Scrambling Results, Model 19

Components

LOO q2

SEP

1
2
3
4
5
6
7
8

-0.260
-0.546
-0.498
-0.833
-0.863
-0.827
-0.765
-0.791

1.210
1.349
1.335
1.486
1.507
1.501
1.485
1.505

Interestingly, the addition of molecular descriptors for lipophilicity, polar surface
area, and steric bulk did little to improve the predictive ability of the model. While in
most cases, the addition of the global molecular descriptors didn’t weaken the models
significantly, they did little to benefit them either. This may be due to the fact that most
of the compounds in the training set had suitable physicochemical properties (cLogP 15) to penetrate the TB cell wall. As can be seen from Figure 5.3, although there is a
clear trend of increasing activity with increased molecular weight, there is little
correlation with cLogP in the range that our active compounds fall into. This is reflected
in the QSAR models built in this study.
We noted above that the CoMFA steric field contribution of the final model (74%)
greatly outweighed the electrostatic field contribution. As can be seen from the CoMFA
fields shown in Figure 5.9 as well as the CoMSIA fields shown in Figure 5.10, the steric
effects were isolated to the side chain while electrostatic effects were contributed from
both the side chain and the nitrofuran scaffold. We believe this can be explained by the
two processes discussed above, activation of the compounds by a nitro reducing
enzyme (electrostatic effects, low steric contribution) and binding of the compound to its
ultimate biological target (electrostatic and steric contribution). The CoMFA and
CoMSIA fields clearly indicate regions of interest (both to avoid and to target) that will be
used when performing CoMFA and/or CoMSIA guided activity predictions of nitrofurans
for proposed synthesis and testing.
Another interesting result that we note is the improved performance of the QSAR
models both in terms of internal validity and external (test set) predictivity when using
alignment 2 versus alignment 1. In alignment 2, the side chains of the tertiary amide
nitrofuran compounds adopted a conformation that was significantly different when
compared to the unhindered nitrofurans and fell into a region not occupied by the
unhindered compounds (see Figure 5.4, A). It is possible that this is reflecting the dual
processes of compound activation and binding to the ultimate biomolecular target. While
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it may seem from initial inspection of the CoMFA and CoMSIA fields in Figures 5.9 and
5.10 that these tertiary amide compounds contributed little to the final model, we point
out that the test set included two such compounds whose activity was predicted with a
fair degree of accuracy (within .5 pMIC units).
Further experiments are ongoing to investigate if our best performing models can
be expanded to examine the nitroimidazole class of anti-tuberculosis agents.
Preliminary evidence indicates that CoMFA model 23, discussed here, is suitable to
predict MIC activity of these compounds as demonstrated by the reasonably accurate
predictions of MIC’s for PA824 (predicted 1.2 μg/mL, actual 0.5 μg/mL) and OPC67638
(predicted 0.0075 μg/mL, actual 0.006 μg/mL). This suggests that steric and electronic
requirements for entry and nitro activation are shared by the nitrofuran and
nitroimidazole anti-tuberculosis agents and are major contributors to this QSAR model.
The final model was optimized by outlier removal and region focusing and
validated by a variety of methods; including cross-validation, progressive scrambling,
and test set predictions. The model developed has high internal validity (cross-validated
r2 (q2) above 0.5) and high predictive ability (test set r2 above 0.7). It is being used to
predict the anti-tuberculosis activity of proposed new compounds and to prioritize their
synthesis by activity ranking. We believe this is an new important tool for the
development of next generation nitrofuranyl and related nitroaromatic anti-tuberculosis
agents.233
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CHAPTER 6. DISCUSSION AND CONCLUSIONS
6.1 General Dissertation Overview
This dissertation has presented my work on two research projects: the DHPS
project focused on the identification of novel compounds that bind to the pterin subsite of
dihydropteroate synthase and thereby inhibit enzyme activity; and the nitrofuran project
focused on the advancement of a series of compounds with whole-cell activity against
M. tuberculosis, both in terms of inhibitory activity and physical properties. These two
projects afforded me the opportunity to use and evaluate a variety of computational tools
to accomplish these research goals.
The availability of DHPS crystal structures with a variety of substrate and product
analogs bound in the active site enabled the use of several structure-based drug design
techniques, and were presented in chapters 2, 3 and 4. In Chapter 2, I presented my
studies on the structure and function of DHPS and the mechanism of acquired
resistance to sulfonamide agents. Using a series of molecular dynamics simulations, I
was able to model the positions of loops that were either missing or incorrect from our
crystal structures and visualize the locations of several residues that play key roles in
both the reaction and resistance. Additionally, key insights into the role of the pterin
subsite residues in ligand binding and the implications of these binding determinants in
the design of pterin site inhibitors was discussed. An active site model was developed
for use in subsequent high-throughput docking studies.
Chapter 3 presented the results of an extensive validation study of docking
programs and scoring functions for use in high-throughput docking against the pterin
binding site of DHPS. A variety of docking programs and scoring functions were
thoroughly evaluated using several validation techniques including pose selection and
scoring of a bound ligand, enrichment studies using receiver-operating characteristic
curves, and a new metric designed specifically for this study, the SSLR statistic, which
rewards both early enrichment and correct rank ordering by activity of known active
compounds. In addition to selecting the best performing docking/scoring combination for
use against DHPS, I was able to make general observations on the utility of the different
validation metrics for use in validating against a single target.
Chapter 4 concluded my discussion of the DHPS virtual screening project by
presenting the results of several large-scale, high-throughput molecular docking studies
against the DHPS pterin site using fragment-based drug design concepts. These
studies were built upon the work presented in the previous two chapters. Two
successive rounds of docking were performed against the target using different
screening techniques and the docking programs validated in Chapter 3. The first round
of virtual screening used pharmacophore pre-filters, which enabled the screening of a
very large number of compounds. Unfortunately, this led to “hit” compounds with
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undesirable physico-chemical properties. The pharmacophore filtering step was
removed for the second round of virtual screening, and resulted in far fewer compounds
that we were able to screen, but with improved properties and novel scaffolds when
compared to the first round. Ultimately, 15 fragment compounds were identified that had
reasonable inhibitory activity against DHPS and they have been advanced to
crystallography trials.
The second project discussed in this work was the nitrofuran project, which was
presented in Chapter 5. This project used a series of compounds for which whole-cell
activity against M. tuberculosis was known, but no structural target information was
available. In this case, ligand-based techniques were employed, specifically 3D-QSAR
studies, to generate a model which could be used to predict the activity of similar
compounds that have not been synthesized or tested. The goal of these studies was to
develop a model that can be used to advance the development of next generation
nitrofuran compounds with improved physico-chemical properties and metabolic stability.
The models developed in this study were generated using two new advanced
techniques, Region Focusing and Progressive Scrambling, and were extensively
validated. The combined use of these two methods allowed us to develop models with
excellent predictivity.

6.2 Computational Medicinal Chemistry: A Diverse and Expanding
Field
When employed by a skilled researcher with training and experience, the
methods discussed below have the capability to identify active compounds which can be
advanced to the clinic. This can be seen from the numerous examples of marketed
drugs initially identified by these structure-based and ligand-based drug discovery
methods (shown in Table 1.1). The key to success when applying these methods to
drug discovery is the user. In addition to possessing expert skills in the use and function
of the programs or algorithms which are being employed in the virtual screening study
the Computational Medicinal Chemist should also be knowledgeable in four key
complementary areas.
First, a working knowledge of organic chemistry is very important, even if the
user is not performing any chemical reactions themselves. It is often necessary to filter
out compounds from screening libraries that contain reactive or unstable functional
groups. When making these filtering decisions, a background or working knowledge of
organic chemistry is advantageous. Also, virtual libraries are often created using
synthetic chemistry rules and building blocks available from commercial vendors. When
designing virtual screening libraries, knowledge of synthetic organic chemistry is
extremely helpful. Finally, the results of virtual screening studies are often used by
synthetic chemists to either prioritize their synthesis projects or select compounds with
high predicted activity for synthesis and testing. It is an advantage if the computational
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chemist is able to provide suggestions to the organic chemists that are synthetically
feasible, and a working knowledge of synthetic organic chemistry is helpful in facilitating
discussion and interaction between the computational and synthetic organic chemist.
Second, knowledge of the basic principles of structural biology and the
techniques used in the preparation of the atomic models that are used in structure-based
drug design are absolutely essential. Knowing the limitations and uncertainties of an Xray crystal or NMR structure being used for virtual screening is essential when preparing
the structure for screening as well as when interpreting the results. An excellent paper
published by Davis, et al. in 2003 highlighted important considerations the computational
chemist must consider when using an X-ray crystal structure for a structure-based
design project.258 The biggest factor that must be understood is the uncertainty in the
atomic positions of the structure being used and how to determine this uncertainty.
Alternative side chain conformations and B factors can help the user identify areas of
uncertainty in the atomic model. Molecular modeling environments are often inadequate
for identifying these areas and expert interpretation of the structural files is necessary.
Additionally, the laboratory methods and the experimental conditions used for
determining these structures can have an effect on the structural model obtained, and
this must be clearly understood by the computational chemist.
Third, an understanding of molecular biology techniques is also very important in
terms of the experimental methods that are employed to measure the activity of any
compounds being investigated. It has been said that high-throughput screening is only
as good as the experimental assay being used in the screen. I would say that this is just
as true when considering virtual screening because the “hit” compounds are typically
intended to be tested for activity in an experimental assay. Knowledge of the assay
conditions and limitations can be very important when identifying hit compounds and
selecting compounds for testing because the physico-chemical properties of the
compounds may be incompatible with the assay or assay conditions. In fact, a priori
knowledge of the assay conditions and assay limitations can often influence the virtual
screening parameters so as to select for compounds that are compatible with the assay.
An understanding of other molecular biology techniques such as protein expression and
isolation, gels, blotting, and arrays can also be useful to the computational medicinal
chemist.
Finally, other areas that can be equally important include Anatomy and
Physiology, Pharmacology, Pharmacokinetics and Pharmacodynamics, and
Microbiology. Clearly, when attempting to discover compounds with biological activity
for use in treating human disease, working knowledge of human pathophysiology and
the molecular basis of drug action are very important. Traditionally, the
pharmacokinetics and pharmacodynamics of lead compounds were optimized after
identifying compounds with potent activity against the molecular target. However, due to
the large number of clinical trial drug failures observed recently due to PK/PD issues and
the exponential increase in the cost of bringing a drug to them market, these issues are
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more frequently being addressed at earlier stages of drug discovery, even during hit and
lead identification. There are now multiple algorithms and programs that are being used
with increasing frequency to identify and eliminate compounds during the initial
screening which are predicted to have unfavorable ADME or toxicological properties.259
An understanding of these programs and properties is obviously very important.

6.3 Discussion of Methods
The studies discussed in this dissertation describe the use of a variety of
molecular modeling and computer-aided drug design techniques, ranging from ligandbased methods of activity prediction to structure-based docking methods for hit
compound identification. Every technique discussed in Chapter 1 has been used in
these studies to some degree. These methods can be powerful tools to aid in the
discovery, design and development of novel therapeutic agents, but it must be
remembered that they are not without their limitations. Their full potential is only realized
when their use is supported by other experimental methods, such as structural biology,
molecular biology, microbiology, and organic synthesis. The studies presented here
would not have been possible without contributions from researchers in each of these
areas in multi-disciplinary, collaborative drug discovery projects. In Chapter 1, I
introduced the virtual screening methods and tools used in these studies and discussed
their theory and application. In this section, I present a critical assessment of the same
by addressing their strengths and weaknesses in terms of their performance in these
studies and discuss their future potential in more general terms.
6.3.1 Molecular Dynamics Simulations
When applied by a skilled user, molecular dynamics simulations can be
employed to complement crystal studies by visualizing the motions of the atoms or
residues of a biomolecular system. A crystal structure is a snapshot of a system, which
may or may not represent the biomolecule in its native or active state. Simulations, on
the other hand, can be used to visualize small scale movements such as loop
movements, ligand binding, and possibly transition states. However, MD is not without
limitations, and the studies discussed in Chapter 2 have demonstrated several that merit
discussion. First and foremost, it must be remembered that MD simulations are just that:
simulations. The methods used to obtain the energies and atomic positions are often
approximations of approximations, and the results obtained from these studies must
always be interpreted with this in mind and with a fair amount of caution.
MD simulations are time consuming and computationally expensive processes.
In order to visualize loop movements (one of the goals of our simulations), an MD
simulation must extend into the nanosecond range. Even when using time-saving
shortcuts such as the SHAKE algorithm, energy cut-offs, PME electrostatic calculations,
periodic boundary conditions, and implicit solvation, a nanosecond simulation can take a
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week or more to run across multiple processors. A more rigorous simulation using
explicit solvation can take up to several weeks. Additionally, in order to validate the
model and results, it is often necessary to run multiple simulations to demonstrate the
reproducibility of the results obtained. A project such as this can easily extend into
months of work, as was the case in these studies. Visualization of large scale protein
movements, protein folding, and rare events would require simulations into the
millisecond range, and this is not possible with the current technology and computing
power available.
Perhaps the most important consideration when setting up MD simulations is the
parameterization of the non-native residues (ligands, cofactors, etc) present in the model
being investigated. Most of the commonly used MD packages, such as the AMBER
suite used in our studies, have developed parameters for the most common residues
seen in biomolecules (amino acids, carbohydrates, nucleic acids, and even some
commonly seen cofactors), and these have been extensively tested and validated.
However, parameters (energy force constants and reference values for bond lengths,
angles, torsions, etc.), must be developed, tested, and validated for any ligand or cofactor for which these parameters are not available, as was the case in our studies. We
utilized the program Antechamber and the General Amber Force Field (GAFF) to derive
parameters for non-native residues. Although this process is quick and usually reliable,
it does not remove the need for testing and validating the derived parameters. This was
the case for the parameters for our pyrophosphate ligand, which required extensive
modification from those suggested by Antechamber before they could be used in our
simulations to obtain reliable results. The main point here is that with molecular
simulations, in order to obtain reliable results, both effort and skill are required to prepare
the system prior to running any simulations. The old computational adage applies:
garbage in, garbage out.
Finally, it should be mentioned that although the simulation methods employed in
these studies are useful for visualizing small-scale protein movements and positions of
ligands and side chains during binding, the force field methods used to obtain the
energies are unable to show reactions, catalysis, or any process involving the flow of
electrons. New methods including polarizable force fields and hybrid quantum
mechanics/molecular modeling (QM/MM) methods have been recently reported that
hope to address some of these deficiencies, but the methods still require extensive
development and validation. Notwithstanding the limitations mentioned above, MD is a
powerful tool that can be used very effectively in projects such as the one reported in
this work, if one has a clear understanding of the limitations of the methods and keeps
these limitations in mind when interpreting their results.
6.3.2 Structure-Based Drug Design
In a virtual screening project it is a definite advantage to know the structure of the
biomolecular target being investigated. An X-ray, NMR, or even a homology modeled
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structure makes a variety of structure-based design tools available to the researcher,
most importantly docking and scoring techniques. Although these methods have
demonstrated utility in the identification of lead compounds (as discussed in Chapter 1),
they are not without their limitations. An understanding of these limitations is important
to the successful application of these methods in a drug discovery project.
An obvious advantage of using docking and scoring as a lead identification
method is the larger number of compounds that can be screened when compared to
traditional high-throughput screening. Additionally, there is an added advantage in
terms of both cost and time savings. However, expert decision making is necessary for
both the preparation of the receptor for docking and the screening library which will be
docked. Decisions regarding protonation states of ligands and side chains, charge
calculation methods, and initial conformations must be made by the user prior to
beginning the screen. These decisions typically require significant expertise on the part
of the user with the program or programs that are being used to perform the docking run.
A very large number of docking programs are now available for use today and it is
unreasonable to expect a computational medicinal chemist to have achieved a high
degree of expertise with more than a small number. Unfortunately, as has been
demonstrated by several studies published to date, the performance of the docking
program being used is at least partly dependent on the level of familiarity that the user
has with the program.185 In many docking program validation studies, the developers of
a docking program are able to achieve significantly greater enrichment rates over other
users, even when using identical program versions, biological targets, and screening
libraries.
As mentioned in Chapter 3, not all docking programs and scoring functions will
perform equally well when used to screen against a given target, regardless of the level
of skill the user has with the programs. This is because there is a dependence on the
nature of the binding site on the performance of the docking programs and scoring
functions.196 This can be attributed primarily to the functional form and parameterization
of the scoring functions, with some performing better against polar active sites and
others performing well against lipophilic sites. A clear understanding of these limitations
is essential when selecting the appropriate docking and scoring functions for use against
the screening target. In the absence of a thorough validation study as was described in
Chapter 3, the computational chemist should make every effort to select a
docking/scoring function combination with a proven record against the class of receptor
into which they are docking.
Another limitation with structure-based virtual screening is the scoring functions
themselves. A docking score is essentially an approximation of the binding affinity of a
ligand for the receptor and should theoretically scale well with the experimentally
determined binding affinity (Kd or IC50). However, although scoring functions have a
demonstrated ability to identify active compounds from screening sets, they are nearly
universal in poorly predicting the absolute binding affinity of active compounds. This has
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direct ramifications on the selection of compounds from a virtual screen for testing.
Compounds are often selected in one of two ways, either by taking the top n% of scored
compounds or by taking every compound scoring above a certain cut-off. Either of these
methods is acceptable, however the value selected (top n% or score cut-off) should be
knowledge-based, that is based upon the results of a carefully designed validation study
of the docking/scoring combination that was used against the target. A recommendation
would be to select the n% value based on enrichment factor studies such that 80 to 90%
of the active compounds were selected at the given n% value. Correspondingly, the
score cut-off can be selected based upon receiver-operating characteristic curves by
selecting the score above which 80 to 90% of the active compounds were identified.
Beyond this, however, a testing priority for compounds based upon their actual score
would be irrelevant.
Because of these limitations, it is very important to perform extensive validation
of the docking/scoring function to be used in a virtual screening project. Additionally, a
Medicinal Chemist who is performing molecular docking and scoring as part of their
research should familiarize themselves with the functional form and parameterization of
the scoring functions that are available for their use, and they should make every effort
to obtain expertise with at least one docking program from each class (incremental
construction, Monte Carlo, Genetic Algorithm, Tabu Search, etc.).
A final issue that deserves mention is compound procurement. Although not a
direct limitation of a virtual screening project, the procurement of the “hit” compounds for
testing is definitely a factor that requires consideration, as this process can require
considerable expenditure of time and resources. In Chapter 4, I discussed the
acquisition failure rates from the two rounds of virtual screening. Noticeable
improvements to the failure rate were obtained when we selected only databases from
reliable vendors, as determined from our experiences in the first round of virtual
screening. In the absence of favorable experience otherwise, I would recommend
limiting database screening to U.S. suppliers due to the high cost of shipping from
foreign countries, customs issues, and questions of compound purity. In fact, although
not specifically addressed in the research presented here, it is highly recommended to
perform quality control analyses on all compounds ordered from any vendor. In the
absence of some independent rating system for chemical suppliers (which does not exist
to my knowledge), following these recommendations may help to alleviate some of the
frustrations that were experienced in our studies.
6.3.3 Ligand-Based Drug Design
A recent article by Johnson, et al. entitled “The trouble with QSAR (or how I
learned to stop worrying and embrace fallacy)” proposed that QSAR has not met the
expectations for predicting biological activity.260 The authors suggested that chance
correlation, incorrect functional forms, and model overtraining have contributed to this
problem and attributed the Cum Hoc, Ergo Propter Hoc fallacy (with this, therefore
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because of this) to the poor prediction seen with many QSAR models.260 They conclude
that the manner in which QSAR is applied is more responsible for its lack of success
than any other cause. The authors state their case convincingly and their paper
correctly identifies issues and limitations with QSAR that must be addressed before any
developed QSAR model can be used to make reliable activity predictions. However, I do
believe that it is possible to develop and utilize a predictive QSAR model in a ligandbased drug design study if one understands the limitations mentioned above, takes them
into account when developing the QSAR model, and extensively validates the model.
A question that I feel should be answered here is: Is there an advantage of using
a QSAR model in drug discovery over general structure-activity observations? In other
words, is QSAR a lesson in the obvious? In the case where a QSAR model tells you
what you already know, what it the utility? The answer to these questions is that QSAR
models do often tell us what we already know, a charged group favored in this position
or steric bulk disfavored in that position. However, the true utility of QSAR models is in
virtual screening. Knowing that a charged group is favored in this position and steric
bulk disfavored in that is not helpful when predicting activities of a large number of
compounds as a researcher cannot possibly be expected to visually inspect every
compound for favored or disfavored groups within a reasonable period of time.
However, a validated QSAR model can be used to screen very large libraries (of
compounds covered by the physico-chemical space of the QSAR model) quickly and
efficiently, providing the researcher a much more manageable number of “hit”
compounds that can be visually inspected and ordered or synthesized.

6.4 Overall Themes (“The Big Picture”)
Throughout the research presented in this thesis, there have been several
recurring “themes” which deserve special attention. In this section I present a brief
discussion of what I believe to be the two most important overall themes of the research
I have conducted and the implications in virtual screening generally and with respect to
the research projects discussed in this thesis.
6.4.1 Method Validation
The studies presented in this thesis predominately dealt with the use of
computers, programs, and algorithms in the discovery of compounds with activity against
our targets. I have implied above that these programs are essentially only as good as
the researcher who is using them and that, in addition to expertise with the individual
programs, a competent researcher should possess skills or a knowledge base in several
fields contributing to drug discovery. In the previous section I highlighted and briefly
discussed the multiple weaknesses of the methods used in these studies. Considering
the expertise required for using these programs and their inherent weaknesses, the
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question may be asked: How can one rely on the results obtained from the application of
these methods?
The answer is perhaps the most important overall theme of this research:
Validation. Each of the methods used in these studies, molecular dynamics, docking
and scoring, and QSAR must be extensively validated against the target or system of
interest before any results from their application can be reliable interpreted. It is not
enough that the programs have been validated by their developers in a general sense;
their use by a specific user against a specific target must also be validated. Chapter 3
presented an extensive validation of the docking and scoring methods we used in the
virtual screening work presented in Chapter 4. The results presented in Chapter 3
highlight a key point that must be stressed here. The results obtained by the
computational methods employed here are dependent on three factors: the expertise
and training of the user, the abilities and limitations of the programs themselves, and the
targets or systems against which they are being employed. This is demonstrated in
Chapter 3 by the poor performance of several docking programs such as FlexX and
GOLD when compared to others, although each of these programs has performed
exceptionally well in other published studies. The question may be asked, when
validating using the methods employed in these studies, which of the factors mentioned
above is being investigated, the human factor, the programming factor, or the target
factor? In many ways, the answer is all three. This of course has potential implications
if the person or persons performing the validation studies are not the same who will be
using the validated programs in the performance of the virtual screening, for example.
Fortunately this was not the case in these studies.
Each of the computational techniques and programs used in these studies was
validated using a variety of methods specific to the program or technique being utilized.
For molecular dynamics simulations, validation methods include testing parameters by
attempting to reproduce known experimental data such as thermodynamic properties,
binding or conformational energies. Additionally, it is often necessary to run multiple
simulations, often from different starting conformations, to investigate whether final
structures and positions obtained can be reproduced. The results of a molecular
dynamics simulation are questionable if they are not reproducible. Chapter 3 discussed
the different validation methods currently employed for docking and scoring functions,
and we have even developed a new validation method which we hope will be well
received by the modeling community. The QSAR models developed in Chapter 4 were
extensively validated by a variety of internal and external methods during and after their
development.
6.4.2 Filtering and Compound Selection
The second general theme of this research that deserves special discussion is
the selection of compounds for screening and testing. This is actually two separate but
somewhat related areas, whose application directly influences the results obtained from
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a virtual screen. In virtual screening, filters are frequently applied either before or after
docking and scoring to minimize the computational expense and time required or the
number of compounds required for testing. In our studies, we have used
pharmacophore filtering as a docking pre-filter and cluster analysis as a docking postfilter. Our results, as discussed in Chapter 4, highlight some important issues with the
application of filtering and compound selection that will be addressed in this section.
There are a variety of filters that can be employed for pre-filtering prior to
performing a docking study, ranging from simple 2D filters for molecular weight or other
physico-chemical properties, to advanced pharmacophore or SAR filters, such as those
employed in our studies. In the case of pharmacophore filtering, the filter can be created
from the structures of known active compounds or from key binding features that are
known in the active site. These are known as ligand-based or receptor-based queries.
In our case, we built a ligand-based query using the structural features of several
compounds with DHPS inhibitory activity known to bind to the pterin site (crystal
structures available). The results from the docking performed using this pharmacophore
filter highlighted an important issue. Namely, the nature of the hit compounds from a
virtual screen using this approach are dependent on how rigid the pharmacophore was
that was employed as a pre-filter. A receptor-based pharmacophore filter would
theoretically not be as rigid a pharmacophore, and could potentially enable more
diversity in the hit compounds.
An alternative method would be to employ post-docking filters to minimize the
number of compounds being sent for experimental assay studies. The number of
compounds being docked and scored as well as the number of compounds being
assayed are dependent on the resources available to a given research group. In our
case, we decreased the number of compounds we docked by an order of magnitude and
then applied cluster analysis to the results to select a manageable number of
compounds for testing. Cluster analysis is one method of post-docking filtering that
ideally selects a small number of compounds with maximum diversity, with the hope that
the chemical space of the high scoring compounds is being adequately covered. The
caveat with this method is that there is a greater chance of missing an active compound
within the same bins. Although the testing from our second round of virtual screening is
ongoing, it is my recommendation that a final step be added once more activity data on
the compounds sent for testing becomes available. I suggest that, once a compound
has been shown to have activity above our cut-off, then more compounds from the
corresponding bin that compound was selected from should be procured and tested.
Very often in virtual screening projects, simple 2D filters are applied such as the
Rule of 5 and Rule of 3 filters discussed in Chapter 1 and reactive or cytotoxic functional
group filters such as those employed by the ZINC database curators (listed in Appendix
D.1). These filters can be very useful in removing compounds that are not considered
“drug-like” or “fragment-like”, have undesirable lipophilicity or electrostatic properties, or
may react and interfere with experimental assays. However, it must be considered that
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applying these filters may remove compounds with good activity from consideration. I
will highlight this observation with two examples. First, when screening compounds for
use against bacterial, fungal, or viral targets the use of “drug-like” filters is probably not
appropriate (as mentioned in Section 1.5.3), because many marketed agents in these
classes far exceed the cut-off values. Second, hits from a screen of fragment
compounds are likely to be moved forward to an organic synthesis optimization project,
and it may not be desirable to remove all compounds with reactive functional groups, as
those groups may be advantageous for future synthesis and lead optimization.
Obviously, the decision of what filters to employ and at what point to employ them will
have to be made based upon a given projects goals and target.
Unless one has unlimited computational and experimental resources, which is
rarely the case, filtering and compounds selection methods will almost always have to be
employed in a high-throughput virtual screening project. Our studies have shown us that
the filtering and selection rules employed in a virtual screening study are nearly as
important as the docking and scoring functions in terms of the quality of the lead
compounds obtained.

6.5 Future Directions
So, where do we go from here? Although my contributions to both the DHPS
project and the Nitrofuran project are nearly completed, there are several avenues that
remain to be explored, some revealed by the work presented here. Because both
projects are still active, I present here some possible future directions that may be
explored by DHPS and Nitrofuran researchers.
6.5.1 DHPS Project
The next logical step of this structure-based drug design project is the generation
of co-crystal structures with the hit compounds from our VS studies that showed activity
in our enzyme assay. In addition to validating our VS methods, a co-crystal structure
with one or more of the hit fragments bound into the pterin site could be used by our
synthetic chemistry group to generate more potent binding agents based upon the
observed interactions in the structure and would also feed back into the modeling project
to be used in refining the VS for future rounds.
Of course, virtual screening against the DHPS enzyme is far from complete.
Although I have completed two extensive rounds of screening against B. anthracis, the
DHPS project is also funded to investigate the enzyme from F. tularensis and Y. pestis.
Crystal structures from these bacterial species were not available for my studies and I
focused solely on B. anthracis. However, they should be solved very soon and
investigation of these two enzymes in a manner similar to my investigations of B.
anthracis DHPS is a logical next step. A very important prerequisite to high-throughput
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docking against these enzymes is the development of a suitable assay for testing hit
compounds. Extensive validation of the enzyme assay we are currently using, not only
for F. tularensis and Y. pestis, but also for B. anthracis is necessary.
When we were validating docking programs and scoring functions for use in
screening against DHPS, we investigated 5 commonly used docking programs and 9
scoring functions, all available to our group through University of Tennessee licenses.
There were several notable exceptions missing from the docking programs that were
investigated, and a closer examination of these programs for use in docking against
DHPS would be useful. Two specific examples are the programs AutoDock and FRED,
which are two of the most frequently used docking programs today for virtual screening
studies (Figure 1.4). This is likely due to their free access to academic researchers,
although both programs have also performed very well in validation studies. I was not
able to investigate these programs due to “red tape” issues, but I feel that it is important
to take a look at both AutoDock and FRED’s performance against DHPS in the future.
Additionally, two general classes of docking programs were noticeably missing from our
validation studies, Monte Carlo based programs and Tabu Search based programs. The
These were not available to our group at the time the studies were performed, but it
would be very interesting to see how they compare with the programs that we did
validate.
The “high-throughput” docking studies presented here used a Linux workstation
with the docking jobs run in parallel across 4 processors (the most our University of
Tennessee licenses permit). This enabled us to dock approximately 25,000 compounds
per day. Our collaborators at St. Jude Children’s Research Hospital have a 280-node
Linux cluster and unlimited processor licenses available for their use. Using these
resources, we could theoretically dock the entire ZINC database collection, without any
pre-filtering, in a matter of days or weeks. Reports of this type of “ultra high-throughput
docking” are scarce and this is definitely something that merits investigation by the
group. Of course, the important issues of validation and compound selection for testing
would have to be addressed. The top 1% of 5 million compounds is 50,000 compounds!
In our docking validation study, we investigated nine different scoring functions
for use in screening against the DHPS pterin site. At least one scoring function was
present from each major class of scoring functions: force-field based, knowledge-based,
and empirical functions. Of interest to me personally, and perhaps of utility to future
virtual screening studies, is the use of solvation-based scoring functions. At the most,
each of the energy functions investigated in these studies very generally approximates
the effects of solvation/desolvation on ligand binding, usually through the incorporation
of a protein-ligand desolvation energetic penalty in the scoring function. There are
continuum based approaches that represent an intermediate approach to the
incorporation of solvation effects in scoring, such as GB/SA scoring functions (not
investigated in these studies). The reason that a full solvation-based scoring approach,
such as PB/SA scoring, was avoided here was due to the dramatic increase in time and
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computing power that would have been required. However, new techniques and
increased ability to parallelize such docking and scoring jobs are now available. It would
be of interest to this study to use the Linux cluster at SJCRH with the latest version of
the program DOCK, which is now highly parallelizable using MPI software freely
available, and the PB/SA or AMBER GB/SA scoring function (or both) scoring function
that comes with the DOCK package.
With respect to the Molecular Dynamics simulations performed in this study, I do
not feel that we learned as much as I had hoped. After analyzing the results of multiple
simulations, it seemed that there were more questions than answers. Although, a few
interesting observations were noted and theories proposed as to the nature of certain
key interactions and resistance site mutations, ultimately our simulations failed to answer
any of our research questions clearly. Should any future researcher in this area decide
to take another look at DHPS using Molecular Simulations I would recommend the
following: 1. QM calculations to be used for the development of non-standard residue
parameters. This will avoid the time-consuming trial and error that was experienced in
these studies. 2. Extended duration simulations using product, substrate, and
transition-state analogs using advanced MD techniques such as umbrella sampling261,
replica exchange262, or multicanonical ensembles263, may enable us to visualize loop
movements that were not seen with the 4 nanosecond timescale used in these studies.
3. The use of new Quantum Dynamics or QM/MM simulations to attempt to more
accurately study the transition state and perhaps definitively answer the question of
whether the reaction proceeds via an Sn1 or Sn2 mechanism.
Lastly, there are two important areas that I think should be investigated closely in
future studies. The first is the conserved water binding site which falls deep within the
DHPS active site, near the pterin binding site. Although we avoided targeting this site in
the docking studies presented here due to its conserved nature, this water site has
potential to be displaced by a small molecule moiety to yield slow-, tight-binding
inhibitors of DHPS which could lead to broad-spectrum antibiotics. The displacement of
a structural water has been reported to be one mechanism of slow-, tight-binding and
could theoretically lead to inhibitors that are functionally equivalent to covalent,
irreversible inhibitors with an extended pharmacokinetic half-life of days.264 The
implications in antimicrobial drug design are obvious. The second area is the phosphate
binding site, which was also avoided in our docking studies. There are two reasons for
my belief that this is an area that should also be investigated in future virtual screens or
synthetic efforts. First, in our molecular dynamics simulations we noted a dependence
of an anionic group in this site for stabilization of the pterin product and substrate ligands
in the active site and a rapid ejection of products and substrates when the negatively
charged group was absent. Second, several of our most active hit compounds from the
virtual screening studies and other preliminary studies contain a negatively charged
group which could theoretically be falling near this anionic site. It is very likely that the
anion stabilizes a key arginine in an extended position that is necessary for binding of
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pterin substrates. Theoretically, inhibitory compounds containing a similar anionic group
would have an increased binding affinity due to their ability to make similar contacts.
6.5.2 Nitrofuran Project
With the development and validation of a predictive QSAR model, the next
obvious step is to utilize the model to predict activities of unknown compounds and to
use this information to prioritize their synthesis and testing. I suggest that the next
researcher who is assigned to assist with modeling on this project develop a series of
virtual nitrofuran (and related compound) libraries based loosely upon the scaffold of the
compounds in our collection with potent activity. I recommend that the modeler work
closely with the synthetic group when preparing these libraries to facilitate the
development of a library containing synthetically feasible compounds. As new
compounds are tested and activities measured, the QSAR model can be expanded to
cover the additional chemical space. Of course any new models developed will have to
be extensively validated.
Finally, the Nitrofuran project would benefit from the application of one or more
lead-hopping techniques to identify novel scaffolds. There are two methods that I would
suggest be applied in this case: similarity searching and topomer searching, both of
which are available through our Sybyl Molecular Modeling suite. The first program I
recommend be employed is Surflex-Sim, which bases similarity on the training set
molecules’ shape, H-bonding, and electrostatic properties using molecular surfaces.
The second is a new technique called topomer searching, which is an extremely fast tool
for ligand-based VS and lead-hopping. It uses topomer fields and pharmacophore
properties of the training compounds to screen for whole molecules, groups, or
scaffolds. The application of either of these methods has the potential to take the
nitrofuran project in exciting new directions.

6.6 Conclusions
I conclude this work by giving my best answer to the following question: What
place do I believe virtual screening has in the future of drug design?
There are still several inadequacies with virtual screening methods that will need
to be overcome before virtual screening can realize its full potential. A key weakness is
the inability of any computational method to accurately predict absolute binding affinity.
Although VS has advanced to the point where it can be used to reliable identify active
compounds from screening libraries, the functions themselves have a long way to go
before they can be used to predict the absolute binding affinity of the compounds with a
reliable degree of certainty. This was demonstrated by our use of the new SSLR
statistic in Chapter 4. If the scoring functions were getting the ordering even close to
correct, the SSLR metric should theoretically have statistically outperformed the AU-
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ROC method. The fact that the performance of these two methods was mostly
indistinguishable reflects on the performance of the scoring functions rather than the
utility of the SSLR method.
However, I still firmly believe that virtual screening as a lead identification method
has strong future in drug discovery. In fact, as the techniques continue to be refined and
improved and as computing power continues to exponentially increase, I believe that the
deficiencies highlighted in this chapter will be resolved and that the role of virtual
screening in drug discovery will continue to expand. Eventually, it may even replace
traditional high-throughput screening as the gold standard of lead identification.
Computational medicinal chemistry, while still an emerging field, will play an increasing
role in the discovery of future clinical drug candidates, not just as a lead identification
tool but also as a lead optimization tool. I foresee an increased demand for researchers
with skill and training in these techniques.
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APPENDICES
A. Molecular Dynamics Force Field Parameter Files for Non-Standard Residues
A.1 Pterin-SMX Parameter/Topology File
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H6
N6

18
18
18
21
22
22
22
25
26
26
26
29
30
30
30

16
16
16
18
21
21
21
22
25
25
25
26
29
29
29

15
15
15
16
18
18
18
21
22
22
22
25
26
26
26

1.102
1.099
1.505
1.508
1.096
1.098
1.437
1.606
1.491
1.492
1.606
1.605
1.491
1.490
1.491

110.446
106.410
113.974
119.414
108.569
106.819
116.106
135.494
112.442
104.553
116.062
119.125
108.993
113.198
110.520

129.399
-111.398
5.741
173.133
-90.894
153.769
36.793
-73.898
68.982
-179.581
-61.355
36.344
165.384
45.487
-77.439

0.20505
0.18287
0.47902
0.14476
0.13155
-0.00181
-0.58527
1.56950
-0.91530
-0.90410
-0.82164
1.46331
-0.95009
-0.96046
-0.94965

N9
N6

IMPROPER
C7
H1
N4
N9
C2
C7
C3
N4
C2
C5
C3
N9
C12
C5
C12 C13
DONE
STOP

A.6 DHPP Additional Parameters

remark goes here
MASS
BOND
cd-nf

597.70

ANGLE
c -cd-nf
cd-nf-c2
nf-cd-cc
nh-c3-c2

1.280

68.400
70.800
71.300
67.571

DIHE
c -cd-nf-c2
nf-X
cc-cd-nf-c2
nf-X

same as c2-nf

120.890
118.180
126.010
107.790

same as c -cd-n2
same as c2-n2-c2
same as c2-c2-n2
Calculated with empirical approach

1

4.150

180.000

2.000

same as X -c2-

1

4.150

180.000

2.000

same as X -c2-
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IMPROPER
cd-hn-nh-hn
1.1
180.0
2.0
value
n -nc-cd-nh
1.1
180.0
2.0
value
c -cd-n -hn
1.1
180.0
2.0
improper torsional angle (2 general atom types)
cd-n -c -o
10.5
180.0
2.0
improper torsional angle (2 general atom types)
c -cc-cd-nf
1.1
180.0
2.0
value
cd-nc-cc-nh
1.1
180.0
2.0
value
c3-cc-nh-hn
1.1
180.0
2.0
value
c3-c3-c2-nf
1.1
180.0
2.0
value

Using default
Using default
General
General
Using default
Using default
Using default
Using default

NONBON

A.7 PPi Parameter/Topology File

0

0

2

This is a remark line
molecule.res
PPI
INT 0
CORRECT
OMIT DU
BEG
0.0000
1 DUMM DU
M
0 -1
2 DUMM DU
M
1
0
3 DUMM DU
M
2
1
4 O1
o
M
3
2
5 P3
p5
M
4
3
6 O10
o
E
5
4
7 O11
o
E
5
4
8 O3
os
M
5
4
9 PO4
p5
M
8
5
10 O5
o
E
9
8
11 O6
o
E
9
8
12 O4
o
M
9
8

-2
-1
0
1
2
3
3
3
4
5
5
5

0.000
1.449
1.522
1.540
1.489
1.485
1.487
1.647
1.647
1.485
1.487
1.489

LOOP
IMPROPER
DONE
STOP
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.0
.0
111.1
111.208
128.443
111.856
111.295
101.563
131.548
109.960
106.882
101.559

.0
.0
.0
180.000
117.576
-155.385
-26.083
87.357
161.142
42.494
-82.185
161.071

.00000
.00000
.00000
-1.02198
1.49384
-1.02198
-1.02198
-0.85581
1.49384
-1.02198
-1.02198
-1.02198

A.8 SO4 Parameter/Topology File

0

0

2

This is a remark line
molecule.res
SO4
INT 0
CORRECT
OMIT DU
BEG
0.0000
1 DUMM DU
M
0 -1
2 DUMM DU
M
1
0
3 DUMM DU
M
2
1
4 O4
o
M
3
2
5 S
s6
M
4
3
6 O2
o
E
5
4
7 O1
o
E
5
4
8 O3
o
M
5
4

-2
-1
0
1
2
3
3
3

0.000
1.449
1.522
1.540
1.420
1.423
1.410
1.399

LOOP
IMPROPER
DONE
STOP
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.0
.0
111.1
111.208
97.201
119.786
118.162
117.454

.0
.0
.0
180.000
111.356
-82.939
43.175
154.257

.00000
.00000
.00000
-0.88594
1.54374
-0.88593
-0.88596
-0.88592

B. Chapter 2 Supplemental Material
B.1 Molecular Dynamics Equilibrium Energy Plots

Figure B.1. DHPS Pterin-SMX 4ns, Explicit Simulation Total Energy Plot
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B.2 DHPS Molecular Dynamics RMSD Calculations

Figure B.2. DHPS RMSD Calculation, Full Enzyme
This is a standard RMSD calculation plot referenced to initial frame DHPS simulation 217. In this figure, RMSD is calculated for backbone atoms of the entire protein.
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Figure B.3. DHPS RMSD Calculation, Loop 1
This is a standard RMSD calculation plot referenced to initial frame DHPS simulation 217. In this figure, RMSD is calculated for all atoms of loop 1, from Val28 to Val40.
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Figure B.4. DHPS RMSD Calculation, Loop 2
This is a standard RMSD calculation plot referenced to initial frame DHPS simulation 217. In this figure, RMSD is calculated for all atoms of loop 2, from Glu65 to GLU77.
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Figure B.5. DHPS RMSD Calculation, Helices and β Strands
This is a standard RMSD calculation plot referenced to initial frame DHPS simulation 217. In this figure, RMSD is calculated for all backbone atoms of the helix and strand
secondary structures and excludes all atoms in flexible loop regions.

198

Figure B.6. DHPS RMSD Calculation, Full Protein to Minimum Energy Structure
This is a standard RMSD calculation plot referenced to the lowest energy conformation
from DHPS simulation 2-17. In this figure, RMSD is calculated for backbone atoms of
the entire protein.
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Figure B.7. DHPS RMSD Calculation, Full Protein to Average Structure
This is a standard RMSD calculation plot referenced to the average conformation from
DHPS simulation 2-17. In this figure, RMSD is calculated for backbone atoms of the
entire protein.
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Table B.1. DHPS Average and Minimum Energy Structure RMSD Values
DHPS MD Structure

RMSD Calculation

RMSD (Å) Value

Minimum Energy Structure

All Backbone Atoms
Loop 2 Backbone Atoms
Loop 2 All Atoms

3.091
3.017
4.321

Average Structure

All Backbone Atoms
Loop 2 Backbone Atoms
Loop 2 All Atoms

2.600
3.055
4.388

The RMSD values reported above are referenced to a DHPS crystal structure that was
solved by our group after our MD studies were completed. In this new structure, loop 2
is visible in its entirety, although there is no ligand bound in the pterin binding site. Loop
1 is missing from the new structure, indicating that the crystal contact has been lost and
the loop is highly mobile.
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B.3 Trajectory Analysis
B.3.1 Phe33 Dihedral Analysis

Figure B.8. Phe33 Phi Dihedral Map

Figure B.9. Phe33 Psi Dihedral Map
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Figure B.10. Phe33 Chi1 Dihedral Map

Figure B.11. Phe33 Chi2 Dihedral Map
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B.3.2 Thr67 Dihedral Analysis

Figure B.12. Thr67 Phi Dihedral Map

Figure B.13. Thr67 Psi Dihedral Map
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Figure B.14. Thr67 Chi Dihedral Map
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B.3.3. Pro69 Dihedral Analysis

Figure B.15. Pro69 Phi Dihedral Map

Figure B.16. Pro69 Psi Dihedral Map
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B.3.4. Arg68 Dihedral Analysis

Figure B.17. Arg68 Phi Dihedral Map

Figure B.18. Arg68 Psi Dihedral Map
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Figure B.19. Arg68 Chi1 Dihedral Map

Figure B.20. Arg68 Chi2 Dihedral Map
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Figure B.21. Arg68 Chi3 Dihedral Map

Figure B.22. Arg68 Chi4 Dihedral Map
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C. Chapter 3 Supplemental Tables and Figures
Table C.1. DOCK Docking of the ACD Decoy Set
Docking
Program /
Validation Set

Grid
Score

F-Score

PMFScore

G-Score

D-Score

ChemScore

Grid Score
F-Score
PMF-Score
G-Score
D-Score
ChemScore

--.237
.975
<.001
<.001
.001

.748
--.154
.002
.024
.003

.155
.298
--<.001
<.001
<.001

<.001
.016
<.001
--.008
.265

<.001
.551
.006
.004
--.043

<.001
.004
<.001
.764
.041
---

Table C.2. DOCK Docking of the Schrödinger Decoy Set
Docking
Program /
Validation Set

Grid
Score

F-Score

PMFScore

G-Score

D-Score

ChemScore

Grid Score
F-Score
PMF-Score
G-Score
D-Score
ChemScore

--.161
<.001
.008
.056
.047

.762
--.774
.002
.053
<.001

.003
.125
--<.001
<.001
<.001

.002
.005
<.001
--.267
.467

.003
.333
<.001
.076
--.165

.007
<.001
<.001
.422
.085
---
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Table C.3. DOCK Docking of the ZINC Decoy Set
Docking
Program /
Validation Set

Grid
Score

F-Score

PMFScore

G-Score

D-Score

ChemScore

Grid Score
F-Score
PMF-Score
G-Score
D-Score
ChemScore

--.310
<.001
<.001
<.001
.008

.862
--.665
.002
.077
.001

.030
.119
--<.001
<.001
<.001

<.001
.002
<.001
--.005
.911

.002
.515
.001
.005
--.162

.001
.001
<.001
.924
.074
---

Table C.4. FlexX Docking of the ACD Decoy Set
Docking
Program /
Validation Set

F-Score

PMFScore

G-Score

D-Score

ChemScore

F-Score
PMF-Score
G-Score
D-Score
ChemScore

--.485
.002
.017
<.001

.537
--<.001
<.001
<.001

<.001
<.001
--.001
.331

.019
.003
.005
--.033

<.001
<.001
.918
.010
---
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Table C.5. FlexX Docking of the Schrödinger Decoy Set
Docking
Program /
Validation Set

F-Score

PMFScore

G-Score

D-Score

ChemScore

F-Score
PMF-Score
G-Score
D-Score
ChemScore

--.076
.021
.030
<.001

.032
--<.001
<.001
<.001

<.001
<.001
--.049
.184

.011
<.001
.023
--.028

<.001
<.001
.324
.001
---

Table C.6. FlexX Docking of the ZINC Decoy Set
Docking
Program /
Validation Set

F-Score

PMFScore

G-Score

D-Score

ChemScore

F-Score
PMF-Score
G-Score
D-Score
ChemScore

--.051
.010
.042
<.001

.052
--<.001
<.001
<.001

<.001
<.001
--.013
.224

.017
<.001
.006
--.028

<.001
<.001
.471
.001
---
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Table C.7. Glide Docking of the ACD Decoy Set
Docking
Program /
Validation Set

Glide
Score

F-Score

PMFScore

G-Score

D-Score

ChemScore

Glide Score
F-Score
PMF-Score
G-Score
D-Score
ChemScore

--.985
.142
<.001
<.001
.003

.909
--.317
<.001
<.001
<.001

.054
.027
--<.001
<.001
.002

<.001
<.001
<.001
--.031
<.001

<.001
<.001
<.001
.022
--.981

<.001
<.001
<.001
<.001
.870
---

Table C.8. Glide Docking of the Schrödinger Decoy Set
Docking
Program /
Validation Set

Glide
Score

F-Score

PMFScore

G-Score

D-Score

ChemScore

Glide Score
F-Score
PMF-Score
G-Score
D-Score
ChemScore

--.371
.089
<.001
<.001
<.001

.124
--.529
<.001
<.001
<.001

.021
.140
--<.001
<.001
.005

<.001
<.001
<.001
--.342
.625

<.001
<.001
<.001
.338
--.811

<.001
<.001
<.001
.236
.966
---
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Table C.9. GOLD Docking of the ZINC Decoy Set
Docking
Program /
Validation Set

GOLD
Score

F-Score

PMFScore

G-Score

D-Score

ChemScore

GOLD Score
F-Score
PMF-Score
G-Score
D-Score
ChemScore

--.005
.007
<.001
<.001
<.001

.077
--.708
.002
.002
<.001

.029
.863
--<.001
<.001
<.001

<.001
<.001
<.001
--.639
.221

<.001
<.001
<.001
.958
--.012

<.001
<.001
<.001
.024
.010
---

Table C.10. Surflex Docking of the ACD Decoy Set
Docking
Program /
Validation Set

Surflex
Score

F-Score

PMFScore

G-Score

D-Score

ChemScore

Surflex Score
F-Score
PMF-Score
G-Score
D-Score
ChemScore

--.460
.003
<.001
<.001
<.001

.963
--<.001
<.001
<.001
<.001

.002
.008
--<.001
<.001
<.001

<.001
<.001
<.001
---

<.001
<.001
<.001
.001
--.447

<.001
<.001
<.001
<.001
.460
---
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<.001

Table C.11. Surflex Docking of the ZINC Decoy Set
Docking
Program /
Validation Set

Surflex
Score

F-Score

PMFScore

G-Score

D-Score

ChemScore

Surflex Score
F-Score
PMF-Score
G-Score
D-Score
ChemScore

--.475
.194
<.001
<.001
<.001

.499
--.472
<.001
<.001
<.001

.172
.327
--<.001
<.001
<.001

<.001
<.001
<.001
--.021
<.001

<.001
<.001
<.001
.006
--.258

<.001
<.001
<.001
<.001
.249
---
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Figure C.1. DOCK - ACD Decoy Set, ROC Curves
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Figure C.2. DOCK - Schrodinger Decoy Set, ROC Curves
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Figure C.3. DOCK - ZINC Decoy Set, ROC Curves
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Figure C.4. FlexX - ACD Decoy Set, ROC Curves

219

Figure C.5. FlexX - Schrodinger Decoy Set, ROC Curves
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Figure C.6. FlexX - ZINC Decoy Set, ROC Curves
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Figure C.7. Glide - ACD Decoy Set, ROC Curves
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Figure C.8. Glide - Schrodinger Decoy Set, ROC Curves
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Figure C.9. Gold - ZINC Decoy Set, ROC Curves
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Figure C.10. Surflex - ACD Decoy Set, ROC Curves
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Figure C.11. Surflex - ZINC Decoy Set, ROC Curves
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Figure C.12. ZINC Decoy Set, Enrichment at 2%
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Figure C.13. Schrodinger Decoy Set, Enrichment at 2%
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Figure C.14. ACD Decoy Set, Enrichment at 2%

229

D. Chapter 4 Supplemental Material
D.1 ZINC Databases Filtering Rules
#special flags
50.0 500.0 MOLWT
STRIPSALTS yes
0 10 CHIRALITY enumerate
ALLOWED_ATOMS C N O S P Cl F Br I H
# normal format is (min, max, name, SMARTS)
#rules
5 40 Non-Hydrogen_atoms [a,A]
2 40 carbons [#6]
1 20 N,O,S [#7,#8,#16]
0 1 Sulfonyl_halides S(=O)(=O)[Cl,Br]
0 1 Acid_halides [S,C](=[O,S])[F,Br,Cl,I]
0 1 Alkyl_halides [Br,Cl,I][CX4;CH,CH2]
0 0 Phosphenes cPc
0 0 Heptanes [CD1][CD2][CD2][CD2][CD2][CD2][CD2]
0 0 Perchlorates OCl(O)(O)(O)
0 7 Fluorines F
0 6 Cl,Br,I [Cl,Br,I]
0 0 Carbazides O=CN=[N+]=[N-]
0 0 Acid_anhydrides C(=O)OC(=O)
0 0 Peroxides OO
0 1 Iso(thio)cyanates N=C=[S,O]
0 1 Thiocyanates SC#N
0 0 Phosphoranes C=P
0 0 P/S_halides [P,S][Cl,Br,F,I]
#0 0 Carbodiimides N=C=N
0 0 Cyanohydrines N#CC[OH]
0 0 Carbazides O=CN=[N+]=[N-]
0 1 Sulfate_esters COS(=O)O[C,c]
0 1 Sulfonates COS(=O)(=O)[C,c]
0 0 Pentafluorophenyl_esters C(=O)Oc1c(F)c(F)c(F)c(F)c1(F)
0 0 Paranitrophenyl_esters C(=O)Oc1ccc(N(=O)=O)cc1
0 0 HOBt_esters C(=O)Onnn
0 0 Triflates OS(=O)(=O)C(F)(F)F
0 0 Lawesson's_reagents P(=S)(S)S
0 0 Phosphoramides NP(=O)(N)N
0 0 Aromatic_azides cN=[N+]=[N-]
0 2 Quaternary_C,Cl,I,P,S [C+,Cl+,I+,P+,S+]
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0 2 Beta_carbonyl_quaternary_N C(=O)C[N+,n+]
0 2 Acylhydrazides [N;R0][N;R0]C(=O)
0 0 Chloramidines [Cl]C([C&R0])=N
0 0 Isonitriles [N+]#[C-]
0 0 Triacyloximes C(=O)N(C(=O))OC(=O)
0 0 Acyl_cyanides N#CC(=O)
0 0 Sulfonyl_cyanides S(=O)(=O)C#N
0 0 Cyanophosphonates P(OCC)(OCC)(=O)C#N
0 0 Azocyanamides [N;R0]=[N;R0]C#N
0 0 Azoalkanals [N;R0]=[N;R0]CC=O
0 2 (Thio)epoxides,aziridines C1[O,S,N]C1
0 2 Benzylic_quaternary_N cC[N+]
0 2 Thioesters C[O,S;R0][C;R0](=S)
0 3 Diand_Triphosphates P(=O)([OH])OP(=O)[OH]
0 2 Aminooxy(oxo) [#7]O[#6,#16]=O
0 2 nitros N(~[OD1])~[OD1]
0 2 Imines C=[N;R0]*
0 2 Acrylonitriles N#CC=C
0 2 Propenals C=CC(=O)[!#7;!#8]
0 4 Quaternary_N [n+,N+]
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D.2 Virtual Screen Round 1, All Compounds Selected for Screening

Figure D.1. Virtual Screening, Round 1 Hits, Part 1
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Figure D.2. Virtual Screening, Round 1 Hits, Part 2
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Figure D.3. Virtual Screening, Round 1 Hits, Part 3
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D.3 Virtual Screen Round 2, All Compounds Selected for Screening

Figure D.4. Virtual Screening, Round 2 Hits, Part 1
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Figure D.5. Virtual Screening, Round 2 Hits, Part 2
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Figure D.6. Virtual Screening, Round 2 Hits, Part 3
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